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The prevalence of human cytomegalovirus (HCMV) pp65-, ppl50-, IEl-exon4-, gB- and 
pp28-specific cytotoxic T lymphocyte (CTL) responses was compared among 34 healthy in-
dividuals, grouped by neutralizing antibody titers. Moderately and highly seropositive donors 
showed predominantly pp65- and IEl-exon4-specific CTL responses (92% and 76% of the 
donors, respectively), with similar precursor frequencies in the 2 donors tested. In addition, 
highly seropositive and a few moderately seropositive donors showed CTL responses to gB 
and ppl50 (33% and 30% of the donors, respectively). No individual recognized pp28 as a 
target in the CTL assay. Phenotypic analysis revealed a mixed effector population of CD4* 
and CD8+ (1 donor) or only CD8* cells for pp65-specific effectors (2 donors). IEl-exon4-
and pplSO-specific effectors were CD8* (2 donors and 1 donor, respectively), whereas gB-
specific CTLs were CD4* (1 donor). These data may help to design a cellular immunity-based 
vaccine effective against HCMV diseases. 
Human cytomegalovirus (HCMV) is a member of the her-
pesvirus family and infection is widespread in the population. 
Although primary HCMV infection is often asymptomatic, in-
fection or reactivation in the immunocompromised host is as-
sociated with significant morbidity and mortality. In allogeneic 
bone marrow transplant recipients, HCMV infection is the prin-
cipal cause of death [1, 2]. HCMV is also the most common 
congenital or intrauterine viral infection, with an incidence be-
tween 0.2% and 2% of live births [3]. Studies in immunosup-
pressed humans have pointed to the importance of the cellular 
immune response, particularly CTLs, for controlling HCMV 
disease [4, S], and recovery of HCMV-speciiic CTL responses 
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in bone marrow and renal transplant recipients correlates di-
rectly with protection from CMV disease [6-9]. Thus, an ef-
fective HCMV vaccine will probably need to induce a specific 
CTL response. 
Studies to identify which HCMV antigens might be impor-
tant for immunity have shown that the lower matrix protein 
pp65 is the immunodominant target for HCMV-specific CTLs 
[8, 10-13]. Indeed, high pp65-specific CTL precursor frequen-
cies were shown in seropositive donoTS [12, 13]. Epitope speci-
ficity of pp65-specific CTLs and the presenting HLA alleles 
were also identified in some donors [11, 12, 14], HCMV IE1-, 
pplSO-, gB-, and/or gH-specific CTLs have also been detected 
in studies, but the data are scarce, and the prevalence of protein-
specific CTLs remains controversial [8, 12, 13, 15-20]. To our 
knowledge, the only study to examine CTL responses specific 
to pp28, which is a potent inducer of antibody production [21], 
reported the absence of these CTLs in all 4 seropositive donors 
tested [13]. At least some of the conflicting results might rest 
in the haplotype differences that affect antigen presentation in 
different racial groups and in the dominance of CTL epitope 
variations in HCMV strains in one geographical area but not 
in another. 
In the present study, we compared the prevalence of IE1-
exon4-, pp65-, ppl50-, gB- and pp28-specific CTLs in a ran-
domly selected population of 34 donors, representing a large 
panel of naturally seropositive, racially and geographically di-
vergent, HLA-typed donors. We were especially interested in 
the nonstructural IEl-exon4 protein, which is abundantly ex-
pressed very early after infection (earlier than pp65) and con-
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Class I Class II CTL activity5 
Race A B DR DQ pp65 !EI-exon4 gB pplSO pp28 
Seronegative 
H-26 W < 1 : 8 1 ,3 7, 8 _ _ _ _ _ 
H-62 W < 1 : 8 24/9, 25/10 51/5, 37 - - - - -
H-61 B < 1 : 8 26/10, 31/19 13, 35 - - - - -
H-40 B < 1 : 8 NT - - - - -
H-27 B < 1 : 8 1, 17 8 - - - - -
K W < 1 : 8 2 8, 27 - - - - -
PVL W <1 :8 3, 10/26 7 - - - - NT 
GG W < 1 : 8 2, 3 7, 13 2/15, 10 1 - - - - NT 
Moderately seropositive 
H-6226 W 1 :12 3,9/24 12, 18 + _ _ _ 
KL W 1 :32 2, 11 8, 18 + - NT NT NT 
H-626S W 1 :64 NT + + - - -
H-34 B 1:64 24/9, 11 7, 62/15 + - - - -
H-22 W 1 :64 3, 24 7, 8 3, 15 2, 6 + + - - -
MA W 1:64 9/24, 19/32 15/62, 27 2/16,4 1, 3 + - - NT -
MBM W 1 :64 3, 19/29 7, 12/44 + + - - NT 
TK W 1:64 3, 19/29 12/44, 14 + + + + NT 
BJ W 1 :96 1, 2 8, 17/57 + + - - NT 
BK W 1 :96 2 35, 40/60 4 + + - + -
Highly seropositive 
H-23 B 1:128 NT + + NT _ _ 
H-12 B 1:128 1, 33 60,65 1, 13 5 ,6 - + - - -
H-33 B 1:128 30, 74 14, 70 11, 13 2 , 6 + + + - -
H-P A 1 : 128 NT + NT NT NT NT 
CK W 1 : 128 2, 10/25 5/51, 18 5/11, 6/14 + + - - -
MT A 1 : 128 9/24, 19/31 5/51, 40/61 9, 6/14 + + + + -
NJ W 1 : 128 10/25, 19/29 7, 18 1, 10 1 - + - - -
GE W 1 : 128 3, 32 8, 60 3, 7 + - + - -
H-35 B 1 :256 68 7, 70 7, 17 2, 6 + + + + -
H-36 B 1 :256 2, 3 58 4, 13 3, 5 + + + + -
BI W 1 :256 2,28 35, 53 1, 5/11 1, 3 + - - KU- -
H-48 B 1 :348 NT + + NT NT NT 
H-47 B 1 :348 NT + + NT NT NT 
H-49 B 1:512 28 51/5, 35 + + - - -
KI W 1 :512 9/24, 11 7, 18 3, 5/11 2, 3 + + - - -
DF W 1 : 512 3,28 14, 40/61 1, 5/11 + + + + -
% positive/tested 92 76 33 30 0 
NOTE. Peripheral blood mononuclear cells were restimulated in vitro with canarypox-pp65, -IEl-exon4, -pplSO, -gB, or -pp28. W, white; B, black; 
A, Asian; NT, not tested. 
* Donor's code with the initial H and nos. or H-P indicates donor in the United States; code with any other capital letters indicates donor in Hungary. 
b Positivity reflects »10% HCMV antigen-specific lysis at eflector-lo-taiget ratios «SO: I. 
tinues to be expressed throughout the replicative cycle, making 
it an attractive vaccine candidate antigen together with pp65 
for CTL induction. 
Materials and Methods 
Study population. Thirty-four healthy adults enrolled in the 
blood donor program of the Wistar Institute (Philadelphia, PA) 
and the Albert Szent-Gyorgyi University (Szeged, Hungary) were 
studied. The group was composed of 12 blacks, 1 Chinese, 1 Jap-
anese, and 20 whites (age range, 22-60 years). HCMV seroposi-
tivity was determined by microneutralization assay [22], where sera 
with a neutralizing antibody (NA) titer <12 were considered neg-
ative, with an NA titer of 1 : 12 to 1 :96 were "moderately" se-
ropositive, and with an NA titer s i : 128 were "highly" seropos-
itive. Seropositivity was confirmed by standard ELISA by use of 
purified HCMV as a coating antigen and lysates of uninfected 
MRC-S cells as a control antigen. For each serum dilution, optical 
density (OD) values obtained in control antigen-coated wells were 
subtracted from those obtained in HCMV antigen-coated wells. 
Sera with HCMV-specific OD values s0.2 than the reference nega-
tive serum, at a dilution of 1: 100, were considered positive. Pe-
ripheral blood mononuclear cells (PBMC) were typed for major 
histocompatibility complex (MHC) class I and class II antigens by 
standard complement-mediated cytotoxicity assay and by poly-
merase chain reaction (PCR) testing, which were performed by the 
Immunology and Histocompatibility Laboratory of the Hospital 
of the University of Pennsylvania, Philadelphia, and by the Blood 
Transfusion Center at the Albert Szent-Gyorgyi University. Table 
I lists the characteristics of each donor. 
Viruses. Human CMV strain Towne was propagated and ti-
tered on MRC-S cells (obtained from Coriell, Camden, NJ) in 
monolayers. HCMV stocks were stored at -70°C. 
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The pp65 gene was PCR amplified by use of genomic HCMV 
DNA as a template (Towne strain) and cloned as described else-
where [23], The IEl-exon4 gene (AD169 strain) was amplified by 
PCR from the pJD083 plasmid [24], The ppl50 and pp28 genes 
were amplified from HCMV genomic DNA (Towne strain) by PCR. 
For restimulation of CTL effector cells in vitro, canarypox re-
combinants that express individual HCMV proteins were used. The 
gB-expressing canarypox recombinant has been described else-
where [25]. pp65, ppl50, IEl-exon4, and pp28 canarypox recom-
binants were constructed by placing these genes under the control 
of a vaccinia virus promoter in a canarypox donor plasmid, from 
which a nonessential gene was specifically deleted, as described 
elsewhere [25]. 
The WR strain of vaccinia virus (Vac-WR) and Vac-WR-based 
recombinants (Vac-gB, Vac-pp65, Vac-IE 1, and Vac-pp28) that en-
code HCMV proteins were used for infection of target cells in 
cytotoxicity assays. The WR-gB recombinant (Vac-gB) was derived 
in the WR L variant vaccinia virus by use of previously described 
methods [26, 27], WR-pp65, IEl-exon4, and pp28 recombinants 
(Vac-pp65, Vac-IE I, and Vac-pp28) were derived by use of a host-
range selection system [27] that consists of WR virus deleted of the 
K1L host-range gene and an insertion plasmid that contains the 
K.1L gene and the relevant HCMV gene. Expression of inserts in 
all recombinants was confirmed by immunoprecipitation of radio-
labeled-infected cell extracts by use of specific monoclonal anti-
bodies (MAbs) and polyacrylamide gel electrophoresis analysis. 
The Vac-ppl50 construct was kindly provided by Stanley Riddell 
(Fred Hutchinson Cancer Research Center, Seattle, WA). 
Vaccinia viruses were propagated and titered on Vero cells 
(American Type Culture Collection, Rockville, MD). Canarypox 
viruses were grown and quantitated on primary chick embryo fi-
broblast cultures. Virus stocks were stored at -70°C. 
Target cell lines. Autologous B-lymphoblastoid cell lines (B-
LCL) were established from each donor by incubation of PBMC 
with supernatant from the Epstein-Barr virus (EBV)-producing 
marmoset cell line B95.8 (American Type Culture Collection). 
Transformed cell lines were grown in RPMI 1640 with 15% fetal 
calf serum (FCS) and were cryopreserved until use. 
Effector cells. PBMC were separated from freshly drawn he-
parinized venous blood by centrifugation on Ficoll-Paque (Phar-
macia, Piscataway, NJ) density gradients. Our preliminary results 
showed no difference between fresh or cryopreserved effector cells 
in their CTL activity; thus, fresh or cryopreserved PBMC were 
stimulated in vitro with autologous PBMC expressing HCMV pro-
teins in the bulk CTL assays. Stimulator cells were prepared by 
infecting PBMC with canarypox virus vectors that encode HCMV 
pp65, IEl-exon4, gB, ppl50, or pp28 at a multiplicity of infection 
(MOI) of 5. After a 1-h incubation, stimulator cells, infected sepa-
rately with the canarypox virus constructs or with control parental 
canarypox virus, were washed and mixed with responder PBMC 
ataresponder-to-stimulatorratioof5 :1. The mixture of responder 
and stimulator cells was placed in 24-well plates at 3.5 X 10' cells/ 
2 mL medium/well. The culture medium was RPMI 1640 (Medi-
atech Cellgro, Herndon, VA), supplemented with 10% FCS (Hy-
clone, Logan, UT, or Cansera Atlanta Biologicals, Norcross, GA), 
4 mM L-glutamine (Sigma, St. Louis), 60 jig/mL gentamicin 
(Sigma), and 5 pM 2-mercaptoethanol (Sigma). PBMC cultures 
were supplemented with 330 U/mL interleukin (IL)-7 (R&D Sys-
tems, Minneapolis, MN) at the start of culture, and with 20 U/mL 
IL-2 (Genzyme, Cambridge, MA) on days 4 and 8. Cell lines were 
tested for CTL activity between days 8 and 13 of culture. 
Restimulation of PBMC with HCMV-infected autologous mono-
cytes. Monocytes were separated from PBMC by plastic adher-
ence: 30 X 10' PBMC were incubated on 96-well plates for 1 h at 
37°C, nonadherent cells were aspirated, and plates were washed 3 
times with warm medium. Adherent cells were infected with HCMV 
(MOI, 2-4 plaque-forming units per cell). After a 3-h virus ad-
sorption, cells were washed with medium, and PBMC were added 
as responder cells (responder-to-stimulator ratio, 4 : 1). pp65- and 
IEl-exon4-specific lysis were tested after 8 days of in vitro restim-
ulation by use of vaccinia recombinant-infected target cells. 
Infection and labeling of target cells. Each of 5 individual 
HCMV protein-expressing vaccinia recombinants was used to in-
fect 2 X 10'-6 x 10' B-LCL (MOI, 10) for 1 h. Cells were diluted 
to I0'/1.5 mL with culture medium and were incubated an addi-
tional 16 h, washed, and labeled with 100 pCi of "Cr-NaCrO, 
(Amersham, Arlington Heights, IL) for 1 h. Labeled cells were 
washed 3 times before assay. 
Cytotoxicity assays. Cytolytic activity of antigen-driven effec-
tors that are present in bulk cultures established from PBMC was 
measured in a 4-h "Cr-release assay. Nonadherent effector cells 
were collected, washed once, and plated in triplicate round-
bottomed 96-well microtiter plates at effector-to-target ratios 
(E: T) indicated for individual experiments. Targets were autolo-
gous B-LCL or heterologous B-LCL or B-LCL matched with 
effectors in a single HLA class I allele. Chromium release was 
measured in a gamma counter (Cobra II Packard Instrument, Men-
den, CT). Percentage-specific lysis was determined as follows: 
100 X (experimental release-spontaneous release)/(maximal release-
spontaneous release). For each target, spontaneous release was de-
termined from wells containing medium only, and maximal release 
was calculated from wells containing 1% NP-40. Spontaneous re-
lease was always <30%. Effector cells were considered positive for 
CTL activity if the percentage specific lysis of test wells was s=10% 
above background lysis (cytotoxicity directed at WT-Vac-infected 
autologous target cells). Nonspecific background cytolysis was re-
duced by adding a 30-fold excess of unlabeled, WT-Vac-infected 
target cells to each well of the "Cr-release assay. 
Limiting dilution assay. Fresh effector PBMC were plated at 
different cell numbers in 30 replicate wells and were cultured with 
y-irradiated (3000 rad delivered by an MKA model 68A irradiator; 
Shepherd, Glendale, CA) autologous PBMC as feeder cells 
(6 X 10VPBMC per well) and with 4 X 103 autologous EBV-trans-
formed lymphoblasts infected with Vac-pp65 or Vac-IEl for 6-16 
h, Y irradiated (3000 rad), and ultraviolet irradiated (10 min at a 
distance of 25 cm with a germicidal lamp) as stimulator cells. After 
12-14 days, pp65- or IEl-specific CTL activity of each well was 
determined on autologous Vac-pp65- or Vac-EE 1-infected, autol-
ogous WT-Vac-infected, and HLA-mismatched Vac-pp65- or Vac-
IE1-infected target cells. CTL precursor frequency was estimated 
as the input cell number that resulted in 37% negative cultures 
against the pp65- or IEl-specific target [28]. "Cr-release in each 
well was considered significant at >3 SD above mean lysis observed 
in control wells (containing only feeder and stimulator cells). 
Determination of CTL phenotype. Bulk CTL cultures were es-
tablished from PBMC. After 8-13 days of culture in vitro, effector 
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cells were harvested, and aliquots of 3 X 10® cells were depleted of 
CD4+ lymphocytes by anti-CD4 MAb + complement (C), or of 
CD84 lymphocytes by anti-CD8 MAb + C', or of both CD4* and 
CD8+ by both antibodies + C'. Antibodies were from Caltag Lab-
oratories (Burlingame, CA) and were used at a predetermined con-
centration (16 /ig/mL). Nontoxic rabbit complement was from Ac-
curate (Westbury, NY) and was used at a final dilution of 1 ; 10. 
Effector cells were incubated with the antibodies at 4°C for 45 min. 
After washing with medium, cells were further incubated with com-
plement for 30 min at 37°C, washed, and resuspended in the prede-
pletion volume of medium so that nondepleted cells would remain 
at the original concentration, and CMV antigen-specific lysis was 
determined in a 4-h 5lCr-release assay. 
Statistical analysis. Linear regression analysis was done on 
results of limiting dilution assays (LDAs). Precursor frequency was 
determined by solving the equation of the best-fit line where the 
fraction of nonresponding wells equaled 0.37. 
Results 
CTL responses to pp65, IEl-exon4, gB, pp!50, and pp28 in 
HCMV-seropositive donors. PBMC were either separated 
from fresh heparinized blood or reconstituted after cryopres-
ervation, and effector cells were restimulated by individual 
HCMV antigen-expressing canarypox recombinants. Lytic ac-
tivity of restimulated memory CTLs was tested in antigen-spe-
cific 5lCr-release assays. The seronegative donors tested showed 
no CTL activity against the HCMV antigens. CTLs specific for 
pp65 and IEl-exon4 proteins were detected in 92% and 76% 
of the seropositive donors, respectively, whereas gB- and ppl 50-
specific CTLs were identified in 33% and 30% of the seropositive 
donors tested, respectively; no pp28-specific lysis of target cells 
was detected in any individual (table 1). The number of PBMC 
obtained from the blood of 4 donors (KL, H-P. H-47, and 
H-48) was sufficient for testing only pp65- or pp65- and IE1-
specific CTLs; therefore, we cannot exclude the presence of 
CTLs specific for CMV antigens other than pp65 and IE1. Of 
the volunteers tested for 4 or 5 different CMV antigens, 5 (TK, 
MT, H-35, H-36, DF) were positive for 4 antigens (pp65, IE1-
exon4, gB, and ppl50). As shown in figure 1, for 1 of these 
donors (H-36), the autologous target cells infected with Vac-
pp65, Vac-IEl, Vac-gB, or Vac-ppl50 showed significant lysis 
at E : T ratios of 40 : 1, whereas autologous WT-Vac-infected 
and HLA-mismatched (not shown) Vac-recombinant-infected 
target cells were not lysed, indicating that the cytotoxic response 
was MHC restricted. No CMV antigen-specific lysis of target 
cells was detected when PBMC from the same donor were re-
stimulated in vitro with parental canarypox-infected autologous 
PBMC (not shown). Two donors (BK and H-33) were positive 
for 3 antigens (pp65, IEl-exon4, and gB or ppl50); 9 donors 
showed double-CTL specificity (pp65 and gB in donor GE; 
pp65 and IEl-exon4 in donors H-6265, H-22, MBM, BJ, H-
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Figure 1. pp65-, IE1-, gB-, and ppl50-specific cytotoxic T lympho-
cyte (CTL) activity of donor H-36. Cytomegalovirus antigen-specific 
CTL activity was measured in bulk cultures. Peripheral blood mono-
nuclear cells (PBMC) were restimulated in vitro with canarypox re-
combinant-infected autologous PBMC for 11 days. Cytolytic activity 
of effectors was measured in 4-h 5lCr-release assays by use of autolo-
gous and human lymphocyte antigen-mismatched Epstein-Barr vi-
rus-transformed B lymphoblastoid cell lines as target cells. Significant 
lysis of autologous target cells infected with Vac-pp65 or Vac-IEl, Vac-
gB, or Vac-ppl50 was observed at effector-to-target ratios of 40 : 1, 
whereas autologous WT-Vac-infected target cells were not lysed. 
(H-6226, H-34, H-12, NJ, MA, and BI). Of these latter 6 do-
nors, 2 highly seropositive donors (H-12 and NJ) exhibited only 
IEl-exon4-specific CTLs; repeated testing of these donors (5 
times over a 2-year period for donor H-12; 3 times over a 1-
year period for donor NJ) consistently revealed IEl-exon4 CTL 
positivity, as well as pp65, pp 150, and gB negativity. In addition, 
the profile of CTL specificity remained stable over a 27-month 
observation time, as exemplified in figure 2 for a highly sero-
positive individual (H-35) who had specific CTLs for IE1-
exon4, pp65, gB, and ppl50 (shown only for IEl-exon4 and 
pp65). 
Strong pp65- and I El-specific CTL activity of bulk cultures 
reflects similar pp65 and IE1 CTL precursor frequencies. 
LDAs were done to determine CTL precursor frequencies with 
PBMC of 2 donors who were repeatedly positive for both pp65 
and IEl-exon4 in bulk cultures. Figure 3 shows the results 
obtained with donor KI (NA titer, 1 : 512). Both the IEl-exon4 
and pp65 antigens that were shown to be CTL targets in bulk 
assays were also detected at similarly high frequencies in LDAs, 
that is, 566/10® PBMC and 699/10® PBMC, respectively. Pre-
cursor frequencies were also similar for the 2 antigens in donor 
in 
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Figure 2. IE1-and pp65-specific cytotoxic T lymphocyte (CTL) ac-
tivity of peripheral blood mononuclear cells (PBMC) of donor H-35 
over a 27-month period. Cytomegalovirus IEl-exon4- and pp65-spe-
cific CTL were repeatedly measured in bulk cultures with PBMC from 
donor H-35. PBMC were restimulated in vitro with canarypox recom-
binant-infected autologous PBMC for 11-13 days. Cytolytic activity 
of effectors was measured in 4-h "Cr-release assays by using autologous 
and human lymphocyte antigen-mismatched Epstein-Barr vi-
rus-transformed B lymphoblastoid cell lines as targets. IEl-exon4-(D) 
and pp65- ( • ) specific lysis of target cells was observed at an effector-
to-target ratio of 50 : 1. Antigen-specific lysis was calculated by sub-
tracting percentage lysis of autologous WT-vaccinia-infected target 
cells from percentage lysis of autologous vaccinia recombinant-infected 
target cells. 
D F (NA titer, 1 : 512), for whom IEl-exon4- and pp65-specific 
CTL precursor frequencies were 78/106 PBMC and 67/10* 
PBMC, respectively. 
HCMV-infected monocytes restimulate both IEl-exon4- and 
pp65-specific memory CTLs. To test whether IEl-exon4 pre-
sented together with pp65 by the same stimulator cells can 
restimulate IEl-exon4-specific CTLs, we performed experi-
ments by using effector cells restimulated with HCMV-infected 
monocytes, that is, cells that express HCMV IE antigens at 
very low levels [29-31]. Presentation of the input pp65 to CTLs 
has also been reported [32]. PBMC from IE1- and pp65-
responder donor H-22 were restimulated for 8 days with au-
tologous monocytes infected with the Towne strain of HCMV 
(MOI, 2-4), and effector cells were tested for IEl-exon4- and 
pp65-specific CTL activity on autologous and MHC-mis-
matched Vac-recombinant-infected B-LCL cells. IEl-exon4-
and pp65-specific CTL activity was detected (table 2), indicating 
that both pp65 and IEl-exon4 proteins in monocytes can re-
stimulate CTL memory cells. Effector cells of the same donor 
restimulated with canarypox-pp65 or canarypox-IEl lysed cells 
coinfected with Vac-IEl and Vac-pp65, indicating that expres-
sion of both antigens did not interfere with pp65- or IE 1 -specific 
CTL activity (table 2). 
HLA restriction of effector populations. It is generally ac-
cepted that activated T cells recognize antigens on the surface 
of antigen-presenting cells in the context of M H C molecules. 
To determine the M H C restriction of the stimulated CTL ef-
fectors, cells were tested against a panel of partially HLA-
matched and HLA-mismatched targets that express CMV pro-
teins. Figure 4 shows the results obtained from donor H-36, 
whose cells consistently generated high levels of CTL against 
pp65, IEl-exon4, and ppl50. The pp65-specific CTLs of this 
donor were directed by the HLA-A2 molecule (figure 4A), be-
cause only target cells sharing the A2 allele were lysed. IE1-
exon4 was also presented by HLA-A2, because only partially 
matched target cells sharing HLA-A2 were significantly lysed 
(figure 4B). The ppl50 antigen was presented through the 
A3 allele (figure AC). Analysis of effectors from donor H-36 
on partially HLA-matched target cells of donors sharing 
alleles other than HLA-A2 or HLA-A3 revealed no pp65-, IE1-
exon4-, or ppl50-specific lysis of target cells (not shown). The 
percentage-specific lysis of class I HLA-matched targets was 
similar to the cytotoxic response against the autologous targets, 
which suggests a predominance of activated CD8+ cells specific 
for epitopes presented by the particular HLA allele. Further 
analysis of selected CTL responders to identify other restricting 
alleles for pp65-, IEl-exon4-, and ppl50-specific CTLs indi-
Figure 3. pp65-and IE 1-specific cytotoxic T lymphocyte (CTL) pre-
cursor frequencies in donor KI. pp65- and IEl-specific CTL precursor 
frequencies were determined in limiting dilution assays (see Materials 
and Methods). Effector peripheral blood mononuclear cells (PBMC) 
were plated at different cell numbers per well and cultured with y-
irradiated autologous PBMC as feeder cells and autologous Epstein-
Barr virus-transformed lymphoblasts infected with Vac-pp65 or Vac-
IEl as stimulator cells. After 12-14 days, pp65- or IEl-specific CTL 
activity in each well was determined on autologous Vac-pp65-infected 
or Vac-IEl-infected autologous WT-Vac-infected and human lym-
phocyte antigen-mismatched Vac-recombinant-infected target cells. 
CTL precursor frequency was estimated as the input cell number that 
resulted in 37% negative cultures against the pp65- or IEl-specific tar-
get. A, Vac-IEl-infected target cells; Vac-pp65-infected target cells. 
1 7 11 14 27 
Time points of testing (months) 
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Table 2. Human cytomegalovirus (HCMV) (Towne strain)-infcctcd autologous monocytes (donor H-22) stimulate both IE1- and 
pp65-specific cytotoxic T lymphocyte (CTL). 
Lysis (%) of autologous B-LCL Lysis (%) of mismatched B-LCL 
targets infected with* targets infected with 
Effectors restimulated with Vac-pp65 Vac-IEl Vac-IEl + Vac-pp65 Wt-Vac Vac-pp65 Vac-IEI Vac-IEl + Vac-pp65 
Canaiypox-pp65-infected PBMC 39 ± 3.2 NT 58 ± 3.9 3 ± 1.3 5 + 1 . 6 NT 9.8 ± 2.1 
Canaiypox-IEl-infected PBMC NT 65 + 2.8 68 + 4.5 6 ± 1.5 NT 4.3 ± .8 10.9 ± 2.6 
HCMV-infected monocytes 40 + 2.8 45 ± 2.4 65.9 + 6.5 17 + 2.3 18 ± 1.6 11 + 1.2 21 + 2.5 
NOTE. Percentage lysis (±SD) at effector-to-target ratios of 50 :1. B-LCL, B-lymphoblastoid cell line; PBMC, peripheral blood mononuclear 
cells; NT, not tested. 
* Target cells were coinfected with Vac-pp65 and Vac-IEI or with Vac-pp65 combined with WT-Vac or Vac-IEI combined with WT-Vac or with 
WT-Vac only (final multiplicity of infection, 10). 
cated that pp65 was presented by Al, A2, A28, A68, B7, and 
B12/44 alleles; IEl-exon4 was presented by class I HLA alleles 
Al , A2, A3, B7, B8, B18, and B70; and ppl50 was presented 
by the A3 and B14 alleles (table 3). Analysis of the restricting 
allele for gB-specific effector cells identified the class II antigens 
DR 7, DR15, and DQ 2 or 6 (not shown). 
Phenotype of effector cells. The phenotypic characteristics 
of the pp65-, IEl-exon4-, ppl50-, and gB-specific effector cells 
were examined after depletion of CD4+ and/or CD8+ lympho-
cytes by use of the respective MAbs plus complement. The 
subpopulations of the donor effector cells were tested against 
autologous and MHC-mismatched target cells that express 
HCMV antigens (figure 5). Depletion of both CD4+ and CD8+ 
cells completely abrogated killing by the pp65-specific effector 
cells of donor H-35 (not shown), whereas partial inhibition of 
specific lysis was observed when either CD8+ or CD4+ cells 
were depleted (21% and 32% inhibition, respectively; figure 5A). 
The depletion experiment was repeated 3 times with PBMC of 
donor H-35 at different time points with similar results, indi-
cating the consistent presence of both CD4+ and CD8+ pp65 
effector cells in this donor. To exclude the possibility that the 
long restimulation in vitro and the addition of IL7 and IL2 
favored the growth of CD4+ effector cells, we tested pp65-
specific effector cells after a short (6 days) restimulation in vitro 
without cytokines; phenotypic analysis again revealed mixed 
effector populations of CD4+ and CDS* pp65-specific CTLs 
(data not shown). In contrast, phenotypic analysis of pp65-
specific effector cells from another donor (H-36) showed that 
effector cells were CD8+, whereas the CD4+ population showed 
no significant pp65 CTL activity (figure 5fl). The CTL response 
was exerted mainly through CD8+ cells specific for pp65 in an 
additional donor (H-33), ppl50 (donor H-36), and IEl-exon4 
(donors H-35 and H-36), because killing of specific target cells 
after depletion of CD4+ cells was similar to the killing of non-
depleted cells (table 4). gB-specific effector cells, however, lost 
their activity after CD4+ depletion, but not after CD8+ deple-
tion (donor H-35; table 4). The CD8+ phenotype of IEl-exon4 
and ppl50 CTLs and the CD4+ phenotype of gB-specific CTLs 
are consistent with the finding that IEl-exon4 and ppl50 are 
presented by class I alleles, whereas gB is presented by class II 
alleles. 
Discussion 
In the present study, we analyzed the HCMV-specific CTL 
responses of naturally seropositive healthy adult blood donors, 
comprising different racial groups in different geographic areas 
with a variety of HLA haplotypes, to determine the prevalence 
of CTLs specific to various HCMV proteins. We used in vitro 
cytotoxicity assays, which, to date, remain the best way to 
examine antigen-stimulated T cells that function as CTLs. All 
26 HCMV-seropositive donors mounted specific CTL responses 
against at least 1 of the HCMV proteins, pp65 or IEl-exon4. 
In addition, PBMC of some of the seropositive donors revealed 
CTLs specific to the ppl50 and/or gB proteins. However, no 
pp28-specific CTLs were evidenced, indicating that this protein 
is not among the immunodominant CTL targets induced by 
natural HCMV infection. In the experiments described earlier, 
no obvious differences were observed among racial groups of 
different geographic areas in the cytotoxic pattern of response 
to the specific antigens. However, CTL responses did correlate 
with HCMV NA levels, that is, donors with HCMV NA titers 
3=1 :128 were more likely to have CTLs positive for multiple 
CMV antigens, whereas all but 2 of the moderately seropositive 
donors (HCMV NA titers s i : 96) had CTLs specific for only 
pp65 or for pp65 and IEl-exon4 (table 1), indicating the im-
munodominance of these 2 antigens. These results also suggest 
that high NA titers are indicative of a broad spectrum of CTL 
targets in seropositive donors. 
Previous reports have implicated the most abundant protein 
constituents of the HCMV virion, including the major matrix 
proteins pp65 and ppl50, in CTL induction [32], and pp65 was 
identified as the immunodominant CTL target [8, 11]. CTLs 
have also been shown to recognize exogenously introduced 
pp65, suggesting that the pp65-specific CTL response acts on 
virus-infected cells soon after infection and that recognition and 
cell lysis occur before the onset of viral replication and virion 
assembly [32]. In a study to determine pp65-specific CTL pre-
cursor frequencies, Wills et al. [12] found that all 7 donors tested 
had CTLs specific for the pp65 protein, and a very high pro-
portion of all HCMV-specific CTLs in any given donor was 
specific for this single virus protein. In our study, 24 of the 26 
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Figure 4. Human lymphocyte antigen (HLA)-class I restriction of 
pp65- (A), IE1- (B), and ppl50- (C) specific cytotoxic T lymphocytes 
(CTLs) of donor H-36. Peripheral blood mononuclear cells (PBMC) 
were restimulated in vitro, and effector cells were tested against a panel 
of partially HLA-matched and HLA-mismatchcd targets expressing 
individual cytomegalovirus proteins. Percentage specific lysis of target 
cells is shown at an effector-to-target ratio of 50 : 1. A. pp65-Specific 
effector cells of donor H-36 tested against partially HLA-matched tar-
gets of donor MF and donor K sharing HLA-A2 alleles with donor 
H-36, and HLA-mismatched targets of donor KI. B, IEl-specific ef-
fector cells of donor H-36 tested against partially HLA-matched targets 
of donor MF and donor BI sharing HLA-A2 alleles with donor H-36, 
and HLA-mismatched targets of donor KI. C, ppl50-Specific effector 
cells of donor H-36 tested against partially HLA-matched targets of 
donor GG sharing HLA-A2 and A3 alleles with donor H-36, partially 
HLA-matched targets of donor GE sharing HLA-A3 alleles, partially 
HLA-matched targets of donor MF sharing HLA-A2 alleles, and HLA-
mismatched targets of donor MA. 
tested seropositive donors responded with pp65-specific CTLs 
on in vitro pp65-specific stimulation. 
The ubiquity of pp65-specific CTLs in natural H C M V in-
fection suggests that pp65 epitopes can be presented by a wide 
variety of HLA alleles. Indeed, HLA-B35 [11], A2, B7, B8, and 
B35 [12] were identified as pp65 epitope-presenting alleles. In 
our panel, by using partially HLA-matched target cells, we 
confirmed and identified alleles A l , A2, A28, A68, B7, and 
B12/44 presenting pp65. 
The pp65-specific effector cells of donor H-35 comprised a 
mixed population of CD4+ and CD8 + cells, in contrast to the 
exclusively CD8 + pp65-specific CTLs reported in the literature. 
The discrepancy might reflect our use of EBV-transformed B 
lymphoblastoid cells that express both M H C class I and II 
antigens, in contrast to the use by other investigators of mainly 
fibroblast target cells that express only M H C class I alleles, 
which do not enable detection of CD4+ effector cells. We also 
found donor variability in the phenotype of pp65-specific CTLs, 
because donors H-36 and H-33 showed only CD8+ effector 
cells. The percentage of pp65-specific CTL responders with both 
CD4 + and CD8 + effector cells is unclear. Although the role of 
CD8 + CTLs in prevention of H C M V disease is well known, 
the significance of CD4 + effector cells remains unclear. CD4 + 
CTLs may be effective against latently infected cells with ex-
pressed HLA-class II alleles. 
Studies in the murine CMV (MCMV) model have shown the 
important contribution of IE1 proteins to M C M V immunity 
and protection against the disease, and an antigenic peptide 
has been mapped to IE1 [33-36], In 1 study, a high proportion 
of HCMV-specific CTLs recognized IE1 in 2 donors tested [15], 
IEl-specific CTLs were also shown in bulk culture assays [8, 
19, 32], but only in a few donors, and IE1 CTLs were less 
dominant than pp65 CTLs. Split-well LDA revealed CTLs di-
rected to the IE1 protein in 3 of 5 donors tested, but with 
significantly lower precursor frequency than that of pp65 CTLs 
[12]. In a recent study, the frequencies of CD8 + T cells that 
were directed against IE1 were similar to those directed against 
pp65 in donors tested by a flow cytometric assay [20]. In our 
study, IEl-exon4-specific CTLs were nearly as prevalent as 
pp65-specific CTLs, with similar precursor frequencies. More-
over, this response was maintained over a prolonged period of 
Table 3. Human lymphocyte antigen (HLA) alleles presenting hu-
man cytomegalovirus (HCMV) pp65, IEl-exon4, and ppl50. 
Donor 
HLA class I alleles presenting HCMV antigens 
pp65 IEl-exon4 ppl50 
H-22 B7 B8 
H-33 B70 
H-35 A68 B7 
H-36 A2 A2 A3 
BJ Al , A2 Al 
TK B12/44 A3 BI4 





NOTE. Effector cells were tested against a panel of partially HLA-matched 
and HLA-mismatched targets expressing cytomegalovirus proteins. 
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time, as shown in 10 donors, specifically for donor H-35 who 
showed IEl-exon4- and pp65-specific lysis of target cells at 
multiple time points during a 27-month period. This result sug-
gests that detectability of the IEl-exon4speci f ic CTLs is not 
a random phenomenon due to a HCMV-reactivation episode 
or other reasons in some donors, but instead, that IE1-
exon4-specific memory CTLs are constantly present in the cir-
culation at detectable levels. The broad spectrum of HLA alleles 
that present IEl-exon4 (Al , A2, A3, B7, B8, B18, and B70) 
also supports the high prevalence of IEl-exon4-specific CTLs. 
Note that 2 donors in our highly seropositive study group had 
IEl-exon4-specific CTLs but not pp65-, ppl50-, or gB-specific 
effector cells. It is possible that restimulation of individual 
HCMV-specific CTLs by use of canarypox recombinants en-
hances the detection of IEl-exon4-specific CTLs, compared 
with the use of vaccinia-IE 1 recombinants or CMV-infected 
fibroblasts for restimulation. Gilbert et al. [18] reported that 
pp65 diminishes the IEl-specific CTL activity exerted by IE1-
specific CTL clones through a selective abrogation of IE 1-pep-
tide presentation by pp65 and its associated kinase activity. In 
our study, IEl-specific effector cells readily lysed target cells 
coinfected with Vac-pp65 and Vac-IE 1. We did not observe this 
inhibition in bulk CTL assays where HCMV-infected autolo-
gous monocytes were used to restimulate memory CTLs, a 
situation perhaps more relevant to the in vivo milieu. During 
HCMV reactivation, IE1 appears earlier than pp65, so that 
IEl-exon4-specific CTLs may be more effective than pp65-
specific CTLs for preventing reactivation. It is not clear why 
donors H-12 and NJ were negative for pp65-specific CTLs, 
although both donors have HLA class I alleles (Al and B7, 
respectively) that presented pp65 CTL epitopes in other donors. 
Perhaps HLA Al and B7 subtypes not identified in this study 
are involved. 
Although 2 of the recently identified 10 CTL epitopes were 
outside exon4 [20], inclusion of the full-length IE1 protein in 
an HCMV vaccine may be problematic because of the known 
transactivating ability of the HCMV-IE1 proteins [37]. Im-
munofluorescence analysis to localize the IE1 protein expressed 
in several forms by a panel of poxvirus recombinants revealed 
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Figure 5. Phenotype of pp65 cytotoxic T lymphocyte (CTL) of do-
nors H-35 (A) and H-36 (B). Bulk CTL cultures were established from 
fresh peripheral blood mononuclear cells. After 11- to 13-day culture 
in vitro, effector cells were harvested, and aliquots of 3 X 106 cells were 
depleted of CD4* lymphocytes by anti-CD4 monoclonal antibody 
(MAb) + C, or of CD8* lymphocytes by anti-CD8 MAb + C. Per-
centage specific lysis is shown at an effector-to-target ratio of 30 : 1. 
the full-length IE1 gene product predominantly in the nucleus 
with some cytoplasmic staining, whereas the exon4 protein was 
found only in the cytoplasm (authors ' unpublished observa-
tions). Recent data show that IEl-exons2 and 3, but not exon4, 
are required for binding to pl07, a member of a family of cell-
Table 4. 
donors. 
Phenotype of pp65-, IE-, ppl50-, and gB-specific cytotoxic T lymphocyte (CTL) of selected 
Specific lysis (%) of target cells by effector cells treated with8 
Donor specificity C Anti-CD4 Anti-CD4 + C Anti-CD8 Anti-CD8 + C 
H-35 IE1 e x o n 4 " 38 ± 2.3 41 ± 2.6 46 ± 3.1 47 ± 3.4 36 ± 2.9 10 ± 1.9 
H-36 IE1 exon4* 18 + 1.5 N D 17 ± 1.1 19 ± 2.3 21 ± 2.6 1 ± .8 
H-36 p p l 5 0 " 33 ± 3.2 35 ± 2.5 39 ± 1.9 54 + 4.3 37 ± 2.1 11 ± 1.6 
H-33 p p 6 5 " 52 + 6.6 N D ND 60 ± 5.4 N D 13 ± 1.8 
H-35 g B " 18 + 2.4 22 ± 1.8 18 ± 1.3 2 ± .8 20 ± 2.2 25 ± 1.9 
NOTE. Human cytomegalovirus (HCMV) antigen-specific lysis ( ± S D ) is shown at effector-to-target ratios 
( E : T) of 20 : 1 (*) and of 30 : 1 (»*). ND, not done. 
8 Peripheral blood mononuclear cells (PBMC) were restimulated in vitro with ALVAC-recombinant-infected au-
tologous PBMC, after 8-12 day in vitro culture effector cells were depleted of CD4+ and CD8+ lymphocytes, and 
their IEl-exon4-, pp65-, ppl50-, or gB-specific CTL activity tested as described in Materials and Methods. 
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cycle inhibitors [38], and that deletion of exon3 eliminates trans-
activation by IE1 [39]. Canarypox recombinants that express 
only exon4 or most of exon3 and exon4 were equivalent in their 
ability to stimulate IE1 -specific CTLs from several HCMV se-
ropositive donors (authors' unpublished observations). Taken 
together, these observations suggest that expression of the 
exon4 segment of IE1 eliminates the cellular activation potential 
associated with IE1 while maintaining most of the CTL 
epitopes. 
gB-specific CTLs were shown in a considerable percentage 
(33%) of seropositive donors, consistent with previous reports 
[15, 40]. Hopkins et al. [19] showed gB-specific CTLs in 4 of 
7 donors and found that these CTLs were MHC class I I -
restricted CD4+ lymphocytes. CD8+ MHC class I-restricted 
gB-specific CTLs have also been described [8, 32]. In donor H-
35, showing gB-specific CTLs in our study, the effector cells 
were found to be CD4+ lymphocytes, and MHC-class II mole-
cules were identified as the restricting alleles. Together, the ev-
idence indicates that gB-specific CTLs characterized as CD8+ 
or CD4+ cells are induced by natural HCMV infection and can 
be shown in in vitro CTL assays. Thus, gB protein can serve 
as an important inducer of NAs in the majority of the popu-
lation and as a target of CTL responses in about one-third of 
the population. 
The pplSO protein has also been reported as an immuno-
dominant target for HCMV-specific CTLs [8,11,13], Our stud-
ies indicated that ppl50 was less dominant than pp65 or IE1-
exon4 protein, that is, ppl50-specific CTLs were detected in 
only 30% of seropositive donors, with A3 and B14 alleles pre-
senting ppl50 to CD8+ cells. 
The lack of detectable pp28-specific CTLs in our study might 
rest in the absence of donors with haplotypes presenting pp28 
CTL alleles. Although vaccinia- and canarypox-HCMV recom-
binants that express pp65, ppl50, IEl-exon4, and gB were con-
structed similarly, we cannot exclude the possibility that pro-
cessing and presentation of pp28 was not authentic in cells 
infected with vaccinia- or canarypox-pp28, resulting in pp28-
specific negativity in the CTL assays. 
Our study shows that (1) regardless of racial and geograph-
ical distribution of the population, IEl-exon4 protein is nearly 
as prevalent a CTL target as is pp65; (2) gB- and ppl 50-specific 
CTLs are detectable in about one-third of the seropositive do-
nors; and (3) pp28 is not an immunodominant CTL target. 
These results, as well as our findings on the phenotype of 
HCMV protein-specific CTLs and the presenting alleles, may 
provide some insight into the immunology of HCMV infection 
and may contribute to the design of a vaccine that elicits ef-
fective CTL responses against both acutely infected cells, which 
express nonstructural IE1 and structural antigens, and latently 
infected cells during reactivation, in which nonstructural an-
tigens are expressed earlier than structural proteins. 
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A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B 
Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne) 
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To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) ex-
pressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated 
CMV vaccine (Towne). Three doses of 10" TCH)90 of ALVAC-CMV(gB) induced very low 
neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether 
ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly re-
ceived either 10s'8 TCH>50 of ALVAC-CMV(gB) or 10" TCID50 of ALVAC-RG, expressing 
the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 
10" pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neu-
tralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and 
persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. 
These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a 
combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies. 
A live, attenuated cytomegalovirus (CMV) vaccine (Towne) 
has been evaluated in normal volunteers and in renal transplant 
patients [1, 2], Towne was immunogenic, reduced the severity 
and incidence of CMV-associated disease among seronegative 
recipients of seropositive kidneys [2], and did not reactivate in 
these patients [3]. Although Towne protected against low doses 
of an unattenuated strain of CMV in an artificial challenge 
study, at a reduced dose that induced low neutralizing titers, 
Towne failed to prevent child-to-mother transmission of CMV, 
whereas naturally seropositive women were protected [4, 5]. 
Avipox viruses, such as canarypox (ALVAC), are candidate 
vaccine vectors because the ALVAC genome accepts large 
amounts of foreign DNA and will direct the synthesis of mul-
tiple foreign proteins. ALVAC does not produce progeny in 
mammalian cells or nonavian species. It does, however, elicit 
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protective immune responses in nonavian species [6, 7]. More-
over, live ALVAC does not produce disease in healthy subjects 
or immunosuppressed patients [8]. 
To develop a vaccine strategy for obtaining high levels of 
neutralizing antibodies against CMV in humans, we evaluated 
the safety and immunogenicity of an ALVAC recombinant ex-
pressing the major CMV envelope glycoprotein (gB) given alone 
or in combination with Towne vaccine. 
Materials and Methods 
Trial A. The first study, conducted at the Hôpital de l'Archet 
(Nice, France), enrolled 20 healthy male and female volunteers (10 
seronegative and 10 seropositive), 18-50 years old. By use of an 
open-label format, each volunteer received three doses of ALVAC-
CMV(gB) vaccine (batch S2723), each dose containing 10«9 TCID» 
of canarypox. The second and third doses were administered 28 
and 180 days after the initial dose. Volunteers were monitored for 
30 min after each injection and then were examined by a study 
physician on days I, 2, 3, and 7 after each injection, to monitor 
local and systemic reactions. Blood samples were taken on days 
-14, 0, 2, 7, 28, 30, 35, 56, 180, 182, 187, and 208. Samples of 
saliva and urine were taken on days -14, 0, 7, 28, 35, 56, 180, 
187, and 208. 
D-ial B. The second vaccine study, conducted in Richmond, 
VA, enrolled 20 healthy CMV-seronegative male and female vol-
unteers, 20-43 years old. By use of a double-blind format, vol-
unteers were randomized to receive either an initial injection of 
10" TCIDjo ALVAC-CMV(gB) (batch S3145) and a second, similar 
injection 1 month later or a first injection of 10" TCID» of AL-
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VAC-RG (batch S3106) and a second, similar injection 1 month 
later. Both groups received a single dose of 10" pfu of Towne 
vaccine 90 days after the initial dose of ALVAC vaccine. Samples 
of blood, urine, and saliva were collected for each subject on days 
30,60, 90,97, 114,120,180,270, and 360 after immunization. Two 
subjects, both assigned to the ALVAC-RG group, withdrew from 
the study prior to completion for reasons unrelated to study par-
ticipation. The data on their immune responses were not included. 
All Richmond subjects were monitored for vaccine-associated 
illness: (1) the subjects maintained a temperature chart for 2 weeks 
after vaccination; (2) the subjects were contacted by phone by a 
research nurse 3 days after each vaccine administration; (3) the 
subjects self-reported (via a diary card) any acute local or systemic 
reaction, including any pain, swelling, or erythema; and (4) at fol-
low-up visits, an interval history was obtained. 
Vaccines. The Towne vaccine (lot C-107) was prepared by Pro-
gram Resources (Rockville, MD). The seed strain was Towne pool, 
passage 131. The vaccine pool was prepared in cultures of MRC-
5 cells. A harvest pool was clarified by centrifugation at 1200 g for 
20 min and then aliquoted into 3 mL vials for lyophilization. The 
vials were stored at 2°C-8°C for 19 days, then at -20°C, and finally 
at -70°C. 
The mean infectivity titer was 10" pfu/lyophilized vial (0.5 mL), 
which constituted a single dose. Before use, the vaccine was re-
constituted in sterile water, maintained on ice, and administered 
subcutaneously in the deltoid region within 1 h of reconstitution. 
ALVAC was developed by Virogenetics (Troy, NY) and manu-
factured by Pasteur Mérieux Connaught (Marcy l'Étoile, France). 
ALVAC-CMV(gB), laboratory designation vCP139, is a recombi-
nant canarypox virus encoding the full-length gB gene of the Towne 
strain of CMV, whereas ALVAC-RG, laboratory designation 
vCP65, expresses the glycoprotein G gene of the ERA strain rabies 
virus. Both vaccines were prepared in primary chick embryo fi-
broblasts derived from specific pathogen-free eggs. Clarified lysates 
of infected cells were diluted in serum-free virus stabilizer and lyo-
philized. Titrations were performed on QT35 cells by the endpoint 
dilution method. Batches S3106 (ALVAC-RG), S2723 (ALVAC-
CMVfeB]), and S3145 (ALVAC-CMV[gB]), with titers of 10s *, 10", 
and 10" TCIDjo per dose, respectively, were used in the trials. Both 
recombinants were tested in small animals [9], and ALVAC-RG 
was previously tested in humans and has an extended record of 
safety [8]. The lyophilized preparations were reconstituted in 1.0 
mL of sterile water. The vaccines were given by injection (1.0 mL) 
into the deltoid muscle within 15 min of reconstitution. 
Laboratory methods. Seronegativity prior to enrollment was 
established by measuring IgG to CMV by use of an enzyme im-
munoassay, as described elsewhere [10]. Neutralizing antibodies 
were determined by a standard reduction assay [11]. A titer was 
defined as the reciprocal of the highest dilution of serum that fully 
inhibited viral cytopathic effect (CPE), compared with 100% CPE 
in control wells. 
IgG antibodies to gB in sera were measured by an enzyme im-
munoassay, as described elsewhere [12]. Antibodies to the cana-
rypox vector (ALVAC) were measured at Pasteur Mérieux Con-
naught by use of an enzyme immunoassay with plates coated with 
purified ALVAC-CPpp virus (ALVAC vector without insert). 
CMV-specific lymphocyte responses were determined as de-
scribed elsewhere [13]. Lymphocyte proliferation responses were 
expressed as stimulation indices, defined as the ratio of counts per 
minute (CPM) in CMV antigen-stimulated cultures to CPM in 
control antigen-stimulated cultures. To measure lymphocyte re-
sponses to CMV(gB), purified gB was used at 3.0 pg/mL. 
Urine and saliva samples of trial B were cultured, before and 
after concentration, in duplicate on MRC-5 fibroblasts, and white 
blood cells were prepared from each plasma sample and cultured 
for CMV. 
Statistical analysis. Groups were compared with repeated-mea-
sures analysis of variance assessing group versus time interactions. 
For antibody data, the log of the reciprocal titers was analyzed. 
A neutralizing titer of 1 was attributed to sera showing incomplete 
neutralization at the lowest dilution tested (1 :4 or 1 : 8). 
Results 
Safety and reactogenicity. No severe adverse reactions oc-
curred in either trial. Local and systemic reactions were mild, 
consisting mainly of pain and redness at the injection site. All 
three immunizations were well tolerated in all recipients. Se-
ropositive and seronegative subjects had the same frequency of 
local and systemic reactions. 
In trial B, for the first two doses, reactogenicity was mild, 
and both ALVAC-CMV(gB) and ALVAC-RG were well tol-
erated. Towne vaccine (dose 3) induced a frequency of local or 
systemic reactions similar to that for the ALVAC vaccines. No 
subject had Towne vaccine virus recovered in urine, saliva, or 
blood. 
Immunogenicity. In trial A, three doses of ALVAC-
CMV(gB) administered on days 0,28, and 180 failed to increase 
neutralizing titers among the 10 seropositive subjects or to in-
duce significant neutralizing titers among the 10 seronegative 
subjects. No intercurrent CMV infections occurred. 
We performed a second trial to determine whether ALVAC-
CMV(gB), while not eliciting detectable levels of antibodies 
itself, could prime an immune response to gB. Two groups were 
randomly assigned to receive two injections, 1 month apart, of 
either ALVAC-CMV(gB) (10 volunteers) or ALVAC-RG (8 vol-
unteers). Both groups received a single injection of Towne vac-
cine 90 days after the first ALVAC injection. 
After two injections of ALVAC and before booster with 
Towne on day 90, a low increase (P< .057) in anti-gB ELISA 
titers was observed in ALVAC-CMV(gB) recipients, whereas no 
change was observed in the neutralizing titers. No change in 
either anti-gB ELISA or CMV-specific neutralizing antibodies 
was observed in ALVAC-RG recipients (table 1). 
After administration of the Towne vaccine on day 90, the 
ALVAC-CMV(gB) group developed significantly higher mean 
ELISA titers against CMV gB [F(9144) = 4.03, Fc.OOOl] and 
mean neutralizing titers [F(9142) = 8.9, P < .0001 ] than the AL-
VAC-RG group. The kinetics of the responses of the two groups 
were also different: in the ALVAC-CMV(gB) group, the ELISA 
anti-gB response increased as early as day 7 and the neutralizing 
response as early as day 14 after Towne booster, whereas 28 
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Table 1. ELISA antibody responses to cytomegalovirus gB and neutralizing titers in trial B. 
IgG to gB (reciprocal titers) Neutralizing titers (reciprocal titers) 
ALVAC-gB ALVAC-RG ALVAC-gB ALVAC-RG 
Days after (n=IO) (n=8) (»=10) (n=8) 
first dose* mean (range) mean (range) Ratio" mean (range) mean (range) Ratio1 
0 115 (100-400) 119(100-400) 1.0 1.0(1-1) 1.0(1-1) 1.0 
30 163 (100-1600) 100 (100-100) 1.6 1.1 (1-3) 1.0(1-1) 1.1 
60 303 (100-1600)° 119(100-400) 2.5 1.6 (1-10) 1.0(1-1) 1.6 
90 303 (100-1600)° 100 (100-100)" 3.0 1.2 (1-8) 1.0(1-1) 1.2 
97 566 (100-1600) 141 (100-1600)" 4.0 1.5 (1-8) 1.0(1-1) 1.5 
104 3676 (100-6400) 141 (100-1600)" 26.0 10 (1-25) 1.1 (1-2)" 9.1 
120 38,802 (100-409,600) 1345 (100-6400)" 28.8 207 (39-670) 23 (15-39)" 9.1 
180 89,144 (25,600-409,600) 15,222 (100-102,400)" 5.9 266 (105-839) 89 (56-128)" 3.0 
270 58,813 (25,600-409,600) 10,764 (100-102,400)" 5.5 109 (46-419) 36 (2-128)" 3.0 
360 22,286 (6400-102,400) 4526 (100-25,600)" 4.9 96 (26-364) 33 (2-257)" 2.9 
NOTE. ALVAC, canarypox virus; gB, glycoprotein. 
* The ALVAC vaccines were given at days 0 and 30 and Towne at day 90. 
b At each timepoint, ratios are the values of the ALVAC-gB group divided by the ALVAC-RG group. 
c A value of I was used in the calculation of the geometric means for neutralizing titers < 1 : 4 (or in some cases <1 : 
8) and gB titers <1 : 100. 
d Significantly lower (P<.0S) than the values for the ALVAC-gB group at the corresponding time. 
days were needed to obtain a response, measured by either 
ELISA or neutralizing titers, in the ALVAC-RG recipients. The 
titers also persisted at significantly higher levels up to day 360 
in the ALVAC-CMV(gB) group, compared with the ALVAC-
RG group (table 2). An IgG antibody response to the cana-
rypox vector was induced in all vaccinees in both trials (data 
not shown). 
Priming with ALVAC-CMV(gB) allowed the Towne vaccine 
to induce peak ELISA titers to gB and CMV neutralizing titers 
at levels significantly higher than those observed among the 
naturally seropositive subjects in trial A. For the naturally se-
ropositive subjects at entry (day 0), the geometric mean ELISA 
antibody titer to gB was 1 : 25591, compared with a peak (180 
days) geometric mean titer of 1 : 89321 for the subjects primed 
with ALVAC-CMV(gB) in trial B (P = .03). The same was true 
for neutralizing titers. At entry, the naturally seropositive sub-
jects in trial A had a geometric mean neutralizing titer of 1 : 
79, compared with a peak (180 days) geometric mean titer of 
1 ; 259 for the subjects primed with ALVAC-CMV(gB) in trial 
B (P = .008). 
Lymphoproliferative responses. Lymphoproliferative re-
sponses were measured monthly in trial B over the first 180 
days in each subject by use of two antigens: purified gB and 
extracts of Towne CMV-infected cells. There were no statis-
tically significant differences in the mean lymphoproliferative 
responses between the group primed with ALVAC-CMV(gB) 
and the group primed with ALVAC-RG (table 2). 
Discussion 
The results of these trials demonstrated that an ALVAC re-
combinant containing the gene coding for CMV gB could prime 
the immune system to produce a strong neutralizing response 
to the gB produced by an attenuated CMV virus. 
Like other ALVAC recombinants tested in humans, the AL-
VAC-CMV(gB) vaccine was well tolerated: only mild local re-
actions and minimal systemic reactions were observed. These 
reactions were similar to those observed with the CMV Towne 
vaccine. 
The very low levels of gB-specific IgG and neutralizing ac-
tivities induced by ALVAC-CMV(gB) in humans were unex-
pected, because this vaccine induces detectable levels of these 
activities in mice and guinea pigs [9]. Mammalian cells support 
only an abortive infection by canarypox, with viral gene ex-
pression limited to only early genes and for a relatively short 
duration. As there is no evidence that expression of CMV gB 
is lower in humans than in small mammals, CMV gB may be 
a poorer immunogen in humans than in laboratory animals. 
The observation that two immunizations of ALVAC-CMV(gB) 
induced a low immune response in trial B but none in trial A 
can probably be explained by a difference in the titer of the 
two batches of vaccine used. 
An important observation made in this trial is that this AL-
VAC vaccine could prime for an immune response to a live, 
attenuated vaccine (Towne) and induced peak ELISA anti-gB 
Table 2. Lymphoproliferative responses to either cytomegalovirus gB 
antigen or Towne antigen in trial B. 
Mean stimulation index 
(range) 
Towne antigen gB antigen 
Days after ALVAC-gB ALVAC-RG ALVAC-gB ALVAC-RG 
first dose (n=10) (n=8) (n=10) (n=8) 
0 1.9 (1-5.6) 1.6 (1-3.5) 1.3 (1-3.2) 1.3 (1-1.9) 
30 2.7 (1-9.3) 2.3 (1.4-3.5) 1.6(1-6.7) 1.5 (1-3.4) 
60 2.1 (1-6.2) 2.2 (1.6-4.1) 1.1 (1-1.7) 1.5 (1-6.4) 
90 3.2 (1.3-12) 3.1 (1.4-9) 2.6 (1-8.6) 1.6 (1-4.1) 
120 9.7 (1.8-113.7) 9.6 (1.7-122) 2.3 (1-46.2) 3.4(1.2-8.6) 
180 19.1 (3.7-74.3) 21.0 (3.9-66.2) 6.6 (1.5-53.1)* 3.9 (1-22.9) 
NOTE. ALVAC, canaiypox virus; gB, glycoprotein. 
* Not significantly highef^P>705)-than for those primed with ALVAC-RG. 
<> * 
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titers and neutralizing titers at levels equal to or higher than 
those observed among the naturally seropositive subjects. 
For CMV, the majority of the immunogenic neutralizing ep-
itopes occur on the gB envelope glycoprotein of the viral par-
ticle [14], and the data of the current study are consistent with 
this, as both antibodies to CMV gB and neutralizing activity 
were boosted to high levels after priming with CMV gB. 
Lymphoproliferative responses to the Towne vaccine were 
not primed by gB. We previously found that induction of max-
imal lymphoproliferative responses to Towne antigen required 
less antigen than that required to induce maximal antibodies, 
suggesting that the Towne vaccine is an effective inducer of 
lymphoproliferative responses [5]. The lack of priming of lym-
phoproliferative responses by ALVAC-CMV(gB) suggests that 
gB expressed in ALVAC-infected cells is an inefficient inducer 
of lymphoproliferative responses. 
Results of this trial confirm similar trials using ALVAC ex-
pressing HIV-1 MN gpl60 [15]: ALVAC alone induces a weak 
antibody response but primes for subsequent exposure to HIV 
envelope. 
We previously evaluated the ability of the Towne strain of 
CMV to prevent the child-to-mother transmission of CMV [5]. 
Women who were naturally seropositive appeared to be pro-
tected from acquiring a CMV infection, but women who re-
ceived the Towne vaccine were unprotected. In this previous 
trial, the Towne vaccine was used at a very low dose and pro-
duced neutralizing titers that were 10- to 20-fold lower than 
those produced by a wild-type infection. Furthermore, we ob-
served that naturally seropositive adults and those with vaccine-
induced immunity who had serum neutralizing titers : 64 
also had detectable levels of IgG antibodies to CMV gB in 
nasal washes and saliva [12], Because gB contains the majority 
of neutralizing epitopes, we proposed that serum neutralizing 
titers >1 : 64 would be necessary for protection against wild-
type infection [12]. The current trial has demonstrated the feas-
ibility of using low doses of ALVAC-CMV(gB) to prime the 
immune system to the gB protein and obtain enhanced antibody 
responses and neutralizing titers >1 : 64. These results define a 
vaccine strategy to induce potentially protective levels of neu-
tralizing antibodies. The recall antigen could be either a live 
virus or, potentially, a subunit antigen. 
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A Canarypox Vector-Expressing Cytomegalovirus (CMV) Phosphoprotein 65 
Induces Long-Lasting Cytotoxic T Cell Responses in Human 
CMV-Seronegative Subjects 
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Steve Pincus,4-* William I. Cox,4 Susan Michelson,5 
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The major matrix phosphoprotein 65 (pp65) of cytomegalovirus (CMV) is an important 
target of HLA-restricted cytotoxic T cells (CTL) after natural infection. A canarypox-CMV 
pp65 recombinant was studied for its ability to induce CMV pp65-specific CTL, helper T 
lymphocytes, and antibodies in a phase I clinical trial. Twenty-one CMV-seronegative adult 
volunteers were randomized to receive immunizations at months 0, 1, 3, and 6 with either 
canarypox-CMV pp65 or placebo. In canarypox-CMV pp65-immunized subjects, pp65-spe-
cific CTL were elicited after only 2 vaccinations and were present at months 12 and 26 in all 
subjects tested. Cell-depletion studies indicated that the CTL were phenotype CD84. Peripheral 
blood mononuclear cells proliferated in response to stimulation with purified pp65, and anti-
bodies specific for pp65 also were detected. Canarypox-CMV pp65 is the first recombinant 
vaccine to elicit CMV-specific CTL responses, which suggests the potential usefulness of this 
approach in preventing disease caused by CMV. 
Cytomegalovirus (CMV) infection occurs in nearly half the 
persons in the Western hemisphere and in almost all persons 
elsewhere. Infection is usually asymptomatic in immunocom-
petent persons; however, under certain conditions, it may have 
serious consequences. Each year in the United States, ~8000 
CMV-infected infants are born with congenital defects, includ-
ing deafness, blindness, and mental disorders. Although some 
data point to the importance of recurrent infection [1], the 
majority of studies indicate that CMV-induced defects result 
from a primary maternal CMV infection during pregnancy. In 
contrast, such defects are rare in children born to mothers who 
were CMV-seropositive before pregnancy [2, 3], which suggests 
a protective effect of maternal immunity. 
Organ transplantation is also affected by CMV-related com-
plications in 20%-60% of subjects, depending on the immune 
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status of the donor and recipient. A graft from a CMV-sero-
positive donor may lead to serious and sometimes life-threatening 
disease in a seronegative recipient; symptoms are usually less 
severe in a seropositive recipient [4]. The relative significance of 
cellular and humoral immunity in defense mechanisms against 
CMV disease is uncertain, but the following observations point 
to the importance of cellular responses. First, kidney transplant 
recipients have more frequent and severe CMV infections in the 
posttransplantation period after the use of antithymocyte globu-
lin or monoclonal antibody (MAb) directed to CD3+ lympho-
cytes [5, 6]. Second, there is an inverse correlation between the 
presence of CMV-specific cytotoxic T lymphocytes (CTL) and 
CMV-related complications of transplant recipients, and CMV-
specific T cell immunity after renal transplantation mediates pro-
tection from CMV disease by limiting systemic virus load [7-10], 
Third, the transfer of T cells obtained from HLA-matched-
seropositive donors reduces the incidence of severe CMV disease 
in bone marrow transplant recipients [11-13]. 
Infection-induced CTL in naturally infected people target 
several CMV proteins, including the major matrix protein, 
phosphoprotein 65 (pp65; UL83), immediate-early 1 (UL123), 
ppl50 (UL32), glycoprotein B (gB; UL55), and glycoprotein H 
(UL75). pp65 is considered to be the dominant CTL target 
[14-23] and thus the most likely vaccine candidate to induce 
CTL-mediated protection against CMV diseases. 
Induction of CTL responses by vaccination is best achieved 
by methods that allow for intracellular processing of antigens 
such as live attenuated viral vaccines, plasmid DNA carriers, 
or recombinant viruses. Canarypox recombinants based on an 
attenuated strain of canarypox virus (ALVAC) [24-26] are well 
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tolerated when administered to humans and induce antibody 
responses against many viral antigens, including rabies virus 
glycoprotein [27, 28], measles virus hemagglutinin and fusion 
proteins [29], and human immunodeficiency virus (HIV) type 
1 envelope glycoproteins [30]. CTL responses to HIV glyco-
proteins were elicited in 30%-39% of vaccinated persons, with 
60%-70% positive responses at 2=1 time points [30, 31]. In ad-
dition, immunization with an ALVAC vector expressing mul-
tiple HIV-1 genes that was followed by a boost with recom-
binant gpl20 resulted in durable CTL responses in all of the 
encoded genes [32]. We recently reported that canarypox-CMV-
gB recombinant primes for antibody responses to the Towne 
vaccine strain of CMV [33]. 
The ALVAC vector system offers several advantages, in-
cluding a genome that can easily accommodate large or multiple 
foreign genes from heterologous pathogens and the ability to 
abortively infect mammalian cells. Expression of the foreign 
gene product is induced in the absence of productive viral repli-
cation. Thus, the ALVAC vector system provides a strong safety 
barrier against potential vaccine-associated complications in 
humans. In fact, live ALVAC has been administered to im-
munosuppressed mice and HIV-infected adults without serious 
adverse effects [25, 26]. 
The present study was designed to test the ability of a can-
arypox-CMV pp65 recombinant to elicit pp65-specific CTL 
and antibody responses in CMV-seronegative humans. We 
characterized the level and duration of the CTL activity, pre-
cursor frequency, lymphoproliferation, and antibody response 
and determined the phenotype of the cytotoxic effector cells. 
Materials and Methods 
Study design. This randomized placebo-controlled clinical trial 
was conducted at Children's Hospital of Philadelphia. Healthy 
adult volunteers, 18-35 years old, were eligible to participate unless 
they had s i of the following exclusion criteria: history of severe 
adverse reaction or allergy to any vaccine; known or suspected 
allergies to eggs, monosodium glutamate, or neomycin; history of 
any immunosuppressive disease or major chronic disorder; receipt 
of immunoglobulins, blood or blood products, steroids, oral or 
parenteral immunosuppressive therapy, or cimetidine within the 
previous 6 months; prescription medication use (other than oral 
contraceptives); planned immunization with other vaccines within 
7 months of the study period; and pregnancy. 
Two months before the first immunization, eligible volunteers were 
screened for CMV antibodies and for hematologic and biochemical 
status by means of commercial ELISA kit (Wampole Laboratories). 
Screenings were done for neutralizing antibodies to CMV [34], as 
well as for ELISA antibodies to CMV pp65, HIV, hepatitis C, and 
hepatitis B surface antigen. A complete blood cell count was done, 
and levels were determined of aspartate aminotransferase, alanine 
aminotransferase, blood urea nitrogen, and creatinine. 
Subjects were admitted to the study if they had no abnormal 
laboratory results and no detectable CMV antibodies. Inclusion 
was also proposed to an additional 4 subjects with high titers of 
CMV neutralizing antibodies. All subjects had 50 mL of blood 
drawn for preparation of Epstein-Barr virus (EBV)-transformed 
lymphoblastoid cell lines and for HLA typing. 
Two months later, the seronegative subjects were randomized to 
receive canarypox-CMV pp65 (vCP260) or placebo (sterile saccha-
rose reconstituted with diluent) at a ratio of 2:1. The 4 subjects with 
high titers of CMV neutralizing antibody were immunized with ca-
narypox-CMV pp65 (vCP260). All subjects received 4 immuniza-
tions intramuscularly at months 0, 1,3, and 6. To increase the dose 
of canarypox-CMV pp65 administered, 2 injections (1 in each arm) 
were given concomitantly on each occasion. A negative urine preg-
nancy test was required for female participants before each vacci-
nation. Subjects were seen monthly for the first 7 months after the 
first immunization and at month 12. During each study visit, blood 
was drawn for hematologic, biochemical, and immunologic tests. 
Specific immunologic assays were done on the following schedule: 
CMV pp65-specific lymphocyte proliferation at months 0, 3, 4, 6, 
7, 12, and 26; CTL at months 0, 3, 4, 5, 7, 12, and 26; and ELISA 
antibodies to CMV pp65 at months 0, 1,3, 6, and 7. 
All subjects were observed for 30 min after each immunization 
to detect immediate adverse effects. Telephone inquiries were made 
on days 2 and 9 after each immunization to document reactions. 
In addition, subjects were required to maintain postvaccination 
diaries that included a list of systemic reactions (fever, chills, 
generalized pruritus, urticaria, rash, headache, nausea, vomiting, 
diarrhea, dizziness, malaise, abdominal pain, arthralgia, myalgia, 
wheezing, dyspnea, and lymphadenopathy) from days 0 to 7 and 
local reactions (erythema, induration, bruising, swelling, tender-
ness, pain, pruritus, and regional adenopathy) at day 3 after each 
dose. Interim medical histories were obtained at each study visit 
to detect unreported events, including hospitalizations and medical 
office or emergency room visits for any reason. 
We graded adverse reactions as follows: mild (grade 1), subject 
is aware of symptom, but symptom is tolerated and does not in-
terfere with daily activities; moderate (grade 2), symptom interferes 
with or restricts the subject's ability to perform usual activities; 
and severe (grade 3), symptom is incapacitating and prevents the 
subject from working or carrying out usual activities. Statistically 
significant differences were calculated by using Student's 2-tailed 
t test. P<.05 was considered to be significant. 
Viruses. The canarypox-CMV pp65 (ALVAC pp65, vCP260) re-
combinant containing the pp65 gene derived from the Towne strain of 
human CMV [23] and the parental canaiypox (ALVAC, CPpp) were 
used for restimulation of CTL effector cells in vitro. We used the WR 
strain of vaccinia virus (Vac-WR) and Vac-WR-based recombinant 
encoding CMV pp65 protein (Vac-WR-pp65) to infect target cells in 
cytotoxicity assays [23]. Vaccinia viruses were propagated and titered 
on Vera cells (American Type Culture Collection [ATCC]). Immuni-
zations were with batch S3227 of canarypox-CMV pp65, which con-
tained 10" TOD,, per dose. Canaiypox viruses were grown on pri-
mary chick embryo fibroblast and were titered on QT35 cells. 
CTL assays. CTL assays were done at months 0 (26 subjects), 
3 (13 subjects), 4 (24 subjects), 5 (13 subjects), 7 (19 subjects), 12 (24 
subjects), and 26 (10 subjects). An internal positive control subject 
(pp65-specific CTL-positive naturally seropositive person) and a neg-
ative control subject (CMV-seronegative and pp65-specific CTL neg-
ative person) were included in each assay. Control subjects were 
volunteers from the Wistar Institute's blood donor program; their 
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pp65-specific CTL reactivity was established in preliminary experi-
ments. Peripheral blood mononuclear cells (PBMC) were typed for 
major histocompatibility complex class I and class II antigens by 
means of standard complement-mediated cytotoxicity assays and of 
polymerase chain reaction testing at the Immunogenetics Laboratory 
at the Children's Hospital of Philadelphia. 
Target cell lines. Autologous B lymphoblastoid cell lines (B-
LCLs) were established from each donor by incubation of PBMC 
with supernatant from the EBV-producing marmoset cell line B95.8 
(ATCC). Transformed cell lines were grown in RPMI 1640 with 
15% fetal calf serum (FCS; Cansera Atlanta Biologicals) and were 
cryopreserved until use. 
Effector cells. Bulk CTL assays were done, as described else-
where [23]. In brief, PBMC were separated from freshly drawn 
heparinized venous blood by centrifugation on Ficoll-Paque (Phar-
macia Fine Chemicals) density gradients. Stimulator cells were pre-
pared by infecting PBMC with canarypox-CMV pp65 or parental 
canarypox at an MOI of 5. After incubation for 1 h, infected cells 
were washed and were mixed with responder PBMC at a responder: 
stimulator ratio of 4:1. The mixture of responder and stimulator 
cells was placed in 24-well plates at 3.5 X 10' cells in 2 mL/well of 
culture medium (RPMI 1640; Cellgro; Mediatech), supplemented 
with 10% FCS (Hyclone [for restimulation cultures] or Cansera 
Atlanta Biologicals [for chromium release tests]), and 4 mM l -
glutamine (Sigma Chemical), 60 pg/mL of gentamicin (Sigma), and 
5 pM 2-mercaptoethanol (Sigma). PBMC cultures were supple-
mented with 330 U/mL of interleukin (IL)-7 (R&D Systems) at 
the start of culture and with 20 U/mL of IL-2 (Genzyme) on days 
4 and 8. Cell lines were tested for CTL activity between days 10 
and 13 of culture. 
Infection and labeling of target cells. We used Vac-WR-pp65 
or Vac-WR to infect 2 X 10s to 6 X 106 of B-LCLs at an MOI of 
10 for 1 h. Cells were diluted to 10' cells/1.5 mL with culture 
medium, were incubated an additional 16 h, and were washed and 
labeled with 100 pCi of Na[3lCr]04 (Amersham Life Sciences) for 
1 h. Labeled cells were washed 3 times before use. 
Cytotoxicity assays. We measured cytolytic activity of antigen-
driven effectors present in bulk cultures established from PBMC 
in a 4-h "Cr release assay. Nonadherent effector cells were collected, 
were washed once, and were added in triplicate to round-bottomed 
96-well microtiter plates at effector-to-target ratios (E:T) indicated 
for individual experiments (typically 50:1, 25:1, 12.5:1, 6:1, 3:1, 
and 1.5:1). Targets were autologous B-LCLs infected with Vac-
WR-pp65 or Vac-WR or heterologous (HLA mismatched) B-LCLs 
infected with Vac-WR-pp65. Nonspecific background cytolysis was 
reduced by adding a 30-fold excess of unlabeled, Vac-WR-infected 
target cells to each well in the assay. Chromium release was mea-
sured by gamma counter (Cobra II; Packard Instrument). Per-
centage of specific lysis was determined as follows: 100 X [(exper-
imental release - spontaneous release)/(maximal release -
spontaneous release)]. For each target, spontaneous release was 
determined from wells containing medium only, and maximal re-
lease was calculated from wells containing 1% NP-40. Spontaneous 
release was always <30%. Effector cells were considered to be posi-
tive for CTL activity if percentage of specific lysis of canarypox-
CMV pp65-restimulated effector cells on Vac-WR-pp65-infected 
autologous target cells was & 10% above background. Background 
was defined as percentage of specific lysis of canarypox-CMV 
pp65-restimulated effector cells against Vac-WR-infected autolo-
gous target cells or Vac-WR-pp65-infected HLA-mismatched tar-
get cells or percentage of specific lysis of ALVAC-restimulated ef-
fector cells against Vac-WR-pp65-infected autologous target cells, 
whichever was highest. 
Limiting dilution assay. Fresh or cryopreserved effector PBMC 
were plated at different cell numbers in 24-30 replicate wells and 
were cultured with gamma-irradiated (3000 rad delivered by an 
MKA model 68A irradiator; Shepherd and Associates) autologous 
PBMC as feeder cells (6 X 104 PBMC/well) and 4 X 103 autologous 
EBV-transformed lymphoblasts infected with Vac-WR-pp65 for 16 
h and gamma irradiated (3000 rad) and UV irradiated (10 min at 
a distance of 25 cm with a germicidal lamp) as stimulator cells. 
After 12-14 days, pp65-specific CTL activity was determined for 
the cells of each well on autologous Vac-WR-pp65-infected, 
autologous Vac-WR-infected, and HLA-mismatched Vac-WR-
pp65-infected target cells. CTL precursor (CTLp) frequency was 
estimated as the input cell number resulting in 37% negative wells 
against the pp65-specific target [35]. Linear regression analysis was 
done, and precursor frequency was determined by solving the equa-
tion of the best-fit line, in which the fraction of nonresponding 
wells equaled 0.37. "Cr release for each well was considered to be 
significant at >3 SD above mean lysis observed in control wells 
(containing only feeder and stimulator cells). 
Determination of CTL phenotype. Bulk CTL cultures were es-
tablished from freshly prepared PBMC. After 10-13 days of culture 
in vitro, effector cells were harvested, and aliquots of 3 X 106 cells 
were depleted of CD4+ lymphocytes by anti-CD4 MAb plus com-
plement (C) or of CD8+ lymphocytes by anti-CD8 MAb plus C or 
of both CD4* and CD8+ by both antibodies plus C. Antibodies 
(Caltag Laboratories) were used at a predetermined concentration 
(16 pg/mL). Nontoxic rabbit complement (Accurate Chemical) was 
used at a final dilution of 1:10. Effector cells were incubated with 
the antibodies at 4°C for 45 min. After a wash with medium, cells 
were further incubated with complement for 30 min at 37°C and 
were washed and resuspended in the predepletion volume of medium, 
to maintain nondepleted cells at the original concentration. CMV 
antigen-specific lysis was determined in a 4-h slCr release assay. 
Lymphocyte proliferation assay. Freshly separated PBMC or, 
in a few cases, cryopreserved PBMC were resuspended to a con-
centration of 2 X 10' cells/mL in RPMI medium supplemented with 
10% autologous plasma (when available) or with human AB serum 
(Sigma). We added (in triplicate) a 100-pL aliquot containing 
2 X 10s cells to wells of a 96-well microtiter U-bottom plate. pp65 
purified by high-pressure liquid chromatography from CMV-in-
fected (strain Towne) MRC-5 cells, as described elsewhere [36], or 
MRC-5 antigen (control antigen) at final concentrations of 2.5,0.6, 
and 0.15 pg/mL in 100 pL was added to wells in triplicate. Plates 
were incubated at 37°C in 5% C02 for 6 days. In some experiments, 
2 identical plates were set up and were incubated for 5 and 6 days. 
[3H]Thymidine (0.5 pCi) was added to each well for the last 6 h 
of incubation. Cells were harvested in an automatic cell harvester 
(Tomtec), and incorporated radioactivity was measured by using 
a beta plate reader (Packard). 
We determined the stimulation index (SI) as the count in the 
presence of pp65 antigen divided by the count in wells with MRC-
5 control antigen. An SI 5=3 and a difference in experimental counts 
(count in the presence of pp65 antigen minus the count in the 
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Table 1. Reactogenicity in healthy volunteers 
after vaccinations with canarypox-cytomegalo-
virus phosphoprotein 65 (CMV pp65). 
Reactogenicity in subjects 
immunized with 
Canarypox- Placebo 
Reaction CMV pp65" (n = 7) P" 
Local 
Any 100 57 .013 
Pain too 29 .001 
Tenderness 100 57 .013 
Systemic 
Headache 80 43 .049 
Myalgia 65 14 .047 
Malaise 70 57 .856 
Nausea 55 29 .368 
NOTE. Data are percentages unless otherwise 
indicated. 
a Seronegative subjects (n — 16) and seropositive 
subjects (n — 4). 
b P < .05 is significant. 
presence of control MRC-5 antigen) of 500 were considered to be 
indicative of a positive response to pp65. A subject's proliferative 
responses were defined as positive if both criteria were fulfilled with 
s i concentration of the pp65 antigen after 5 or 6 days of incu-
bation. The highest SI for each time point is given in the Results. 
ELISA. pp65- and gB-specific antibodies were determined in a 
standard ELISA. The gB-specific ELISA plates were coated with 150 
ng/well purified gB (Chiron). Serum samples with optical density 
(OD) values >0.100 at a serum dilution of 1:200 were considered to 
be positive for gB antibody. In a pp65-specific ELISA, lysates of 293 
cells transiently transfected with pARC-pp65 were used as coating 
antigen, and lysates of untransfected 293 cells served as control anti-
gen [37]. The pp65-specific OD values were calculated as follows: 
OD values obtained in control antigen-coated wells were subtracted 
from those obtained in pp65 antigen-coated wells. Serum samples 
with OD values >0.053 (mean OD of serum 200 X dilution + 2 X 
SD of the originally seronegative subjects at month 0) were consid-
ered to be positive for pp65 antibody. 
Results 
We enrolled 27 volunteers in the trial: 23 were seronegative 
for CMV and received the vaccine (n = 14) or placebo (n = 
9), and 4 were seropositive. Two seronegative canarypox-CMV 
pp65-immunized subjects did not complete the study: one re-
ceived an initial dose, and the other received 2 doses. The pur-
pose in immunizing highly seropositive volunteers was pri-
marily to assess the safety of the vaccine in this population. 
The study subjects (22 women and 5 men) were primarily white 
(n = 23) and were 21-35 years old. 
Reactogenicity. Table 1 shows the rates of the most com-
monly reported postvaccination adverse reactions for all enrolled 
subjects, regardless of the number of vaccinations. Elicited re-
actions recorded on diary cards were more common in subjects 
who received vaccine than in placebo recipients. There was no 
evidence that either the severity of the reaction or the frequency 
of occurrence increased after the administration of successive 
doses. Reactogenicity did not appear greater in the 4 seropositive 
subjects than in the seronegative subjects. Mild-to-moderate pain 
or tenderness lasting 24-48 h were the most frequent local re-
actions. Headache, malaise, nausea, and myalgia were the most 
common systemic reactions. AH of the vaccinated subjects and 
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Figure 1. Kinetics of phosphoprotein 65 (pp65)-specific cytotoxic T cell activity of 25 subjects after initial immunization with canarypox-
cytomegalovirus pp65. pp65-Specific lysis at an effector-to-target (E:T) ratio of 25:1 (E:T of 30:1 for subjects 9, 27, 32, 33, and 38 at month 5). 
pp65-Specific lysis was considered to be significant at 10%. 
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Table 2. pp65-Specific cytotoxic T lymphocyte precursor 
(CTLp) frequencies in healthy volunteers after vaccination with 
canarypox-cytomegalovirus phosphoprotein 65 (CMV pp65). 









27 7 257 
15 12 105 
22 12 61 
29 12 147 
Seronegative placebo inoculated 
25 12 U N D 
Naturally seropositive nonvaccinated 
16 155 
H-35 206 
NOTE. PBMC, peripheral blood mononuclear cells; UND, 
undetectable. 
* Freshly obtained (donors H-35,27, 15,22, and 29) or cryopreserved 
(donor 16) peripheral blood PBMC were used in limiting dilution assays, 
as described in Materials and Methods. 
57% of placebo recipients developed local pain and tenderness. 
Among all systemic symptoms, only headache (P = .049) and 
myalgia (P = .047) occurred significantly more frequently in vac-
cinees. Although there were other reactions among both placebo 
and vaccine recipients, none were of statistical significance. 
Fourteen subjects reported 22 adverse events during the 
study. Only 2 were considered to be related to vaccination (both 
among seronegative canarypox-CMV pp65 recipients): a severe 
local reaction after dose 2 (subject was discontinued from the 
study) and 35 days of rash (contact dermatitis) after dose 3 in 
another subject. Two serious (nonrelated) adverse events (or-
thopedic) were reported, each requiring hospitalization. 
Induction of pp65-specific CTL responses in all originally sero-
negative vaccinees. PBMC obtained from the vaccinees at 
months 0, 3, 4, 5, 7, 12, and 26 were tested for pp65-specific 
CTL activity in bulk cultures. The CMV-seronegative subjects 
were CTL negative at time 0, and the placebo recipients re-
mained CTL negative, whereas all subjects who received the 
canarypox-CMV pp65 vaccine responded with pp65-specific 
CTL activity at each time point tested (figure 1). All 8 sero-
negative vaccinees tested after 2 doses of vaccine exhibited HLA 
class I-restricted pp65-specific CTL activity; after inoculation 
3, all of the 14 originally seronegative vaccinees showed CTL 
activity when tested at months 4, 5, 7, 12, and all of the 5 tested 
were positive at month 26. We tested 1-4 of the naturally sero-
positive subjects at months 3, 4, 7, 12, and 26: all were pp65-
specific CTL-positive and remained positive for the entire study 
period. In the originally seronegative vaccinees, specific lysis 
was obtained even at very low E:T ratios (1.5:1 or 3:1) in 13 
of the 14 volunteers at 1-3 time points after vaccination and 
at an E:T ratio of 6:1 in 9 volunteers at all time points from 
months 4 to 12. Of the 14 originally seronegative vaccinees, 13 
exhibited 3=1 HLA alleles (Al, A2, A3, A68, B7, and B35) 
previously shown to present pp65 epitopes; 1 vaccinee had al-
leles (A31, B49, and B15) not previously shown to present pp65. 
All of these subjects mounted pp65-specific CTL responses after 
vaccination. These results indicate that CMV pp65, as ex-
pressed by the ALVAC recombinant, induced CTL responses 
in persons with different HLA haplotypes, that 2 doses of ca-
narypox-CMV pp65 were sufficient for CTL induction, and 
that CTL activity did not change significantly during the 20 
months after the last vaccine dose in the 5 subjects tested at 
month 26. 
Similarity of pp65-specific CTLp frequencies in canary-
pox-CMV pp65 vaccinees and naturally seropositive persons. 
CTLp frequencies were determined at months 7 or 12 (1 and 
6 months after inoculation 4) in 4 originally seronegative vol-
unteers who received the canarypox-CMV pp65 vaccine and 
in 2 naturally seropositive donors who were not vaccinated. In 
3 of the 4 vaccinees, the CTLp frequencies per 106 PBMC was 
similar to that of the 2 naturally seropositive donors (range, 
105-257/106 PBMC for vaccinees 27, 15, and 29 vs. 155 and 
206/106 PBMC for naturally seropositive subjects), whereas, in 
the fourth subject, it was lower (61; table 2). CTLp frequencies 
were undetectable in volunteer 25, a seronegative subject in-
oculated with placebo. In an experiment to test the number of 
CTLp frequencies in the course of the immunization process, 
PBMC cryopreserved at 0, 4, and 7 months from vaccinee 35 
were used as effector cells. CTLp frequencies were undetectable 
at month 0, were not tested after 1 or 2 doses, and were detected 
after 3 vaccinations (92/10" PBMC at month 4) and after 4 
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Figure 2. Phcnotype of phosphoprotein 65 (pp65)-specific effector 
cells. Bulk cytotoxic T cell (CTL) cultures were established from fresh 
peripheral blood mononuclear cells of donor 15. After 11-day culture 
in vitro, effector cells were harvested, and aliquots of 3 X 10s cells were 
depleted of CD4 lymphocytes by anti-CD4 monoclonal antibody 
(MAb) plus complement (+C) or of CD8 lymphocytes by anti-CD8 
MAb + C or of both CD4 and CD8 by both antibodies + C. pp65-
Specific lysis is shown at an cffector-to-target ratio of 30:1. 
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Table 3. Lymphocyte proliferation responses in healthy volunteers after canarypox-cytomegalovirus phosphoprotein 65 (CMV 
pp65) vaccination. 
pp65-Specific proliferation by month 
Vaccine group 0 3 4 6 7 12 26 
Seronegative canarypox- 1.53 ± 0.63 11.04 ± 12.6 16.6 ± 17.5 12.1 ± 7.1 22.1 ± 26.5 19.02 ± 26.1 24.8 ± 29.9 
CMV pp65 vaccinated (0/14) (9/14) (13/14) (12/14) (11/12) (13/14) (4/5) 
Seronegative placebo 0.93 ± 0.25 1.78 ± 1.4 1.25 ± 0.46 1.6 ± 0.6 1.4 ± 0.SI 2.6 ± 0.82 1.7 ± 0.98 
inoculated (0/7) (0/7) (0/6) (0/7) (0/6) (0/6) (0/2) 
Seropositive canarypox- 26.03 ± 21.87 28.35 ±13 .1 13.1 ± 11.1 7.4 ± 1.4 12.1 ± 0.94 62.7 ± 26.7 22.9 ± 23.4 
CMV pp65 vaccinated (2/2) (4/4) (4/4) (2/2) (3/3) (3/3) (2/2) 
NOTE. Data are mean stimulation index (SI) ± SD (no. of subjects positive/total no. of subjects tested) by months after immunization. 
that the number of memory CTL increased during the repeated 
immunization of this subject with canarypox-CMV pp65. Fur-
thermore, CTLp frequencies detected at 7-12 months after the 
first immunization with the canarypox-CMV pp65 vaccine in 
seronegative persons were similar to that detected in CMV-
seropositive subjects after natural infection that occurred at an 
undefined time in the past and that may have been boosted or 
expanded by multiple exposures. 
Phenotype of pp65-specific CTL The phenotype of pp65-
specific CTL was determined at month 5 in originally seronega-
tive subjects who received the canarypox-CMV pp65 vaccine. 
Figure 2 shows the results of a depletion experiment that used 
cells from vaccinee 15. Although depletion of effector cells with 
anti-CD4 antibodies and C did not change the percentage of 
lysis of the target cells, depletion with anti-CD8 antibodies and 
C or with a mixture of anti-CD4 and anti-CD8 antibodies and 
C decreased the lysis to <10%, which indicates that the effectors 
were CD8+. Of 13 vaccinees analyzed for phenotype of pp65-
specific CTL, 11 exhibited CD8+ effector cells. In 2 vaccinees 
(subjects 38 and 10), the determination of CTL phenotypes did 
not give clear results because of low pp65-specific CTL activity 
(subject 38 had 16% of pp65-specific lysis at an E:T ratio of 30: 
1 and 9% of pp65-specific lysis at an E:T ratio of 15:1) and the 
apparent presence of effector cells partially resistant to CD4 and 
CD8 antibodies and C (subject 10). 
pp65-specific lymphoproliferative responses in vaccinees. To 
determine whether pp65, as expressed by canarypox-CMV pp65, 
elicits helper T lymphocytes, we analyzed pp65-specific lympho-
cyte proliferation responses. Responses to a purified pp65 prep-
aration were measured for all subjects (table 3). In the originally 
seronegative subjects who received the canarypox-CMV pp65 
vaccine, pp65-specific responses were negative (SI, <3) at the time 
of the first immunization but became positive (SI, 2=3; mean SI, 
11.04) after 2 immunizations. All of the vaccinated subjects 
showed pp65-specific lymphocyte proliferation: 7 were positive 
at all time points tested, and 7 were positive at 2-4 time points 
(months 3-12). Four of the 5 vaccinated subjects tested at month 
26 were found to be positive (table 3). Originally seronegative 
persons who received the placebo remained negative. Originally 
seropositive vaccinees remained positive, although there was 
some decrease in lymphocyte proliferation indices after 3 inocu-
lations. By month 12, Sis were greater than before the initial 
immunization process (table 3). 
Antibody responses in vaccinees. Antibodies were measured 
by a pp65-specific ELISA in 21 volunteers at different times 
after the first vaccination. The originally seronegative vaccinees 
who received the canarypox-CMV pp65 vaccine developed 
pp65-specific binding antibodies (mean OD, 0.077-1.261) after 
2 or 3 inoculations and remained positive during the obser-
vation period (table 4). Originally seronegative vaccinees who 
were inoculated with placebo remained negative. 
Discussion 
This ALVAC construct was safe and well tolerated in most 
subjects, which confirms the safety profile observed with all 
ALVAC recombinant vaccines tested in human volunteers. 
CMV pp65 is a major CTL target in naturally seropositive 
persons [16-19, 22, 23], and CTL induction in humans was 
demonstrated after Towne attenuated CMV vaccination in 3 
of 4 immunized volunteers for 6 months [38], although the 
target protein(s) specificity of these CTL was not determined. 
In the present trial, we showed for the first time that pp65-
specific CTL can be induced in humans by a recombinant vac-
cine candidate. Canarypox-CMV pp65 induced CD8+ CTL 
responses in all of the seronegative subjects, and the responses 
were detectable at each time point between months 3 and 12 
and during a 26-month observation period in all 5 persons 
tested. Moreover, the CTLp frequency was comparable with 
that of unvaccinated naturally CMV-seropositive donors, and 
CTL responses were accompanied by CMV pp65-specific lym-
phocyte proliferation and antibody responses. All volunteers 
who were tested after the second of 4 immunizations were al-
ready positive for pp65-specific CTL, which suggests that 2 
immunizations may be sufficient for induction of a CTL re-
sponse. Tests were not done after a single vaccination. The 
possibility that the pp65-specific CTL responses of the origi-
nally seronegative subjects reflected natural intercurrent CMV 
infection during the study period was ruled out by the absence 
of CMV gB-specific ELISA antibodies in these persons (data 
not shown). 
We observed pp65-specific lysis of target cells in bulk CTL 
assays at low E:T ratios («6:1) in most subjects at each time 
point, which suggests that pp65 is a strong CTL inducer in hu-
mans when expressed by the canarypox-CMV pp65 recombinant 
and that CTL responses do not differ significantly among per-
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Table 4. Induction of phosphoprotein 65 (pp65)-specilic antibodies in vaccinees by canarypox-cyto-
megalovirus (CMV) pp65. 
pp6S-Specific OD of serum samples after immunization I by month 
Subject group 0 3 4 6 7 
Seronegative canarypox-
CMV pp65 vaccinated -0.004 ± 0.029 0.077 ± 0.041 1.261 ± 0.771 1.047 ± 0.452 0.9818 ± 0.29 
Seronegative placebo 
inoculated -0.014 ± 0.035 -0.031 ± 0.106 -0.003 ± 0.062 0.028 ± 0.028 0.017 ± 0.029 
Seropositive canarypox-
CMV pp65 vaccinated 1.862 4 1.608 ND ND 1.808 ± 1.685 1.843 ± 1.635 
NOTE. Data are mean OD ± SD. In the group of originally seronegative vaccinees, serum samples of 6-8 subjects at a 
dilution of 1:200 were tested at indicated time points. Cutoff, mean OD of serum 200 X dilution -f 2 X SD of originally 
seronegative subjects at month 0:0.053. ND, not done; OD, optical density. 
sons. The HLA haplotype of the vaccinees was determined before 
the trial, to guide selection of mismatched targets in the CTL 
assays, but vaccinees were not selected for the known HLA hap-
lotypes presenting pp65. CD8 T cell reactivity to pp65 is strongly 
linked to HLA-A2 [39, 40]. Al, A3, A68, B7, and B35 also were 
shown to present pp65 epitopes [18, 19, 23]. Among the cana-
rypox-CMV pp65 vaccinees, 57% were positive for A2, and 93% 
were positive for s i pp65-presenting alleles. One vaccinee (sub-
ject 31) had HLA haplotype with an allele composition not pre-
viously shown to present pp65 (A31, B49, and B15). Therefore, 
our findings indicate that the range of pp65-presenting alleles is 
even broader than that previously shown. 
Restriction maps of DNA extracted from laboratory strains 
and fresh isolates of human CMV show that each strain is 
distinct but related [41-45]. The significance of the restriction 
pattern polymorphism of the different strains is not clear, al-
though genotypes characterized by specific sequence variations 
of the gB gene may be associated with certain CMV diseases 
[46-50]. The pp65 gene of the canarypox-CMV pp65 recom-
binant was derived from CMV Towne strain. It has not been 
demonstrated that the pp65-specific CTL induced by the can-
arypox-CMV pp65 recombinant would recognize target cells 
expressing pp65 from other strains in naturally infected persons. 
However, the use of the same canarypox-CMV pp65 construct 
for restimulation of PBMC obtained from naturally seroposi-
tive donors in an in vitro CTL assay revealed high pp65-specific 
CTL responses in 24 of 26 subjects tested (i.e., memory CTL 
from persons of heterologous HLA haplotypes responded to 
the canarypox-CMV pp65 recombinant [23]), which indicates 
common CTL epitopes in the Towne strain and in the clinical 
strains that infected these persons. 
Our results do not provide direct evidence for the protective 
effect of canarypox-CMV pp65 against CMV disease. How-
ever, the pp65-specific lysis at low E:T ratios in the bulk CTL 
assays and the similar CTLp frequencies of PBMC from vac-
cinees and from naturally seropositive persons suggest that im-
munization with canarypox-CMV pp65 might elicit a sufficient 
immunologic response to confer protection similar to that ob-
tained through natural infection. Although the phenotype of 
pp65-specific CTL in some naturally seropositive persons is 
both CD8+ and CD4+ mediated [23], the CTL phenotype in 
all 11 vaccinees who could be tested was CD8+. Lymphocyte 
proliferation responses specific for pp65 detected in our in vitro 
assays indicate that the canarypox-CMV pp65 recombinant 
also stimulates CD4+ T cells. This suggests the release of cyto-
kines that could contribute to the protective effect of the vac-
cine. In murine models, CD4 helper function, although not 
required for CD8+ CTL generation, is needed for persistence 
of CD8+ cell memory [51, 52], 
The function of the anti-pp65-specific antibodies is uncertain, 
but their induction by the canarypox-CMV pp65 reflects stimu-
lation of B cells by the insert of the ALVAC recombinant. The 
demonstration of an antibody response to pp65 may be useful 
in future vaccine studies as a surrogate for CTL response. This 
clinical trial clearly shows that CMV pp65, when expressed by 
an ALVAC recombinant, induces strong CD8+ CTL responses 
in humans. Thus, we conclude that ALVAC CMV recombinants 
can stimulate functional immune responses and are promising 
candidates for immunization against CMV disease, perhaps when 
combined with antigens that stimulate neutralizing antibodies. 
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The N-terminal 303 amino acids of the 
human cytomegalovirus envelope 
glycoprotein B (UL55) and the exon 4 
region of the major immediate early 
protein 1 (UL123) induce a cytotoxic 
T-cell response 
Klara Berencsi*, Eva Gonczol*, Valeria Endresz*, John Koughf, 
Shin Takedai, Zsofia Gyulay*, Stanley A. Plotkin§ and Robert F. Randoffll 
We reported earlier that an adenovirus (Ad) recombinant expressing the full-length 
human cytomegalovirus (HCMV) glycoprotein B (gB) gene induces gB-specific cyto-
toxic Tlymphocyte (CTL) responses in CBA (H-2k) mice (Berencsi et al., J. Gen. Virol. 
74. 257-2512, 1993). Here we show that mice, immunised with Ad recombinant viruses 
expressing truncated forms of the gB gene containing the first 700 (Ad-700), 465 
(Ad-465) or 303 (Ad-303) amino acids of gB,or an Ad construct containing exon 4 (E4) 
of the HCMV immediate, early 1 (IE1) gene (Ad-IEl (E4)) demonstrate HCMV-
specific CTL responses. These data suggest the importance of the first 303 amino acids of 
the gB polypeptide and the IE1 E4 product in designing a vaccine to induce anti-HCMV 
CTL responses. Copyright © 1996 Elsevier Science Ltd. 
Keywords: CTL epitope; HCMV; IE! exon 4; Ad-HCMV recombinants 
Infections with human cytomegalovirus (HCMV) are 
common and usually asymptomatic; however, the inci-
dence and spectrum of HCMV-induced disease in new-
borns and immunocompromised hosts, including organ 
transplant recipients, establish this virus as an important 
human pathogen1-3. In addition, HCMV has been 
associated with the development of atherosclerosis4 and 
restenosis after coronary angioplasty5. 
Although the exact role of individual HCMV proteins 
in protective immunity in humans is unclear, the viral 
surface glycoprotein B (gB, UL55), glycoprotein H (gH, 
UL75), the major tegument proteins pp65 (UL83) and 
ppl50 (UL32), the major immediate early proteins (IE1, 
UL123 and IE2, UL122) as well as UL69 of the virus, 
appear to be important in the neutralizing antibody 
(NA), lymphocyte proliferation and cytotoxic T lym-
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phocyte (CTL) responses to the virus after natural 
infection6-17. The majority of neutralizing epitopes on 
gB are in the C-terminal part of the molecule, while the 
N-terminal part is considered less important in inducing 
antibody response1519. Recently, we demonstrated that 
purified and subcutaneously inoculated gB induces NA 
and lymphocyte proliferation responses in humans20, 
and NA, lymphocyte proliferation and CTL responses 
when expressed by adenovirus (Ad) or poxvirus recom-
binants in mice and guinea pigs10,21- . However, the 
CTL epitopes of gB have not been precisely localized. 
To date, mapping of CTL epitopes on gB has indicated 
that the N-terminal 513 amino acids and a region 
between amino acids 619 and 628 can be targets of CTL 
recognition in certain seropositive individuals11,24. As 
for mapping of CTL epitopes of the IE protein, CTL 
from one individual specifically lysed target cells sensi-
tized with a peptide spanning amino acid residues 162— 
180 of the exon 4 (E4) region of the IE1 polypeptide25. 
In the present study, we asked whether, the N-terminal 
part of gB is important in eliciting "CTL responses, and 
analyzed the CTL responses induced by Ad recom-
binants expressing truncated forms of the HCMV-gB. 
We also,asked whether the E4 protein, when expressed 
by a-^recombinant virus in vivo, can induce a CTL 
response, in order to confirm its immunogenicity in a 
potential combined vaccine against HCMV infection. 
V <> 
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MATERIALS AND METHODS 
Viruses and cells 
The early region 3 (E3)-deleted Ad-5 mutant virus 
which lacks the Xbal D fragment of Ad (Ad5AE3), the 
Ad-gB recombinant, and the replication of Ad-gB in the 
mouse lung have been described22"6-27. Ad recom-
binants expressing truncated forms of gB or E4 of the 
IE1 gene were constructed by overlap recombination 
using-ptasmid pAd-5 (m.u. 0-75.9), and the correspond-
ing plasmids containing the subfragments of the gB or 
IE genes inserted into the E3-deleted plasmid pAd-5 
(m.u. 59-100) as described26. Truncated gB and IE1 
gene fragments were constructed by amplification of 
plasmids containing the intact gB (pAd-5-gB)"6 or IE1 
(pRL43a)28 genes, using the polymerase chain reaction 
(PCR) technique. The 5' gB- and IE1-specific PCR 
primers were engineered so that an Xbal site was placed 
upstream of the initial ATG codon. The 5' IE1 primer 
was also engineered to change the first codon in the 
E4 region to an ATG, resulting in methionine as the 
first residue of the translated protein product29. The 
sequences of the 5' gB and IE1 PCR primers are 
5'-acacgcaagagaictagacgcgcctcat-3' and 5'-ttatcctcctcta 
gaatgaaacagattaag-3', respectively. The 3' gB-specific 
primers were engineered to place a termination signal 
just downstream of the indicated amino acid of the gB 
gene30. The sequences of the 3' gB-specific primers 
used to generate Ad-700, Ad-465 and Ad-303 are 5'-
tcgtccagactctagaggtagggc-3', 5'-cgactccattctagattaatgag 
ttgc att-3', 5'-caaagtcggagtctagagtctagttcggaaa-3' and 5'-
cagataagtggtctagatctaagcgtagctacg-3', respectively. The 
sequence of thé 3' IE1 PCR primer is 5'-atatatatattctag 
agtttactggtcagc-3'29. Figure 1 shows schematic diagrams 
of the Ad-HCMV recombinant viruses. 
Expression of gB-polypeptides was detected in A549 
human lung carcinoma cells infected with Ad-700, 
Ad-465 or Ad-303 recombinants by an immunofluores-
cence test using monoclonal antibody (Mab) 3C2 
(courtesy of R.C. Gehrz, Biomedical Research Center. 
St. Paul, MN, USA)13-31. This Mab recognizes an 
epitope in the region of the gB protein between amino 
acids 50 and 77. Expression of the E4 polypeptide in 
A549 cells infected with Ad-IE 1 (E4) was confirmed by 
immunofluorescence assay using Mab P63-27 (kindly 
provided by W. Britt, University of Alabama at 
Birmingham, AL, USA). 
The parental Ad strain Ad-5, obtained from the 
American Type Culture Collection (ATCC, Rockville, 
MD, USA), and recombinant Ad were grown and 
titered on A549 cells. For immunization of mice, Ad 
grown on A549 cells was purified by CsCl gradient 
centrifugation26. 
A vaccinia (VVR strain) recombinant carrying the IE1 
gene of HCMV (Vac-IEl) and the parental vaccinia 
(WT-Vac) were provided by Enzo Paoletti (Virogenetics 
Corp., Troy, NY, USA) and used for infection of target 
cells in CTL assays for Ad-IE 1 (E4). The vaccinia 
recombinant carrying the gB gene of HCMV (Vac-gB) 
has been described10. 
Immunization of mice 
Six- to 8-week-old female CBA mice of MHC haplo-
type H-2k (Jackson Laboratories, Bar Harbor, ME, 
USA) were inoculated intraperitoneally with 108 p.f.u. 
of recombinant yjruses or as a control with Ad5AE3 
parental virus; sera and splenocytes were collected and 
analyzed for antibody and CTL responses. 
Neutralization assay 
HCMV (Towne strain) neutralization titers were 
determined on MRC-5 cells by microneutralization and 
plaque-reduction neutralization assays32. Ad-5 neutral-
ization titers were detected by a microneutralization 
assay as described for HCMV32, except that A549 
instead of MRC-5 cells were used. 
ELISA assay 
An ELISA assay was carried out as described33. As 
antigens, HCMV (Towne strain) was collected by high-
speed centrifugation from culture medium of infected 
MRC-5 cells, and as control, lysates of uninfected 
MRC-5 cells, both at a protein concentration of 1.5 pg 
well" were used. Peroxidase-conjugated goat affinity-
purified F(ab')2 fragment to mouse IgG (Cappel, 
Durham, NC, USA) was used as a second antibody. 
The optical density (O.D.) was read by a microtiter 
plate reader (Bio-Tek Instruments, VT, USA) at 490 nm. 
Antibody response was considered positive when 
the O.D. value exceeded the mean density value of 
Ad5AE3-immunized mice plus two standard deviations. 
CTL assay 
CTL assay and the characterization of cells 
responsible for insert-specific lysis were carried out as 
described22. Briefly, spleens of CBA mice immunized 
with the Ad-gB or truncated-gB recbmbinant viruses or 
Ad5AE3 were aseptically removed and cell suspensions 
were prepared from them. Cells were suspended at 
2 . 5 x l 0 6 viable cells m l - 1 in RPMI 1640 medium 
containing 5% fetal bovine serum, 2 x 1 0 " 5 M 
2-mercaptoethanol, 10 m.M-HEPES buffer, 2 mM-
glutamine and 50 pg m l - 1 gentamicin. Spleen cell 
cultures were restimulated in vitro with Ad-gB-infected 
(multiplicity of infection (m.o.i) 10) autologous spleen 
cells (effector:stimu!ator ratio 2:1) for 5 days in 24-weil 
plates. Cytolytic activity of non-adherent spleen cells 
was tested in a 5 lCr release assay. Target cells (L-929 
and MC57) were infected with the Ad5AE3 (m.o.i. 
40-S0, for 40 h) or with Vac-gB, Vac-IEl or WT-Vac 
(m.o.i. 5-10, for 4 h). Cells were labeled with 100 mCi of 
[ Cr]Na2Cr04 (Amersham, Arlington Heights, IL, 
USA; specific activity 250-500 mCi mg" 1 ) for 1 h. 
Labeled target cells were mixed with effector cells at 
various effectortarget ratios in triplicate using 96-well 
U-bottomed microtiter plates and incubated for 4 h. 
Percentage specific 51 Cr release was calculated as 
[(c.p.m. experimental release - c.p.m. spontaneous 
release)/(c.p.m. maximal release — c.p.m. spontaneous 
release)] x 100. Standard deviation of the mean of 
triplicate culture was <10%, and spontaneous release 
was always <25%. Significance of lysis was determined 
by comparing test c.p.m. to control c.p.m. using the 
Student's /-test. 
To characterize the cells responsible for anli-gB cyto-
toxicity, 3 x 106 in vitro restimulated spleen cells of 
Ad-recombinant-immunized mice were incubated with 
anti-mouse CD4 Mab (Pharmingen, San Diego, CA, 
„372 Vaccine 1996 Volume 14 Number 5 
V/ I I c r o ^ u / / o o o . I 










mRNA Start Site 
MIEP Enhancer 




Xba I X b a 1 
Figure 1 Schematic representation of the HCMV gene fragments inserted into the Ad E3 deletion vector. (A) Full-length and truncated versions 
of the HCMV-gB gene are depicted as Xba\ DNA fragments inserted downstream of the Ad E3 promoter. The gB open reading frame starting 
at the first methionine (ATG; amino acid position 1) and the site of proteolytic processing of the gB gene (arrow between amino acids 460 and 
461) are indicated. Also indicated are the gB leader peptide, amino acids 1-24 (• ) , N-terminal part (O), C-terminal part (shaded square), 
transmembrane region (hatched square) and the positions of the Xba\ sites. (B) The E4 region of the major immediate early protein (MIEP) locus 
was amplified using PCR and inserted downstream of the Ad E3 promoter. The PCR primers were engineered so that a methionine (ATG) codon 
begins E4. In addition, a redundant termination signal was placed downstream from the natural stop codon. The positions for the initiation of 
transcription and of the Xba\ sites are indicated. The first four exons of the HCMV MIEP complex are part of the mature mRNA for the HCMV 
IE1 protein. Striped boxes indicate the actual portions of these exons which encode the IE1 protein 
USA; Cat. No. 3:0106ID; 20 /ze/3 x 106 cells) or 
CD8 Mab (Accurate, Westbury, N Y ; Cat N o . CL-8921; 
diluted 1:4) for 60 min at 4°C, and further incubated in 
the presence of rabbit complement (Accurate; Low-Tox 
M; diluted 1:10) for 30 min at 37°C. Cells were washed 
twice and used as effector cells in a 5 , Cr release test. 
RESULTS AND DISCUSSION 
Antibody responses to truncated forms of gB 
Sera obtained from all immunized mice showed a 
significant level of Ad-5 -NA. Sera obtained from mice 
inoculated with Ad-gB or Ad-700, but not sera from 
mice inoculated with the other two truncated gB recom-
binants (Ad-465 and Ad-303), induced a significant level 
of H C M V - N A (Table 1). These data are consistent with 
the well-confirmed observation that the HCMV-gB 
immunodominant antibody neutralizing domain is 
located between amino acids 476-645 of the—gB 
gene 1 5 , 1 8" 0 . In addition, these data show that the neu-
tralizing domain located between amino acids 28-67 1 9 
induced no NA response in CBA mice. 
ELISAs used to confirm production of anti-HCMV 
antibodies in Ad recombinant-immunized mice revealed 
antibodies in all groups [Table 1). However, only 12/16 
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Table 1 Antibody responses to Ad-recombinants expressing trun-
cated forms of HCMV-gB 
Mice inoculated 
Specific neutralizing* antibodies 
with: HCMV Ad-5 ELISA6 HCMV 
Ad-gB 84.2 362.0 1313+120 
Ad-700 76.1 430.5 407 + 201 
Ad-465 5.2 430.5 487+140 
Ad-303 5.6 362.0 266±135 — 
Ad5DE3 4.2 440.5 44±31 
"Geometric mean of serum dilutions of eight mice in each group 
showing complete inhibition in the microneutralization assay. "Mean 
O.D. of sera from 10-16 mice at 490 nm±S.D. at 1:40 serum dilution 
(75%) mice immunized with Ad-303 responded with 
antibody production, whereas all mice in groups immu-
nized with Ad-gB, Ad-700 or Ad-465 were positive for 
anti-HCMV ELISA antibodies (individual data not 
shown). Like the variability in antibody response to 
Ad-303 in our study, Curtsinger et al.n have reported 
antibody responses to a truncated gB antigen containing 
amino acids 1-163 in some seropositive individuals but 
not in others with the same HLA class II haplotype. 
CTL responses to truncated forms of gB 
Because HCMV does not infect mice in vivo or murine 
cells in culture, we used an approach based on two 
distinct viral expression vectors, Vac and Ad, carrying 
the same HCMV genes or gene fragments, to determine 
the CTL response of mice immunized with HCMV 
genes22. This dual vector system allows immunization 
of mice with one vector system (Ad) and infection of 
target cells with the other (Vac). Consistent with the 
Ad-specific N A responses (Table 1), mice immunized 
with any of the recombinants carrying intact or trun-
cated forms of the HCMV-gB gene or with Ad5AE3 
parental strain demonstrated Ad-specific cytotoxic re-
sponses (Figure 2). Ad-gB-, Ad-700-, Ad-465- or Ad-
SOS-immunized mice but not the Ad5AE3-immunized 
mice developed gB-specific cytotoxic responses; per cent 
specific 5lCr-release of Vac-gB-infected target cells sig-
nificantly (/5<0.01 at 50:1 effector-to-target ratio) 
exceeded per cent specific lysis of WT-Vac-infected 
target cells (Figure 2). Infected major histocompatibility 
complex (MHC) class I mismatched MC57 (H-2b) cells 
were not gB-specifically lysed, indicating M H C class I 
(H-2k) restricted lysis of target cells. Treatment of in 
vitro restimulated spleen cells of mice immunized with 
the Ad-gB, Ad-700, Ad-465 or Ad-303 with anti-mouse 
CDS Mab and complement22, abolished the anti-gB 
activity, whereas CD4-depleted cells continued to medi-
ate this activity (data not shown), confirming that the 
CDS lymphocyte subset mediates the gB-specific lysis of 
the target cells. These results suggest the presence of a 
CTL epitope between amino acids 1-303 in • the 
N-terminal fragment of HCMV-gB when it is expressed 
by Ad recombinants in CBA mice, and an authentic 
presentation of gB peptides by the M H C class I mol-
ecules of cells infected with the Ad-700, Ad-465 and 
Ad-303 recombinants. 
CTL responses to IE1 E4 product 
Spleen cells from five individual mice and a pool of 
splenocytes from two mice, obtained 7 or 10 weeks after 
Ad5iE3 
50:1 25:1 12:1 6:1 50:1 25:1 12:1 6.1 50:1 25:1 12:1 6:1 
E:T ratio 
Figure 2 CTL responses in mice immunized with Ad constructs 
containing truncated forms of the gB gene. Ten CBA mice in each 
group were inoculated interperitoneally with Ad recombinants at a 
dose of 1x10s p.f.u., boosted similarly 7 weeks later, and tested for 
HCMV-gB-specific cytotoxicity 2 weeks after booster. Splenocytes of 
two mice from each group were pooled, restimulated with Ad-gB for 
5 days in vitro, and tested in a 51Cr-release assay22. MC57 (H-2b, 
MHC-mismatched), and L929 (H-2\ MHC-matched) cells were used 
as targets. Data are from a representative experiment of three 
performed with superimposable results. Uninfected L929 and MC57 
target cells infected with Ad5AE3, Vac-gB or WT-Vac were not 
significantly lysed (not shown). L929 (H-2k) target cells infected with 
Wt-Ad, O; Vac-gB, Wt-Vac, A 
immunization, respectively, were tested for E4-specific 
CTL responses on Vac-IEl-infected target cells. The 
IE1 E4-specific lysis (per cent specific 2TCr-release of 
Vac-IEl-infected target cells — per cent specific lysis of 
Wt-Vac-infected target cells) was in the range of 19—25% 
in each case at an effector-to-target ratio of 50:1 
(P<0.01, Student's t-test), and almost no anti-IEl 
activity was detected using CDS-depleted spleen cells, 
while CD4-depleted spleen cells retained their activity 
(data not shown). These results indicate a significant 
E4-specific stimulation of CTLs in CBA mice. 
HCMV IE1 stimulates its own synthesis and co-
operates with the IE2 gene product and other trans-
activators in the activation of gene expression34. The 
functional domains for transactivation of this protein 
have not been identified, and it is unknown whether the 
E4 product is involved in the transactivation activity of 
IE 1. Lurther studies are necessary to map this activity 
on the IE1 protein in order to design the antigen without 
transactivating activity. 
Precise mapping of CTL epitopes of the gB poly-
peptide and IE 1 E4 product is a difficult task. There may 
be several CTL epitopes in the gB polypeptide that 
function depending on the M H C class I haplotype of the 
individual. For example, CTLs reactive with epitopes on 
the N-terminal 513 amino acids portion of gB were 
detected in one seropositive individual", whereas an 
HLA-A2.1-restricted CTL recognition has been de-
scribed between amino acid positions 619-628 of 
HCMV-gB using CTL lines generated from two HLA-
A2.1+ donors24. A synthetic peptide encompassing a 
sequence of IE1 E4 gene was identified as a class 
I-restricted CTL determinant using a CTL line derived 
from a human donor25. 
Effective protection against HCMV disease correlates 
with the presence of CTL in the infected individuals35,36. 
Further, treatment of HCMV infection by the adoptive 
transfer of HCMV-specific CTL has shown reconstitu-
tion of immunity in bone marrow transplant recipients7. 
The nature of major viral target antigens to which the 
CTL response is directed in vivo is not clear, but they 
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may comprise pp65 and pp 150-, However, CD8+ CTL 
clones specific for gB have also been isolated from 
certain seropositive individuals6. CTL specific for IE 
were also detected in some HCMV-infected indi-
viduals, especially when target cells were preincubated 
with y-interferon8,37 which might upregulate expres-
sion of class I MHC genes not only in vitro, but "afier 
natural challenge infection. Those findings suggest the 
involvement of the IE protein in protective immunity. 
Our data map a CTL epitope in the amino acids 1-303 
region of the N-terminal portion of gB and suggest that 
both the C-tenninal and the N-terminal portion of gB 
are important in inducing protective immunity and 
should be included in a HCMV vaccine. Our data also 
show that the IE E4 protein is immunogenic and induces 
CTL after presentation by a recombinant virus. How-
ever, the MHC-restriction of individual HCMV proteins 
in the heterogeneous human population is a potential 
obstacle in developing an effective recombinant vaccine. 
One approach towards overcoming this obstacle might 
involve the use of a combination of recombinant pro-
teins. The gB and IE E4 gene products-appear to be 
good candidates for combination, possibly with other 
HCMV gene products. 
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Abstract 
Plasmids expressing the human cytomegalovirus (HCMV) glycoprotein B (gB) (UL55) or phosphoprotein 65 (pp65) (UL83) 
were constructed and evaluated for their ability to induce immune responses in mice. The full-length gB as well as a truncated 
form expressing amino acids 1-680 of gB, and lacking the fragment encoding amino acids 681-907 including the transmembrane 
domain of gB (gB680) were evaluated. Immunization of mice with plasmids coding for gB or gB680 induced ELISA and 
neutralizing antibodies, with the highest titres in mice immunized with the gB680 plasmid. Mice immunized with the gB plasmid 
predominantly produced IgG2a gB-specific antibody, while the gB680 plasmid raised mostly IgGl anti-gB antibody. Mice 
immunized with the pp65 plasmid developed pp65-specific cytotoxic T lymphocytes (CTL) and ELISA antibodies. Immunization 
with a mixture of both gB and pp65 plasmids raised antibodies to both proteins and pp65-specific CTL, indicating a lack of 
interference between these two plasmids. These results suggest that DNA immunization is a useful approach for vaccination 
against HCMV disease. © '998 Elsevier Science Ltd. All rights reserved. 
Keywords: HCMV; Antibody; CTL; DNA immunization 
1. Introduction 
Induction of specific cellular and humoral immune 
responses in experimental animals inoculated with 
plasmid vectors expressing viral proteins has been 
amply documented. Such studies have led to efforts to 
use naked DNA as vaccines against several viral dis-
* Corresponding author. Fax: +1 215 898 3868; E-mail: gonczol 
@ wista.wistar.upenn.edu. 
1 Present address: Department of Microbiology, Semmelweis 
Medical University, Budapest, Hungary. 
eases, including influenza [1-7], AIDS [8-10], 
rabies [11], hepatitis B [12-15] and hepatitis C [16], 
lymphocytic choriomeningitis [17-19], and herpes sim-
plex virus- and murine cytomegalovirus (MCMV)-
induced diseases [20-24]. 
Infection with cytomegalovirus (CMV) in humans is 
common and usually asymptomatic; however, the inci-
dence and spectrum of disease in newborns and immu-
nocompromised hosts establishes this virus as an 
important human pathogen [25]. CMV has also been 
suggested to be an important co-factor in the develop-
0264-410X/98/S19.00 © 1998 Elsevier Science Ltd. AU rights reserved. 
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ment of atherosclerosis [26,27] and restenosis after 
angioplastic surgery [28,29]. 
Among the estimated 200 proteins encoded by the 
human cytomegalovirus (HCMV) genome [30], glyco-
protein B (gB) [31-33] and phosphoprotein 65 
(pp65) [34-37] have been implicated as principal tar-
gets of virus neutralizing antibody and virus-specific 
CTL responses, respectively. Work in our laboratory 
aimed at developing a recombinant vaccine to HCMV 
has shown that the gB protein when expressed by 
adenovirus [38], vaccinia virus [39], or canarypox 
(ALVAC) virus [40] vectors induces neutralizing anti-
bodies in experimental animals, lymphocyte prolifer-
ation upon in vitro antigen stimulation [41], and CTL 
responses in mice of H-2k haplotype [42]. In this 
study, we constructed plasmids containing the full-
length or truncated genes of HCMV-gB or the pp65 
gene, respectively. gB is the major immunogenic pro-
tein of HCMV that induces neutralizing antibodies [31-
33,39], and the 1-680 amino acid fragment of gB con-
tains most of the neutralizing epitopes but lacks the 
transmembrane domain, resulting in the secretion of 
gB from cells [47,48]. Thus, these plasmids are suitable 
for evaluating whether the secreted form or the mem-
brane-bound form of gB induces stronger NA re-
sponses. pp65 is the most prominent target of CTL 
responses after natural infection [34-37]. We report 
here that the gB and pp65 proteins, as expressed by 
mammalian expression plasmids inoculated alone or in 
combination, induce gB and pp65-specific antibody 
and pp65-specific CTL responses. Mice immunized 
with the plasmid encoding gB produced predominantly 
IgG2a gB-specific antibody, while those immunized 
with the gB680 plasmid developed a greater antibody 
response dominated by IgGl gB-specific antibody. 
2. Materials and methods 
2.1. Expression plasmids carrying HCMV gB (UL55) 
and pp65 (UL83) genes 
2.1.1. pK-gB, pARC-gB and pARC-gB680 plasmids 
The gB gene, derived from the plasmid pAd-gB [38], 
was subcloned into pUC-8, obtained as a Hindlll-
BamHl fragment, and inserted into the pARC vector 
digested with Hindlll and BamHl (pARC-gB). pARC-
gB680 was derived from pARC-gB by digestion with 
Xhol and removal of the C-terminal part of the gB 
gene. The pARC vector contains the CMV-IE promo-
ter; it was derived from pRC/CMV (Invitrogen) by 
deleting the Pvull 1290-PvulI 3557 fragment to obtain 
more unique restriction sites. The full-length gB gene 
was also inserted to a plasmid expressing gB under the 
control of a tetracycline-regulatable promoter. This 
plasmid utilizes the tetracycline-regulatable system 
obtained from plasmids pUHD10-3 and pUHD15-l 
(kindly provided by Dr H. Bujard, Heidelberg, 
Germany; described in Ref. [43]). The resulting plas-
mid, pK-gB contains: the tetracycline-regulatable pro-
moter (seven tetracycline operators (Tet°) and the 
HCMV minimal promoter), HCMV-gB, SV40 poly A 
signal, HCMV-IE promoter/enhancer, tTA gene 
(encoding a fusion protein consisting of the tetra-
cycline repressor from Escherichia coli and herpes sim-
plex virus protein-16), and the SV40 poly A signal. 
The fusion protein is a powerful transactivator of the 
7 Tet°-HCMV minimal promoter; however, in the pre-
sence of tetracycline, the transactivation is switched 
off, since tetracycline prevents the attachment of the 
tetracycline repressor to the tetracycline operator 
sequences. pK-gB expresses gB in a tetracycline-regula-
table fashion: tetracycline (1 /ig ml - 1) reduces gB ex-
pression, however, in the absence of tetracycline the 
tetracycline-regulatable promoter is fully functional 
and gB is expressed. 
2.1.2. pARC-pp65 plasmid 
First, the pp65 gene was cloned into a pUC-8 based 
plasmid. The HCMV pp65 gene was PCR-amplified 
using genomic DNA as template (Towne strain), oligo-
nucleotides pp651 (5 'G ATT ATCGCG ATATCCGTT A 
AGTTTGTATCGTAATGGCATCCGTACTGGGT 
CCCATTTCGGG-3') and pp651R (5'-GCATAGG 
TACCGGATCCATAAAAATCAACCTCGGTGCT 
TTTTGGGCG-3'), and Taq I polymerase (Perkin 
Elmer Cetus). The 1.6 kb product was digested with 
Nrul and BamHl (sites present at the 5' end of oligo-
nucleotides pp651 and pp651R, respectively) and 
cloned into Nrul/Bam Hi-digested SPHA-H6 (a pUC-
8-based plasmid containing an irrelevant gene flanked 
by Nrul and BamHl sites), generating plasmid 
CMV65.1 in which the first 30 bp of the pp65 gene 
were missing. 
To derive a plasmid containing the entire pp65 gene, 
oligonucleotides RNApp65I (5 '-TAGTTCGGATCCC 
CGCTCAGTCGCCTACA-3') and pp65R4 (5'-ATC 
AAGGGATCCATCGA AAA AG AAGAGCG-3') were 
used in PCR with genomic DNA. The resulting 1-kb 
fragment was digested with BamHl (BamHl sites pre-
sent at the 5' ends of both oligonucleotides) and 
cloned into BomHI-digested IBI24 (International 
Biotechnologies), generating plasmid pp65.7. Plasmid 
pp65.7 was used in PCR with oligonucleotides pp651B 
(5 '-GATTATCGCGATATCCGTTA AGTTTGTATC 
GTAATGGAGTCGCGCGGTCGCCGTTGTCCCG-
3') and pp65£siXI (5 '-ACCTGCATCTTGGTTGC-3') 
to generate a 0.5-kb fragment. This fragment was 
digested with Nrul and BstXl (sites at the 5' ends of 
oligonucleotides pp651B and pp65RrtXI, respectively) 
and ligated to a 4.8-kb Nrul/BstXl fragment of 
CMV65.1, generating plasmid pCMV65.2. The 1696-
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bp pp65 gene was obtained from plasmid pCMV65.2 
by Nrul-BamHl digestion. The pARC-CMV vector 
was blunt-ended with Klenow polymerase, digested 
with BamHl, and the pp65 gene was inserted. 
Transient transfections of human 293 cells (ATCC) 
were performed using purified plasmid preparations 
(1.5 jtg/3 x 10s cells), and Lipofectamine (BRL, 
Gaithersburg, MD). Two days after transfection, cells 
expressed the HCMV proteins as detected by immuno-
fluorescence assay using gB-specific monoclonal anti-
body (Advanced Biotechnologies, Columbia, MD) and 
pp65-specific monoclonal antibody (Virostat, Portland, 
ME). 
2.2. Preparation and purification of plasmids 
Plasmids were transfected into Escherichia coli strain 
DH5a and stored at -70°C in medium and 10% gly-
cerol solution. Bacteria were grown in LB broth sup-
plemented with ampicillin. Large-scale purification was 
conducted using Quiagen Giga kits (Quiagen, Santa 
Clarita, CA) according to the manufacturer's protocol. 
Purity and concentration of DNA were determined by 
UV spectrophotometry. Purified plasmid DNA was ali-
quoted and stored at —70°C. 
2.3. Immunization procedure 
Seven- to ten-week-old female BALB/c mice were 
used in all immunizations. DNA was inoculated intra-
muscularly into the quadriceps at doses of 50-80 pg/ 
mouse at times indicated in the specific experiments 
(see Results). In co-immunization experiments groups 
of mice were inoculated with either a mixture of both 
pK-gB and pARC-pp65 plasmids (80 pg of each DNA/ 
mouse, 40 pg of each DNA/leg, 160 pg DNA/mouse), 
or each plasmid inoculated into two different legs 
(80 pg DNA of each plasmid/mouse, a total of 160 pg 
DNA/mouse inoculated in left and right legs). Booster 
injections were given 4 and 8 weeks later. 
2.4. Microneutralization assay 
HCMV neutralizing activity of sera was tested in a 
microneutralization assay [44], Neutralizing titres 
higher than 1:8 were considered positive. 
2.5. Cytotoxic T lymphocyte assay 
The pp65-specific CTL assay was performed as pre-
viously described [42]. Briefly, spleen cells of immu-
nized mice were restimulated in vitro with autologous 
spleen cells infected with vaccinia virus recombinant 
expressing HCMV-pp65 [42] (VacWR-pp65) or wild-
type vaccinia (VacWR) for 5 days in 24-well plates 
(m.o.i = 0.2-0.5; effector:stimulator ratio, 2:1). 
Cytolytic activity of non-adherent spleen cells was 
tested in a 4-h slCr-release assay. Target cells (P815 
MHC class I-matched, MC57 MHC class I-mis-
matched) were infected with VacWR-pp65 or VacWR 
(m.o.i = 4-8). Percentage of specific 51Cr-release was 
calculated as [(cpm experimental release—cpm spon-
taneous release)/(cpm maximal release—cpm spon-
taneous release) xl00]. 
2.6. ELISA assay 
A preparation of gB protein purified by immunoaffi-
nity column chromatography was used as coating anti-
gen in assays to detect gB-specific serum antibody 
responses. Optical density values (A) higher than mean 
A +2 S.D. of pre-immune sera or .¿-values greater 
than or equal to 0.05 were considered positive, which-
ever was higher. For pp65-specific antibodies, lysates 
of 293 cells transiently transfected with pARC-pp65 
were used as coating antigen, and lysates of untrans-
fected 293 cells served as control antigen. For each 
serum dilution optical density values obtained in con-
trol antigen-coated wells were subtracted from those 
obtained in pp65 antigen-coated wells and were con-
sidered positive if they were greater than or equal to 
0.05. Plates were blocked with PBS containing Tween 
20 (0.05%, v/v) and skim milk (2.5% w/v) for 1 h. 
Serum samples and peroxidase-conjugated anti-mouse 
antibodies were diluted in blocking buffer and incu-
bated sequentially on the plates. For colour develop-
ment, 0.1 M citrate buffer (pH 4.5) containing 
hydrogen peroxide (0.012%, v/v) and O-phenylenedia-
mine (1 mg/ml) was added for 15min, at which point 
the reaction was stopped with 1 M sulfuric acid. Plates 
were read spectrophotometrically at 490 nm. 
2.7. Isotype assay 
Peroxidase-conjugated rabbit anti-mouse IgG3 and 
rat monoclonal anti-mouse IgGl, IgG2a, and IgG2b 
(Zymed, San Francisco, CA) were used to detect 
specific immunoglobulin isotypes. Each of the second-
ary antibodies was determined to be highly specific for 
the appropriate isotype and quantitatively similar in 
reactivity in the ELISA, allowing quantitative com-
parisons between the levels of each isotype. For deter-
mination of antigen-specific isotype content of sera, a 
standard curve was prepared for each isotype for each 
ELISA using purified mouse IgGl, IgG2a, or IgG2b 
(Cappel, Aurora, OH) as antigens. Serum titres were 
converted to antibody concentration by comparison 
with a standard, calculated from two points of the lin-
ear portion of the curve. 
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3. Results 
3.1. pK-gB and pARC-pp65 induce insert-specific 
antibody and pp65-specfic CTL responses in mice 
Groups of 10 BALB/c mice were inoculated with 
pK-gB or pARC-pp65 (80 /rg/mouse) and then boosted 
with the same amount of plasmid 4 and 8 weeks later. 
In mice immunized with pK-gB, HCMV-gB-specific 
ELISA antibodies were detected in 9 of 10 mice at 8 
weeks and in all mice tested at 13 and 21 weeks 
(Fig. 1). Antibodies were still present in 4 of 5 mice 
tested at 31 weeks (Fig. 1). HCMV neutralizing anti-
bodies were detected in 4 of 10 mice with titres ranging 
between 1:12 and 1:48 (data not shown). All mice 
immunized with pARC-pp65 responded with pp65-
specific ELISA antibodies after the first booster 
(Fig. 2). Six mice were sacrificed at week 13 for CTL 
analysis. Three responded with pp65 specific lysis of 
target cells (Fig. 3). All four remaining mice had sig-
nificant ELISA antibodies at week 13 (Fig. 2). 
Parental vector plasmids did not induce gB or pp65-
specific ELISA antibodies. In additional experiments, 5 
of 9 mice immunized with pARC-pp65 showed strong 
pp65-specific CTL responses (data not shown). 
3.2. Co-immunization with a mixture of pK-gB and 
pARC-pp65 induces antibody and pp65-specfic CTL 
responses 
To determine whether the injection of a mixture of 
the two plasmids pK-gB and pARC-pp65 had an effect 
on the immune response towards each encoded anti-
gen, mice were immunized either with a mixture of 
both plasmids or with each plasmid at different sites. 
0 4 8 13 21 31 
weeks after initial immunization 
Fig. 1. pK-gB induces gB-specific antibody in mice. Mice were 
immunized with pK-gB and boosted at weeks 4 and 8. Serum 
samples were analyzed at the indicated times by gB-specific ELISA. 
Optical density values obtained with 1:40 dilution of serum are 
shown. Each curve represents results of individual mice. Some mice 
died during the course of the study as a consequence of anaesthesia 
and/or bleeding. 
weeks after initial immunization 
Fig. 2. pARC-pp65 elicits pp65-specific antibody responses. Mice 
were immunized with 80 pg pARC-pp65 and boosted at weeks 4 and 
8. Serum samples were analysed at the indicated times by pp65-
specific ELISA. pp65-specific optical density values obtained with 
1:40 dilution of serum are shown. Each curve represents results of in-
dividual mice. 
They were boosted 1 and 2 months later, and serum 
samples collected at different times after the initial im-
munization were assayed for both gB and pp65 anti-
bodies. All ten mice inoculated with the plasmid 
mixture developed both gB (Fig. 4A) and pp65 
(Fig. 4B) specific antibodies 8 or 13 weeks after the 
first inoculation and in those mice where serum 
samples were assayed, antibodies were detected 
E:T ratio 
Fig. 3. pp65-specific CTL responses in BALB/c mice immunized with 
pARC-pp65. Mice were immunized as described in Fig. 2 and sacri-
ficed 1 month after booster. Spleen cell cultures were restimulated 
with VacWR-pp65-infected autologous spleen cells for 5 days. 
Specific lysis was tested on WT-Vac- or VacWR-pp65-infected P-815 
(MHC-matched) and VacWR-pp65-infected MC57 (MHC-mis-
matched) target cells. The figure shows the result obtained with one 
of the three CTL-responder mice. Q P-815 VacWR-pp65-infected; 
0 , P-815 WT-Vac-infected; O, MC57 VacWR-pp65-infected. 
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A 
0 4 8 13 21 31 
weeks after initial immunization 
B 
weeks after initial immunization 
Fig. 4. Kinetics of gB and pp65-specific antibody responses of mice 
immunized with a mixture of pK-gB and pARC-pp65. Mice were 
immunized with a mixture of 80 pg pK-gB and 80 pg pARC-pp65 
and boosted at weeks 4 and 8. Serum samples were analysed at the 
indicated times by gB and pp65-specific ELISA. (A) and (B) show 
gB-specific and pp65-specific optical density values, respectively, 
obtained with l:40 dilution of individual serum samples. Some mice 
died during the course of the study as a consequence of anaesthesia 
and/or bleeding. 
3.3. Immunization with the secreted form of gB (pARC-
gB680) induces a greater gB-specific ELISA and 
neutralizing antibody response than immunization with 
the natural membrane-anchored form of gB (pARC-gB) 
To determine whether a secreted form of gB would 
induce a greater level of antibody response than the 
native membrane-anchored form of the protein, two 
kinds of gB-expressing plasmids were constructed: 
pARC-gB expresses the full-length protein and pARC-
gB680 expresses gB lacking the transmembrane 
domain of the protein. Each plasmid was injected at 0 
and 8 weeks in different groups of mice and the 
ELISA response was assessed at 12 weeks. The mice of 
the pARC-gB680 group responded considerably better 
than the mice of the pARC-gB group. In the pARC-
gB680 group, 9 of 10 mice responded with a mean 
optical density value of 2.833 + 0.194, while 6 of 10 
mice in the pARC-gB group responded with a mean 
optical density value of only 0.436 ± 0.470 at a dilution 
of 1:40. The difference is statistically significant 
(p < 0.01) by Student's Mest. As shown in Fig. 5, 
there is also a difference between the two groups when 
the neutralizing antibody responses are compared. In 
the pARC-gB680-immunized group, 10 of 10 mice had 
neutralizing antibodies with titres ranging from 1:12 to 
1:192, whereas only 4 of 10 mice immunized with 
pARC-gB responded with titres of 1:12 to 1:48. 
3.4. Different gB-specific IgG isotypes are generated by 
the membrane-anchored and the secreted form of gB 
Because the way an antigen is presented to the 
immune system can affect the T-helper cell type and 
ratio of antibody isotypes that are induced [45,46], we 
tested whether antibody isotypes might be differentially 
throughout the 31-week observation period. The time 
course of the gB- and pp65-specific ELISA antibody 
response in the group immunized with the mixture was 
not significantly different from that of the group 
immunized with the two plasmids at separate sites 
(data not shown). 
In another experiment, similar gB- and pp65-specific 
antibody responses were observed. A pp65-specific 
CTL response was detected in 4 of 5 mice immunized 
with a mixture of both plasmids, while a pp65-specific 
CTL response was obtained in 4 of 6 mice that 
received the two plasmids at different sites (data not 
shown). 
These results establish that the injection at the same 
site of a mixture of plasmids coding for pp65 and gB 
does not affect the specific immune response directed 
towards each antigen. 
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Fig. 5. Higher HCMV neutralizing antibody titres are elicited by 
pARC-gB680 than by pARC-gB. Mice were immunized with 50 pg 
pARC-gB or pARC-gB680, and a corresponding booster was given 8 
weeks later. Sera were obtained 8 weeks after the booster and tested 
for HCMV neutralizing antibodies. Neutralizing antibody titres of 
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affected by the immunization with plasmids coding for 
the membrane-bound form of gB versus the secreted 
form. Two groups of mice received two immunizations 
of pARC-gB or pARC-gB680 8 weeks apart and indi-
vidual sera obtained 4 weeks after the booster were 
analysed for gB antibody in IgG isotype-specific 
ELISA assays. Both forms of the protein generated 
IgGl and/or IgG2a gB-specific antibodies (Table 1) 
while other antibody isotypes, including IgG2b and 
IgG3, were either undetectable or present in only mar-
ginal amounts. Both IgGl and IgG2a antibodies were 
formed after pARC-gB immunization, although IgG2a 
antibodies were much more abundant; the ratio of 
IgGl/IgG2a was less than 1 in all but one mouse. 
Mice in the pARC-gB80-immunized group also devel-
oped both IgGl and IgG2a antibody, but IgG2a was 
less abundant than IgGl (except in one mouse), and 
thus IgGl:IgG2a ratios were greater than 1 in these 
mice (Table 1). 
4. Discussion 
The pARC-pp65 and the gB plasmids expressing the 
full-length gB or the 1-680 amino acid fragment of the 
gB polypeptide proved to be good immunogens. 
However, the secreted form of gB induced significantly 
higher ELISA and neutralizing titres than did the 
membrane-bound full-length gB (Fig. 5). It remains 
unclear why pARC-gB680 is a better immunogen; one 
possibility is that the mechanism of antigen presen-
tation is different for the membrane-bound and se-
creted gB. The membrane-bound gB may be presented 
Table 1 
Isotypes of anti-gB Ab generated by immunization with plasmids 
expressing the membrane-bound or the secreted form of gB 
Anti-gB Ab" 
Immunization Mouse # IgGl IgG2a 
pARC-gB 1 20 120 
2 < 10 400 
3 25 67 
4 45 30 
5 < 10 82 
6 50 140 
pARC-gB680 1 928 98 
2 116 204 
3 191 89 
4 114 66 
5 212 74 
6 306 90 
7 611 17 
"Mice were inoculated with 50 pg of pARC-gB or pARC-gB680, 
and boosted 8 weeks later under the same conditions. Sera obtained 
after booster were assayed for isotype-specific anti-gB Ab. Values are 
given as pg Ab per 1 ml of serum. 
by transfected myocytes and/or professional antigen-
presenting cells (APC) that become transfected at the 
site of inoculation, while a secreted protein can be 
taken up and presented by non-transfected resident or 
recruited APCs [11,49]. Our findings are that the mem-
brane-bound form of gB produces an IgG2a-dominant 
response, whereas similar inoculations with the se-
creted gB-expressing plasmid generates a predomi-
nantly IgGl response suggesting a different antigen 
presentation mechanism. Several studies have demon-
strated IgG2a-dominant immune responses after intra-
muscular DNA immunization with membrane-bound 
protein or intracellularly localized protein expressing 
plasmids [11,22,50]. Feltquate et al. [51] compared the 
IgG isotype pattern after immunization with DNA 
expressing the membrane-bound or secreted form of 
influenza haemagglutinin (HA); predominant IgG2a 
induction using the whole protein and IgGl using the 
secreted form of HA was demonstrated. The biological 
significance of the differential isotype pattern induced 
by the membrane-bound and secreted gB is not 
known. In sera from healthy blood donors, IgGl was 
the most frequently detected gB-specific subclass [52], 
and a range of human gB-specific neutralizing mono-
clonal antibodies were found to belong to the IgGl 
isotype [53]. The human IgGl subclass is the func-
tional analogue of murine IgG2a, and in agreement 
with the correlation between neutralizing activity and 
IgGl subclass in humans, in mice immunized with gB 
and QS21 adjuvant, a significant correlation was found 
between the levels of virus-neutralizing antibodies and 
IgG2a anti-gB antibodies [54]. On the other hand, im-
munization with gB given together either with alumi-
num hydroxide or Freund's adjuvant resulted in the 
production of only IgGl antibodies, and these anti-
bodies also neutralized the virus [45,54]. Other studies 
also showed that neutralizing CMV-specific mouse 
monoclonal antibodies may belong to either the IgGl, 
IgG2a or IgG2b isotypes [55-57], Moreover, a syner-
gistic effect was described between two monoclonal 
antibodies in a virus neutralization assay, where one 
monoclonal antibody had a much greater neutralizing 
activity in the presence of a non-neutralizing IgGl 
antibody [55]. Further studies are needed to demon-
strate the possible role of gB-specific IgG subclasses in 
vivo. 
We did not test gB-specific CTL responses since the 
major function of the gB protein is considered to be 
the induction of neutralizing antibodies. We also 
showed previously that BALB/c mice do not respond 
with gB-specific CTL after immunization with an ade-
novirus-gB recombinant, although CBA mice showed 
a strong CTL response [42]. However, in view of 
recent studies on hepatitis B virus surface antigen, 
showing that DNA immunization can induce insert-
specific CTL in mice previously considered non-
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responders [15], we cannot exclude the possibility of 
gB-specific CTL induction in BALB/c mice. We did 
test for pp65-specific CTL responses, since the pp65 
protein is a predominant protein for CTL induction in 
natural infections [34-37]. Indeed, pp65-specific ELISA 
antibodies were detected in all mice, and pp65-specific 
CTL responses were found in 16 of the 26 mice tested. 
It remains unclear why some of the mice failed to 
demonstrate pp65-specific CTL activity. Fuller and 
Haynes [8] also reported variable CTL responses after 
immunization of mice with a DNA-based HIV glyco-
protein 120 vaccine. 
Pande et al. [58] reported the induction of pp65-
specific ELISA antibodies by DNA immunization 
using two plasmid expression vectors, in which the 
inserted gene was expressed under the control of the 
human jS-actin promoter or the HCMV IE promoter 
along with intron A. However, neither plasmid con-
struct induced ELISA antibodies in more than 60% of 
the inoculated mice after two inoculations [58], 
whereas nearly 100% of mice in our study responded 
with pp65-specific ELISA antibodies. The difference in 
the ELISA antibody responses in these studies might 
reside in the use of different vector plasmids, inocu-
lation protocols and antibody detection systems. Our 
results also demonstrate that DNA immunization 
induces CTL specific for pp65. 
Although specific immunity following vaccination 
can last for years or even a lifetime, some vaccines 
induce only short-term protection. The physical prop-
erties of the antigen, its in vivo persistence, route of in-
oculation, dose and frequency of reinoculation all may 
influence the duration of immune response. In our 
study, pp65- and gB-specific antibody responses were 
detectable by ELISA in mice for the duration of the 
observation period, i.e., for nearly 8 months after the 
first inoculation with pARC-pp65 or pK-gB, respect-
ively. Long-lasting antibody responses have been 
demonstrated in mice immunized with DNA expres-
sing the influenza virus haemagglutinin and 
nucleoprotein [3,59], the hepatitis B virus surface 
antigen [14] and rabies virus glycoprotein G [11]. In 
contrast, only transient antibody responses were 
observed in macaques after repeated inoculation with 
a plasmid DNA expressing a simian immunodeficiency 
virus protein [10] and in mice immunized with DNA 
expressing the circumsporozoite protein of malaria [60]. 
pK-gB inoculated in combination with pARC-pp65, 
given as a mixture or separately, induced gB- and 
pp65-specific ELISA antibodies in nearly all mice. 
Four of 5 mice immunized with the mixture of two 
plasmids showed pp65-specific CTL. The presence of 
both gB- and pp65-specific ELISA antibodies and 
pp65-specific CTL in the mice inoculated with the mix-
ture of the two plasmids indicates that gB and pp65 
do not mutually block antigen presentation or B and 
T cell stimulation when expressed in the same cells or 
in close vicinity. 
Our results show that DNA immunization can be 
carried out successfully with plasmid DNA expressing 
the HCMV gB and pp65 proteins and that the secreted 
form of gB is more immunogenic than the membrane-
bound full-length gB. A combination of two plasmids 
expressing the gB and pp65 proteins or a single chi-
meric plasmid would induce both cellular and humoral 
immune responses important in protection against 
CMV disease. 
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POSSIBLE NEW VACCINATIONS IN THE FIRST 
QUARTER OF THE NEXT CENTURY 
The WHO-directed vaccination campaign against 
smallpox in the late 1970s led to the eradication of 
the variola virus and made the anti-smallpox vac-
cination unnecessary. The currently available vac-
cines have also provided substantial protection 
against various infectious diseases. "Convention-
al" vaccines (containing attenuated live or inacti-
vated pathogens or their immunogenic compo-
nents), however, would not afford protection 
against many bacterium-, virus- or parasite-caused 
diseases, or their use would not meet the neces-
sary safety requirements. The increasing knowl-
edge in molecular biology relating to these 
pathogens and basic immunology, and also revo-
lutionary progress in gene technology, have pro-
vided alternative possibilities for the development 
of vaccines against such pathogens. One of the 
alternatives is the production and use of bacterial 
or viral proteins engineered by expression vectors 
(bacterium, virus, yeast or plant), which would 
induce humoral immune responses in the immu-
nised individuals. Another alternative is the use of 
recombinant vectors themselves (bacterium, virus 
or plasmid) for immunisation, which would 
induce not only humoral, but also cellular 
immune response against the inserted gene prod-
uct. The most promising vectors are the virus vec-
tors, which do not fully replicate, but express early 
genes in human cells, and the eukaryotic plasmid 
vectors (DNA immunisation). The application of 
molecular biology in preventive approaches, will 
soon lead to the development of a number of 
effective and safe vaccines against severe human 
and animal diseases. 
A himlőmegbetegedés elleni vakcinációs kam-
pánnyal a W H O az 1970-es évek végén him-
lővírusmentessé tette a Földet, és a himlő 
elleni vakcinációt megszüntette. A jelenleg 
forgalomban lévő baktérium- és vírusvakcinák 
is jelentős védelmet biztosítanak számos fer-
tőző betegséggel szemben. Sok vírus, bakté-
rium és parazita okozta megbetegedéssel 
szemben azonban a konvencionális úton elő-
állított vakcinák (élő attenuált vagy inaktivált 
mikroorganizmusok vagy azok immunogén alko-
tóelemei) nem biztosítanak védelmet, vagy 
alkalmazásuk nem biztonságos. Ezen patogé-
nek molekuláris biológiai ismerete és a gén-
technológia fejlődése alternatív megoldásokat 
tesz lehetővé; ezek között említhetők az 
expressziós vektorokkal (vírusok, baktériu-
mok, gombák, növények) termeltetett bakté-
rium- vagy vírusfehérjék (a patogénnek a vek-
torba beültetett génproduktumai), amelyek 
humorális immunválaszt hoznak létre az 
immunizált egyénben. Az expressziós vekto-
roknak (baktériumok, vírusok és plazmidok) 
az immunizálásra való felhasználása azonban 
még hatásosabb, azaz mind celluláris, mind 
humorális immunválasz létrejön. Az immuni-
zálásra potenciálisan használható vektorok 
között az emberi sejtekben nem replikálódó, 
de a korai géneket kifejező vírusvektorok és 
az expressziós eukaryotaplazmid-vektorok 
(DNS-vakcinák) ígéretesek. A fenti molekulá-
ris biológiai technikák alkalmazásával a 
következő években több új hatásos és bizton-
ságos vakcina kerül általános használatra. 
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Új cikksorozatunkban jeles szakemberek tárják az olvasók elé az orvoslás egyes szakterületeinek ezredvégi kihívásait. 
KOZLEMENYEK LAM 1999;9(2):88-95. 
Az orvostudomány eddigi sikerei közé sorol-hatjuk a vakcináció terén elért eredménye-. ket. Ezek között talán legnagyobb a himlő-
betegség és a himlővírus-fertőzés lehetőségének tel-
jes kiiktatása, amelyet az Egészségügyi Világszerve-
zet (World Health Organization, W H O ) az 1970-es 
évek végén világraszóló oltási kampánnyal bonyolí-
tott le. A kampány után a W H O a himlőoltás meg-
szüntetését javasolta, és az oltást 19S0-ban világ-
szerte elhagyták (1). Ugyancsak sikert jelentett az 
1950-es évek végén az elölt (Salk), majd az 1960-as 
évek elején az élő attenuált poliomyelitis-oltóanya-
gok (Sabin) kiterjedt alkalmazása, amelynek hatá-
sára gyakorlatilag nem fordul elő fertőzés a vad 
poliomyelitisvírussal. A W H O a himlővakcinációs 
kampány analógiája alapján poliomyelitiskampányt 
tervez a 2000-es évek elején, amelytől a világ polio-
myelitismentességét reméli. Ezt követné a kanyaró-
vírus eradikációja, szintén az egész világra kiterjedő 
oltási kampány eredményeképpen, amelyhez élő 
attenuált kanyaróvírust tartalmazó oltóanyagot 
használnak majd. A fentieken túlmenően hazánkban 
a kötelező élő attenuált vírusvakcinák, mint a 
mumpsz és a rubeola, az élő attenuált bakteriális 
vakcina, mint a tuberkulózis (BCG), az inaktivált 
bakteriális vakcinák közül a szamárköhögés (Borde-
tella pertussis) -vakcina biztosítanak lényeges védel-
met. Ezen konvencionális vakcinák tehát vagy a 
patogén inaktiválásával, azaz elölésével (elölt polio-
myelitis, B. pertussis), vagy a patogén attenuálásával, 
azaz virulenciájának megszüntetésével, de ugyan-
akkor immunogenitásának megtartásával (élő atte-
nuált poliomyelitis, kanyaró, mumpsz, rubeola, 
BCG) kerülnek előállításra (2-4). 
A patogén attenuálása rendszerint évekig tartó, 
szuboptimális körülmények között végzett, soroza-
tos továbbolcással történt, és a vakcinációra alkal-
mas mikroorganizmusegyedeket úgy választották 
ki, hogy a továbboltott kultúrák virulenciáját és 
immunogenitását kísérleti állatok szervezetében 
mérték. Ilyen módon az attenuálás során véletlen-
szerű mutációk jöttek létre a patogén genomjában, 
amelyek a virulencia elvesztését és az immunogeni-
tás megtartását eredményezték: a mutáns egyedeket 
in vivo teszteléssel választották ki. Jelenleg, a víru-
sok genomjának ismeretében, a patogenitásért fele* 
lős gének genetikai módosításával végzik az atte-
nuálást. 
A baktériumok protektív hatásért felelős kompo-
nenseinek - amelyek sok esetben a patogenitásért 
felelős komponensek is - felhasználása oltóanyag-
ként szintén gyakorlatban van, természetesen a 
patogén hatásért felelős mechanizmus inaktiválása 
után. Ilyenek a diphtheria- és tetanusexotoxinokból 
készített toxoidok, amelyek a kötelező oltások közé 
tartoznak. Továbbá válogatott, nagy rizikójú cso-
portba tartozó emberek vakcinációja lehetséges a 
1 Bizonyos vírusoknál és intracellulárisan szaporodó bak-
tériumoknál olyan mechanizmusok alakultak ki, ame-
lyek segítségével a fertőzés kiváltotta immunválasz elől 
el tudnak menekülni, azaz az immunválasz nem tudja 
őket elpusztítani. 
A patogének másik csoportjával történt fertőzés vagy 
vakcináció kivált ugyan protektív immunválaszt, de a 
kórokozó különböző törzsei közötti antigénkülönbsé-
gek (például a rhinovirusoknál) vagy a patogén felszíni 
antigénjeinek gyakori változása (például az influenza-
vírus és a HIV esetében) miatt az egyén védtelen az új 
antigénstruktűrával rendelkező patogénnel szemben, 
tehát újrafertőződik. 
Vektor az a mikroorganizmus vagy plazmid, amely 
genetikai állományába egy másik mikroorganizmus 
valamilyen génjét kiónozták, amely gént a vektor saját-
jaként fejez ki és termel. 
A kanáripox rekombináns vírusok protektív immun-
választ váltanak ki különböző emlősfajokban. 
Az izomba vagy bőrbe inokulált DNS az általa kódolt 
fehérjét kifejezve immunogén, és immunválaszt vált ki. 
Ha ismert, hogy a vírus vagy baktérium melyik alko-
tóeleme váltja ki a protektív immunválaszt, ezen alkotó-
részt vakcinaként lehet használni. 
baktérium más alkotórészeinek használatával is, 
ilyenek a Neisseria meningitidis-, a Haemophilus 
influenzae- és a Streptococcus pneumoniae-poli-
szacharidavakcinák. A H. influenzae b (Hib)-poli-
szacharida-hordozó fehérjéhez (tetanustoxoid) 
kötve hatásosabb immunválaszt hoz létre (hosszabb 
ideig tartó B- és T-sejt-aktivációt is jelentő választ), 
és hazánkban 1999-től az általános használatra 
kijelölt vakcinák közé tartozik (5). Járványveszély, 
endémiás területre utazás vagy feltételezetten meg-
történt fertőzés esetén további vakcinák állnak ren-
delkezésünkre, ezek közé tartoznak a Yersinia pes-
tis-, a Vibrio cholerae-baktérium-, a hepatitis A-, a 
sárgaláz-, a kullancsencephalitis- és a veszettségvírus-
vakcinák. Elő attenuált varicellavakcinát állítottak elő 
japán kutatók az 1980-as években, amelyet 19S7 óta 
Japánban és 1995 óta az 
Egyesült Államokban jó 
eredménnyel használ-
nak. Hazánkban még 




de remélhetőleg a vari-
cellavakcina az általá-
nos vakcinációs prog-
ramba is hamarosan 
bekerül (2-5). 
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esetenként azt bővítő, modern vakcinológia első, a 
gyakorlatban is alkalmazást nyert terméke a hepatitis B 
felszíni antigént (HBsAg) tartalmazó rekombináns 
vakcina. A rekombináns HBsAg-vakcina kidolgozása-
kor a felszíni antigént kódoló gént élesztőgomba 
DNS-ébe kiónozták, majd ezt a rekombináns élesztő-
gombát nagy mennyiségben elszaporították, és a 
tenyészkultúrából a HBsAg-t tisztítási eljárással állí-
tották elő (6). A vakcina háromszori oltás után védő 
hatású. A hepatitis B-vírus-fertőzésnek fokozottan 
kitett egyének - mint például a vírushordozó anyák 
gyermekei, a vírust hordozó betegek hozzátartozói, 
vérkészítményeket rendszeresen kapó betegek, homo-
szexuálisok, egészségügyi munkát végzők — eddig is 
részesülhettek oltásban, de 1999-től a HBsAg az álta-
lános használatra alkalmazott vakcinák közé tartozik. 
A vakcinádéval megelőzhető betegségekénél azon-
ban hosszabb listát lehet készíteni azokból a beteg-
ségekből, amelyeknek kialakulását nem tudjuk védő-
oltással megakadályozni. A teljesség igénye nélkül 
említjük a fertőző légúti betegségeket, amelyek min-
den évben az emberek millióit betegítik meg. Leg-
gyakoribb virális okozóik: rhinovirusok (nátha), coro-
navírusok (nátha), respiratory syncytial vírus (bron-
chitis), influenzavírus (influenza), Parainfluenzavirus 
(krupp), adenovirus (pharyngitis); leggyakoribb bak-
teriális okozóik: Staphylococcusok, Streptococcusok, 
Chlamydiák, Legionellák, Mycoplasmák (felső és alsó 
légúti megbetegedések, pneumonia). Nem rendel-
kezünk védőoltással sok szexuális úton terjedő fertő-
zéssel szemben sem, mint a Neisseria gonorrhoeae 
(gonorrhea), a Treponema pallidum (syphilis), a Chla-
mydia trachomatis-spccies tagjai (urethritis), a herpes 
simplex vírus l-es és 2-es típusa (herpes labialis, her-
pes genitalis). Ugyancsak védtelenek vagyunk sok, az 
emésztőtraktust megbetegítő kórokozóval szemben, 
mint a hepatitis C-, D-, E-vírusok (hepatitis), rota-
vírusok (csecsemőkori hasmenés), Norwalk-vírus 
(gastroenteritis), adenovírusok (hasmenés). Nem 
tudunk védőoltással védekezni a congenitalis károso-
dást okozó cytomegalovirussal, a genitalis malignus 
daganatok etiológiai ágenseként számon tartott papil-
lomavírusokkal, bizonyos lymphomák etiológiájában 
valószínűleg szerepet játszó Epstein-Barr-vírussal 
szemben. Nem lehet említés nélkül hagvni a humán 
O* 
immundeficiencia-vírus (HIV) elleni vakcina hiányát, 
amely kidolgozására pedig az elmúlt 15 évben világ-
szerte igen nagy anyagi erőket mozgósítottak. 
Úgy látszik, hogy vannak baktériumok és vírusok, 
amelyek ellen a konvencionális eljárásokkal (inaktivá-
lás és attenuálás) nem lehet vakcinát kialakítani. Ennek 
oka ezen patogének tulajdonságaiban keresendő. Mint 
minden élőlénynek, így a patogén mikroorganizmu-
soknak is az elsődleges célja a túlélés. 
Bizonyos vírusoknál és intracellulárisan szapo-
rodó baktériumoknál olyan mechanizmusok alakul-
tak ki, amelyek segítségével a fertőzés kiváltotta 
immunválasz elől el tudnak menekülni, azaz az 
immunválasz nem tudja őket elpusztítani. 
Ilyen mechanizmusok például az intracelluláris 
perzisztencia/latencia, amelynek kapcsán a patogén 
genomja az akut fertőzés után hosszú ideig, esetleg 
az egész életén keresztül a gazdasejtben tartózkodik, 
de nem öli meg azt, hiszen ezzel önmagát is elpusz-
títaná. Nem világos, hogy ezen perzisztens fertőzé-
sek a gazdasejt milyen károsodását idézik elő, de 
krónikus idegrendszeri (Guillain-Barré-szindróma, 
sclerosis multiplex) és daganatos betegségek eseté-
ben (bizonyos lymphomák) perzisztens vírusfertő-
zések hatását feltételezik. A perzisztens fertőzések 
alatt az intracelluláris parazita genomja reaktiválód-
hat, és aktív produktív szaporodás indulhat el, 
amelynek kapcsán újabb sejtek fertőződhetnek, tehát 
a patogén túlélése biztosított. Az akut fertőzés után 
perzisztens/látens fertőzést alakítanak ki például az 
adeno-, a herpes- és a papillomavírusok (7-9). Ezen 
patogének elleni immunvédelem kidolgozása azért 
nehéz, mert ezekben az esetekben nemcsak a pato-
gén okozta megbetegedéstől kell megvédeni az 
egyént, hanem a fertőzéstől is, ami igen erős 
immunválasz esetén sem biztosított. Ilyen patogé-
nekkel szemben az inaktivált vakcina nem nyújtana 
védelmet, élő attenuált vakcinával pedig a vakcina-
vírussal kialakítható perzisztens/látens fertőzés 
veszélye miatt nem tanácsos az immunizálás. 
A patogének másik csoportjával történt fertőzés 
vagy vakcináció kivált ugyan protektív immunválaszt, 
de a kórokozó különböző törzsei közötti antigén-
különbségek (például a rhinovirusoknál) vagy a pato-
gén felszíni antigénjeinek gyakori változása (például 
az influenzavírus és a HIV esetében) miatt az egyén 
védtelen az új antigénstruktúrával rendelkező pato-
génnel szemben, tehát újrafertőződik (10-13). 
Előfordul, hogy már az egyén szervezetén belüli 
szaporodás során megváltozik a patogén antigén-
struktúrája (például HIV-fertőzésekben), így az 
egyén a reaktivációval szemben is védtelen. 
A molekuláris biológia szemünk előtt lejátszódó 
hatalmas fejlődése új vakcinastratégiák kifejlődését 
tette lehetővé. Ezen stratégiák alapja a mikrobiális 
gének klónozása az expressziós vektorokba. Definí-
ció szerint vektor az a mikroorganizmus vagv plaz-
mid, amelynek genetikai állományába egy másik mik-
roorganizmus valamilyen génjét kiónozták, amely 
gént a vektor sajátjaként fejez ki és termel. Vektorok 
lehetnek vírusok, baktériumok, gombák és bakteriá-
lis plazmidok. Ezen vektorokba kiónozott gének 
produktumait vagy nagy mennyiségben termeltetik 
az expressziós vektorral, és tisztítás után használják 
imrhunizálásra, vagy magát az expressziós vektort 
inokulálják az immunizálandó egyénbe, és a bekló-
nozott gén ott fejeződik ki, és váltja ki az immun-
választ. A kétféle felhasználás eredménye között 
lényeges különbség van: míg a tisztított produktum 
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(fehérje) csak B-sejtes, azaz humorális immunválaszt 
tud kiváltani, addig a rekombináns vektor intracel-
luláris replikációja az immunizálandó organizmuson 
belül nemcsak humorális, hanem T-sejtes, azaz cellulá-
ris (például citotoxikus T-lymphocyta) immunválaszt 
is kivált. A humorális és a celluláris immunválasz 
együttes kialakulása és működése elengedhetetlen az 
intracellulárisan szaporodó organizmusok (vírusok, 
intracelluláris baktériumok) elleni védelemben. 
Vírusvektorok 
Érdekes módon nem sokkal azután, hogy a vaccinia-
vírussal történő immunizálás eredményeként a 
W H O himlőmentesnek nyilvánította a Földet, vek-
torvírusnak a vacciniavírust javasolták (14, 15). 
A vacciniavírus előnye, hogy egy nagyon sikeres 
vakcinációs programot hajtottak már végre vele, 
azaz a himlőmegbetegedést eradikálták, és hogy 
igen nagy méretű DNS-genommal rendelkezik, 
amelybe nagyméretű idegen DNS-szakaszokat, 
esetleg több protein kódolására alkalmas géneket 
tudnak beültetni anélkül, hogy a vírus struktúráját 
és funkcióját megzavarnák. Hátránya, hogy - bár 
nagyon ritkán, 100 000-ből egy esetben - kompliká-
ciókat, főleg encephalitist okoz az immunizált 
egyénnél. Továbbá, immunfunkciójukban károso-
dott egyének immunizálására sem javasolt az esetleg 
kialakuló generalizált vacciniamegbetegedés miatt. 
Rekombináns konstrukciók inokulálásának felté-
tele természetesen a vektor ártalmatlan volta. 
A rekombináns vacciniavírusok potenciális káros 
hatásai miatt kidolgozott poxvírusvektor-alternatí-
vákat egyrészt a további attenuálási folyamatokon 
átvitt vacciniavírus-törzsek, másrészt a madárpox-
vírus-törzsek jelentették. A vacciniavírus további 
attenuálása itt azonban már nem empirikus volt, 
mint a korábbi vírusvakcinák attenuálására használt 
eljárások során, hanem a vacciniavírus-genom szer-
kezetének ismeretében a genomból egy 16 kilobázis 
hosszúságú génszakaszt eltávolítottak, amellyel a 
vírus replikációját gyengítették, de a korai pro-
moterek alá beültetett idegen gének még kifejeződ-
nek a vírussal fertőzött sejtekben. Ezen attenuált 
vacciniarekombinánsok állatkísérletekben a beülte-
tett génproduktumra specifikus immunválaszt hoz-
nak létre, de emberi immunizálásra jelen formájuk-
ban nem használják őket (16) . 
Az emberi felhasználáshoz közelebb állnak a 
madárpoxvírus alapú rekombináns vírusok, ezek 
közül is a canaripox rekombináns vírusok. A kanárit 
megbetegítő poxvírus attenuált formáját használják 
vektornak, amely már a madarat sem betegíti meg, 
az emlőssejtekben pedig a teljes replikációra nem 
képes, de a korai génjeit kifejezi, tehát a korai pro-
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Az utolsó dózis adása után eltelt idő 
O (HCMV-NA-titer): CMV-neutralizdciós ellenanyagtiter (humorális immun-
válasz) 
• gB-specifikus lízis (citotoxikus T-sejt, azaz celluláris immunválasz) 
p.f.u. (plaque farming unit): fertőző víruspartikula, amely szövetkultúra-
sejtekben elszaporodva szemmel látható elváltozást, plakkot okoz 
1. ábra. Immunizálás ALVAC-gB-vel CMV-specifikus 
neutralizáló ellenanyagot és citotoxikus T-sejt-választ 
indukál (18). Három csoportba osztva összesen 58 egeret 
immunizáltak az ALVAC-gB rekombináns vírussal (sc. 
lxl0r' p.f.u./dózis). Az első csoport egerei egy, a második 
csoport egerei kettő, a harmadik csoport egerei három oltás-
ban részesültek. A CMV-gB-specifikus immunválaszt az 
ábrán jelölt időpontokban vizsgálták. Az adatok egyedi 
egerek immunválaszát tüntetik fel egy dózis alkalmazása 
után és két egér immunválaszának átlagát két vagy három 
dózis alkalmazása után. 
A kanáripox rekombináns vírusok protektív 
immunválaszt váltanak ki különböző emlősfajokban. 
Macskaleukémiavírus-fehérjét kifejező kanáripox-
rekombinánssal immunizált macskák védettek voltak a 
macskaleukémiavírus-fertőzéssel szemben (20), és 
kanyaróvírus-fehérjét kifejező kanáripox-rekombi-
nánssal immunizált kutyák védettek voltak a kanyaró-
vírushoz hasonló antigénszerkezetű canine distemper 
vírus fertőzésével szemben. Ugyancsak a védelemhez 
elegendő szintű ellenanyagot váltott ki egy kanáripox-
veszettség rekombináns vírus emberben (20). Mint 
említettük, a beültetett idegen gén expressziója a vek-
torvírus DNS-szintézise előtt megtörténik, de a vek-
torvírus teljes replikációja gátolt a nem madáreredetű 
sejtekben, ami biztonságossá teszi az emlősszerve-
zetek, így az ember immunizálását a kanáripox-rekom-
binánsokkal. Mivel a kanáripox-rekombinánsokkal 
inokuiált egyének szervezetében a beültetett idegen 
gén kifejeződése intracellulárisan történik meg, a 
rekombinánsok mind humorális, mind celluláris 
immunválaszt kiváltanak. Ennek bizonyítása egy 
kanáripox-humán cytomegalovirus glikoprotein B 
(HCMV-gB)-rekombináns preklinikai kipróbálása 
során történt meg (18). Az 1. ábra mutatja, hogy ege-
rek esetében - emberi inokulálásra alkalmas mennyi-
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Az első oltás után eltelt idő 
2. ábra. Immunizálás plazmid-gB-vel CMV-specifikus 
neutralizáló ellenanyagválaszt indukál (24). Az egereket 
50 pg plazmiddal immunizálták im. oltással, a negyedik és 
a nyolcadik héten újraoltásban részesültek. ELISA-val 
mérték a gB -specifikus ellenanyagokat tisztított gB -proteint 
használva antigénként. Az egyedi egerek savóinak OD-
értékeit tüntetik fel a görbék, a savók 1:40 hígításúak. 
ségben (1,5x10'' p.f.u.) adva - egy dózis után alacsony 
ellenanyagszint és a kimutathatóság küszöbértéke alat-
ti citotoxikus T-lymphocyta (CTL)-válasz, két dózis 
után magasabb szintű ellenanyag és kimutatható 
szintű CTL-válasz, a harmadik oltás után az eló'zőhöz 
hasonló ellenanyagszint és magas szintű CTL-válasz 
mérhető', ami a rekombináns vírus jó hatásfokú insert-
specifikus immunogenitását mutatja, és azt a feltéte-
lezést bizonyítja, hogy kanáripox-rekombinánssal 
történő immunizáláskor mind humorális, mind CTL-
válasz kialakul. Mivel az insertspecifikus ellenanyag-
válasz nem volt magas a második dózis inokulálása 
után, és nem fokozódott a harmadik inokulálást köve-
tően (1. ábra), felmerült, hogy specifikus fehérjeanti-
génnel végzett ismételt oltással esetleg nagyobb ellen-
anyagválaszt lehet kiváltani, azaz a kanáripox-rekom-
bináns jó „priming" hatású (az elsődleges immunválasz 
lassabban fejlődik ki és kisebb, mint az azt követő, 
miközben memóriasejtek alakulnak ki), de kevésbé 
hatékony „booster" hatású (az ismételt antigén-talál-
kozáskor gyorsabb és intenzívebb választ kiváltó) vek-
torkonstrukció. Egérimmumzálási kísérletek igazol-
ták, hogy a kanáripox-HCMV-gB rekombináns vírus-
sal végzett első oltás után a második oltásként alkalma-
zott tisztított fehérje igen magas ellenanyagszintet vál-
tott ki az immunizált állat szervezetében. A kanáripox-
rekombináns „priming" hatását az egérlymphocyták 
specifikus stimuláció utáni interferon-y-termelése is 
jelezte, amely a celluláris immunválasz irányában 
elkötelezett T-sejtek jelenlétét igazolta. A z interfe-
ron-y antivirális hatással is rendelkezik, így a védőhatás 
egyik komponense is lehet. 
Mivel a felnőtt populáció (az 1980 előtt született 
egyének) a himlőmegbetegedéssel szembeni védelem 
céljából immunizálva lett vacciniavírussal, kérdés volt, 
vajon a vacciniaimmunitás nem fogja-e gátolni a vacci-
niával rokon kanáripoxvírussal való immunizálás hatás-
fokát. Ezért egereket immunizálták vacciniavírussal, és 
a vacciniaimmunizált egereket később immunizálták a 
kanáripox-HCMV-gB rekombináns vírussal. Az ered-
mények azt igazolták, hogy a vacciniaimmunitás nem 
gátolja a kanáripox-rekombinánssal kiváltható insert-
specifikus immunválaszt, tehát vaccinia-védőoltásban 
részesült emberek is immunizálhatók kanáripox-
rekombinánsokkal. A kanáripox-HCMV rekombináns 
vírusok humán kipróbálás alatt vannak. 
Vektorvírusnak nemcsak poxvírusokat, hanem 
genetikailag modifikált adenovírusokat, herpes simp-
lex vírust, retrovírusokat is javasolnak. Különösen a 
modifikált adeno- és retrovírusvektorok alkalmazha-
tók potenciálisan bizonyos genetikai betegségek (pél-
dául cysticus fibrosis) terápiájára is, azaz a hiányzó 
vagy hibás sejti gének funkcionálisan ép génekkel való 
pótlására, ezáltal a génhiányos állapot tüneteinek 
megszüntetésére. Ezen hibás sejti géneket pótló 
rekombináns vakcinák a rekombinánsok felhaszná-
lásának célját is kiszélesítették, azaz nemcsak fertőző 
betegségek megelőzésére, hanem genetikai betegségek 
gyógykezelésére is alkalmazhatók (21). 
Baktériumvektorok 
Baktériumvektorként elsősorban attenuált Salmo-
nella-törzsek és B C G jönnek szóba. A Salmonella-
vektor előnye, hogy orálisan alkalmazva a gastroin-
testinalis rendszerben szaporodik, és mucosalis 
immunitást vált ki a bélrendszerben, így az enteralis 
betegségek kórokozóinak megfelelő génjeit beül-
tetve ezen enteralis betegségek megelőzésére lenne 
alkalmas. A BCG-vektor előnye, hogy a születés 
után nem sokkal adva vakcinaként kiterjedten alkal-
mazzák, valamint celluláris immunválaszt vált ki, 
így intracellulárisan szaporodó mikroorganizmusok 
(vírusok és intracellulárisan szaporodó baktériu-
mok, paraziták) elleni védelemben hasznos lehet. 
Genetikai vagy DNS-immunizálás, 
azaz expressziós plazmidvektorok 
Az alap- és alkalmazott immunológiai tudományok 
nagy meglepetése volt az 1990-es években annak fel-
ismerése, hogy az izomba vagy bőrbe inokulált D N S 
az általa kódolt fehérjét kifejezve immunogén, és 
immunválaszt vált ki. A technológia lényege az, hogy 
az immunogén fehérje génjét bakteriális plazmidba 
kódolják az eukaryotában funkcionáló promoter és 
enhancer szekvenciák alá. Az ilyen módon elkészített 
plazmid-DNS-t izomba vagy bőrbe adva a génpro-
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duktum (fehérje) hosszú ideig tartó helyi kifejezó'dése 
jön létre, amely hosszú ideig tartó immunválaszt ered-
ményez. Az immunválasz mind B-, mind T-sejtes, 
azaz ellenanyagok és celluláris immunválasz jön létre. 
A celluláris immunválaszt a citotoxikus T-sejtek 
indukciója is jellemzi, tehát a fehérje intracellulárisan 
fejeződik ki, és az M H C I. osztály molekulái mutatják 
be az antigén-prezentáló sejtek felszínén a T-sejtek 
részére. A plazmidvektorok előnye, hogy hosszú ideig 
tartó immunválaszt eredményeznek, az immunválasz 
mind B-, mind T-sejtes, és mivel fertőző ágens bevitele 
nem történik az immunizáció kapcsán, ismételt dózis 
immunogenitását nem akadályozza az előző dózisra 
kiváltott vektorspecifikus immunválasz. További 
előnyük, hogy előállításuk egyszerű és olcsó (22-24). 
A 2. ábra szemlélteti, hogy egy expressziós eukary-
otaplazmid, amelybe a HCMV-gB gént kiónozták, 
egerek esetében gB-specifikus ellenanyagválaszt vált 
ki; a plazmid kétszeri vagy háromszori im. oltása 
után az egerek többségénél tartósan (a vizsgálat közel 
nyolc hónapja alatt) tapasztalható magas szintű ellen-
anyagválasz. Az egerek vérsavójában HCMV neutra-
lizáló ellenanyagokat is kimutattak. 
A 3. ábra azt mutatja, hogy egy expressziós euka-
ryotaplazmid, amelybe a HCMV-65 kD foszfopro-
tein gént (pp65) kiónozták, pp65-specifikus ellen-
anyagválaszt indukált egerek esetében kétszeri ím. 
oltás után. Hasonlóan a humorális immunválaszhoz a 
plazmid pp65-specifikus CTL-választ is kiváltott az 
egereknél. A két plazmid kevert inokulálásakor mind 
gB-, mind pp65-specifikus ellenanyagok és CMV-
neutralizáló aktivitást mértek a savókban. Ugyan-
ezen egerek T-lymphocytái pp65-specifikus CTL-ak-
tivitással rendelkeztek. Ezek az eredmények alátá-
masztják a DNS-immunizálás lehetőségét CMV 
okozta megbetegedések kivédésére is (24). 
Potenciális hátrányuk például a gazdasejt genom-
jába való integrálódás, amely a gazdasejt genetikai 
változását idézheti elő. A plazmidvektorok tanul-
mányozása világszerte intenzíven folyik, azonban 
integrálódást a gazdasejtbe vagy a DNS-immuni-
zálás egyéb esetleges komplikációját eddig nem 
tapasztalták. A legtöbb vírus protektív immun-
válaszban részt vevő génjét plazmidvektorba már 
beklónozták, és kísérleti állatok esetében bizonyí-
tották a hatásosságát. Expressziós eukaryotaplazmi-
dokba kiónozott HIV-génekkel történő emberi 
immunizálási próbálkozások folyamatban vannak. 
Szubunit vakcinák 
Ha ismert, hogy a vírus vagy baktérium melyik 
alkotóeleme váltja ki a protektív immunválaszt, 
ezen alkotórészt vakcinaként lehet használni. Erre 
példa a hepatitis B-vírus felszíni antigénje (HBsAg), 
amely nagy mennyiségben termelődik a vírussal fer-
i 
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E/T arány 
• = Vaccinia-pp65 rekombinánssal fertőzött MCH-I. osztály szerint 
megegyező sejtek 
• = Sz/í/ő (nem rekombináns) vacciniavírussal fertőzött MHC-I. 
osztály szerint megegyező sejtek 
• — Vacciniavírus-ppóS rekombinánssal fertőzött, MHC-I. osztály 
szerint különböző sejtek 
3. ábra. Immunizálás plazmid-pp65-tel CMV-speeifikus 
citotoxikus T-lymphocyta-választ indukál (24). Az ege-
reket a 2. ábránál leírt módon immunizálták, és az utolsó 
oltás után egy hónappal ölték le. A lépsejteket pp65-speci-
ftkusan stimulálták in vitro, és azonos, valamint különböző 
MHC-I. osztályba tartozó sejtekben mérték a citotoxicitást. 
Az ábra egy reprezentatív egér esetében kapott eredményeket 
mutatja. A sziilö-vacciniavírussal fertőzött MHC-I. szerint 
megegyező sejtek és a vaccinia-pp65 rekombináns vírussal 
fertőzött MHC-I. megegyező sejtek lízise közötti különbség 
mutatja a pp65-specifikus lízist. 
tőzött sejtekben, és tisztított állapotban előállítható 
a vírushordozó emberek plazmájából, vagy mosta-
nában rekombináns DNS-technológia segítségével. 
Az utóbbi eljárással előállított HBsAg-vakcinát 
használják jelenleg immunizálására. Több más vírus 
protektív hatásáért felelős fehérjéjét is előállították 
már a rekombináns DNS-technológia módszerével 
(például herpes simplex vírus 2-es típusa, 
cytomegalovirus), azonban ezek immunogenitása 
gyengének bizonyult. A szubunit vakcinák immu-
nogenitásának növelése új adjuvánsok és az immu-
nogenitást fokozó más eljárások kidolgozásának 
segítségével világszerte folyik. 
A szubunit vírusvakcinák közé sorolhatók a szinte-
tikus úton előállított peptidek, amelyek B- vagy 
T-sejt-epitopként viselkednek természetes környeze-
tükben, a vírusproteinben. Előnyük, hogy a protein 
nemkívánatos részeit nem tartalmazzák. A szintetikus 
peptidek azonban általában gyengén immunogének. 
Immunizálásra használhatók, ha a peptideket hordozó 
molekulákhoz kötik, és adjuvánssal együtt adják az 
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1. táblázat. 2025-ig valószínűleg bevezetésre kerülő új 
vagy a jelenleginél fejlettebb vakcinák 
Vírusvakcinák 
Influenzavírus* 
Hepatitis A vírus* 
Parainfluenzavirus 
Respiratory syncytial vírus 
Adenovirus 1, 2, 5-7 típusok 
Rotavirus 
Hepatitis C-, E-vírus 
Humán immundeficienciavírus 
Papillomavirus 
Herpes simplex vírus 2. típus 
Cytomegalovirus 
Epstein-Barr-vírus 






E. coli (orális enterotoxinogén) 
Helicobacter pylori (ulcus duodeni, ventriculi) 
Borrelia burgdorferi (Lyme-kór) 
Malária 
* Jelenleg is meglévő, fejlesztésre kerülő vakcinák 
immunizálandó egyénnek. Több B- és T-sejt-epitop 
összekapcsolásával hatásosabb vakcina állítható elő. 
Több T-sejt-epitop összekapcsolása esetén is előfor-
dulhat, hogy az egyén HLA l-es és 2-es osztályba tar-
tozó molekulái nem hordoznak olyan allélokat, ame-
lyek a szintetikus T-sejt-epitopokat tálalni tudják a 
T-sejtek felé, így az ilyen egyén esetében immunválasz 
nem jön létre. A szintetikus peptidvakcinák alkalma-
sak lehetnek vakcinációra, ha a leírt problémák megol-
dásra kerülnek. Vírusbetegségek profilaxisára még 
nem használják őket. 
Néhány további fontos és nem kellően ismert 
aspektusa a vakcináció tudományának: 
1. Újszülöttek immunizálásának problémái, ame-
lyet az újszülött immunrendszerének működésére 
vonatkozó igen hiányos ismereteink hátráltatnak. 
2. A mucosalis immunitást kiváltó eljárások kez-
detlegesek, amelyek pedig igen fontosak lennének, 
hiszen sok patogén (HIV-, influenza-, herpesvírus) 
behatolási helye elsősorban a mucosalis hártya, így a 
szisztémás immunitás mellett a lokális, mucosalis 
immunitás is szükséges lenne. 
3. Egyetlen dózisban adott, több immunogént 
tartalmazó vakcina lehetősége, amely nemcsak azon 
múlik, hogy például melyik vektorba lehet többféle 
fehérjét kódoló gént beültetni, hanem ezen iramu-
nogének esetleges immunológiai kompetíciójának 
ismeretére is szükség lenne. 
4. Bizonyos patogének (főleg paraziták) patoló-
giájáért felelős immunológiai reakciók megértésé-
nek hiányosságai. 
A vakcinológia mostanihoz hasonló nagy lendü-
letű fejlődése azonban további izgalmas és hasznos 
eredményeket fog produkálni a fent vázolt problé-
makörökben is. 
A világszerte folyó kutatómunkák alapján a 
következő 25-30 évben az 1. táblázatban felsorolt új 
vagy a jelenleginél fejlettebb vakcinák használatba 
lépése jósolható meg (20). 
Meghaladná a dolgozat kereteit annak a megbe-
szélése, hogy a felsorolt vakcinációs próbálkozások 
közül az előre jelzett vakcinák mindegyikére vonat-
kozóan melyik bizonyul optimálisnak, mivel ez a 
patogén antigénjeitől és a betegség patomechaniz-
musától is függ. 
A vakcinológia a dolgozatban érintett mikrobio-
lógiai, immunológiai, molekuláris biológiai kérdés-
csoportokat öleli fel, és napjainkban már önálló 
tudományágként működik. Üj kórokozók felbuk-
kanása (HIV), régi kórokozókkal kiváltott betegsé-
gek újra megjelenése (tbc), vagy annak a felisme-
rése, hogy klasszikus belgyógyászati betegségeket 
fertőző ágensek okozhatnak (Helicobacter pylori-
baktérium az ulcus duodeni és ventriculi eseteinek 
nagy részét), a vakcinológia tudományát fontossá és 
aktuálissá teszik. 
A közlemény az MKM 528, az AMFK 474 és azOTKAT 19 256 
számú pályázatának támogatásával készült. 
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Szisztémás retinoidok 
A 9-cis-retinoidsav a betegek 37%-ánál klinikai 
választ váltott ki, míg 34%-uk stabil maradt (36). 
Saiag mucocutan Kaposi-sarcomában all-trans-
retinoidsavval 40%-os klinikai választ ért el, emel-
lett a betegek 40%-a nem progrediált a vizsgálati 
időszakban (37). 
Humán choriogonadotropin 
Harris valamennyi betegénél tumorregressziót ért 
el 150 000 egység H C G emelkedő' dózisú alkal-
mazásával, Tavio ugyanakkor nyolc betege közül 
csak egynél észlelt részleges javulást intramuscu-
larisan adott 100 000-300 000 egységek alkalma-
zásával (38). 
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A herpesvírusok elleni 
vakcináció lehetőségei 
Gyulai Zsófia 
POSSIBILITIES OF VACCINATION AGAINST 
HERPESVIRUS DISEASES 
Currently available vaccines provide protec-
tion against various infectious diseases, but 
there is an even longer list of infections that 
can not yet be prevented by vaccination, 
including the majority of diseases caused by 
herpesviruses (with the exception of varicel-
la). Herpesviruses are widespread in the po-
pulation, and although most infections are 
asymptomatic or manifest in clinically mild 
symptoms, there are severe, often life threat-
ening diseases seen in the immunocompro-
mized patients and in neonates. The complex 
interplay between host and virus makes it dif-
ficult to mount useful vaccine strategies. Her-
pesviruses have developed a number of suc-
cessful mechanisms to evade immunosurveil-
lance. Following acute infection they estab-
lish latency, during which they express few, if 
any protein antigens. In addition, herpesvirus-
es interfere with cytotoxic T-cell function and 
antigen recognition by different means. An 
ideal herpesvirus vaccine would not only pre-
vent disease development, but also the infec-
tion and the establishment of latency, which 
is not easy to achieve, since even natural 
immunity does not provide complete protec-
tion. Conventional vaccines (containing 
attenuated live or inactivated viruses) do not 
afford protection against these viruses, nor 
their use would meet the necessary safety 
requirements. The use of gene technology has 
opened up an exciting new era in vaccinolo-
gy, providing alternative possibilities for the 
development of effective and safe new vac-
cines. Examples of these alternative possibili-
ties include recombinant vaccines and DNA-
immunization. 
herpes simplex viruses, 
varicella-zoster virus, cytomegalovirus, 
Epstein-Barr virus, recombinant vaccines, 
DNA-immunization 
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A jelenleg forgalomban lévő vakcinák védelmet 
biztosítanak számos fertőző betegséggel szem-
ben, azonban rendkívül sok fertőzés kialaku-
lását még ma sem tudjuk védőoltással meg-
akadályozni. A bárányhimlőt kivéve ide sorol-
hatók a herpesvírusok által okozott megbetege-
dések is. A herpesvírusok igen elterjedtek a po-
pulációban, és noha klinikailag a fertőzés álta-
lában tünetmentes vagy enyhe lefolyású, csök-
kent immunfunkciójú egyéneknél és újszülöt-
teknél súlyos, gyakran életveszélyes megbetege-
dések fordulnak elő. A megfelelő vakcinációs 
stratégia kialakítását megnehezíti a gazdaszer-
vezet és a vírus közötti összetett kölcsönhatás. 
Különböző mechanizmusok segítségével a her-
pesvírusok rejtve maradhatnak a fertőzés kivál-
totta immunválasz elől. A herpesvírusok az akut 
fertőzést követően látenciát alakítanak ki, 
amelynek kapcsán a patogén genomja hosszú 
ideig a gazdasejtben tartózkodik, és a latens fer-
tőzés alatt csak néhány gén transzkripciója, 
esetleg transzlációja megy végbe. A herpesvíru-
sok többféle módon gátolják az adaptív immun-
válaszban szerepet játszó citotoxikus T-lympho-
cyták antigénfelismerő és a fertőzött sejtet 
pusztító hatását is. A hatékony immunvédelem 
kialakítása azért is nehéz, mert nemcsak a her-
pesvirus okozta megbetegedéstől kellene meg-
védeni a szervezetet, hanem a fertőzéstől, így a 
latencia kialakulásától is; erre azonban a termé-
szetes fertőzés által kialakított immunválasz sem 
képes. Ezen megbetegedésekkel szemben a kon-
vencionális úton előállított vakcinák (élő, atte-
nuált, illetve inaktivált vírusok) nem biztosítanak 
kellő védelmet, vagy alkalmazásuk nem bizton-
ságos. A géntechnológia alkalmazása új, izgal-
mas korszakot nyitott a vakcinagyártás területén, 
lehetővé téve hatékony és biztonságos oltó-
anyagok kifejlesztését. Ezen új, alternatív meg-
oldások közé tartoznak a rekombináns vakcinák 
és a DNS-immunizálás. 
herpes simplex vírusok, 
varicella-zoster vírus, cytomegalovirus, 
Epstein-Barr-vírus, 
rekombináns vakcinák, DNS-immunizálás 
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Avakcináció az orvostudomány legnagyobb felfedezései közé tartozik. Jenner korszak-alkotó megfigyelése után, amely a himló' 
elleni sikeres vakcinációhoz és az 1970-es évek 
végére a Föld himló'vírus-mentesítéséhez vezetett, 
80 év telt el, míg Pasteur létrehozta a veszettség 
megelőzésére az elsó' éló', attenuált kórokozót tar-
talmazó vakcinát. Nem sokkal ezután Salmon és 
Smith elölt Salmonella baktériumokkal tudott 
immunizálni. így már több mint száz éve ismert az 
immunizálás két fó' alapmódszere, az éló', attenuált 
mikroorganizmusokkal és az inaktivált, teljes kór-
okozókkal végzett vakcináció. A tisztított, egyedi 
mikrobiális antigénkomponensek immunogenitásá-
nak felismerése megteremtette az alegységvakcinák 
bevezetésének elméleti alapját. Az oltóanyagok 
ezen típusába sorolhatók a tokos baktériumok tisz-
tított poliszacharid-antigénjeit tartalmazó készít-
mények is. A molekuláris biológiai módszerek fejló'-
désével lehetővé vált a mikrobiális gének klónozása 
különböző' vektorokba (vírusok, baktériumok, 
gombák, növények), és az ezek által termeltetett 
baktérium- vagy vírusfehérjéket használják fel 
immunizálás céljára. A tisztított fehérjék általában 
humorális immunválaszt hoznak létre; a rekom-
bináns expressziós vektorok (baktériumok, vírusok 
és plazmidok) felhasználásával végzett vakcinálás 
azonban úgy celluláris, mint humorális immunvá-
laszt eredményez. 
A herpesvírusok családjába tartozó több mint 100 
különböző' vírus közül jelenlegi ismereteink szerint 
nyolcat sorolunk az embert megbetegítő' kórokozók 
közé. Ezen nagyméretű, borítékos, kettó's szálú, 
lineáris DNS-genommal rendelkező' vírusok által 
okozott megbetegedések széles spektrumot alkot-
nak; jellemző' tulajdonságuk, hogy a primer fertó'-
zést követó'en a gazdaszervezetben látenciát alakí-
tanak ki, amelyet a vírus periodikus reaktivációi 
követnek. A herpesvírusok igen elterjedtek, a popu-
láció nagy része fertó'zó'dik velük és immunitással 
rendelkezik. Klinikailag a fertó'zés általában enyhe 
vagy tünetmentes formában zajlik, de csökkent 
immunfunkciójú egyéneknél súlyos, gyakran élet-
veszélyes megbetegedések fordulnak eló'. 
A herpesvírusokat a szaporodási ciklus hossza, a 
sejtkárosító hatás és a latens fertó'zés jellemzó'i alap-
ján három (a-, p- és y-herpesvírus) alcsaládba sorol-
ják. Az a-herpesvírusok közé tartozik a herpes simp-
lex vírus l-es és l-es típusa (HSV-1, HSV-2) és a vari-
cella-zoster vírus (VZV), amelyek érzó' ganglionok-
ban alakítanak ki latens fertó'zést. A cytomegalovirus 
(CMV) P-herpesvírus; latens módon valószínűleg a 
monocyta eredetű sejtek és a nyálmirigy, valamint a 
vesetubulusok epithelialis sejtjei hordozzák. A lym-
photrop humán herpesvírus-6-ot (HHV-6) és humán 
herpesvírus-7-et (HHV-7) szintén a P-herpesvírusok 
közé sorolják. A y-herpesvírusok közé tartozó 
Epstein-Barr-vírus (EBV) az oropharynx és a parotis 
epithelialis sejtjeit, valamint a B-lymphocytákat fer-
tó'zi meg, és a B-lymphocytákban alakít ki látenciát. 
Szintén y-herpesvírus a humán herpesvírus-8 
(HHV-8). Az utóbbi két vírusnak kóroki szerepet 
tulajdonítanak bizonyos humán malignus daganatok 
kialakulásában. A humán patogén herpesvírusok által 
okozott megbetegedéseket és a latencia jellegzetes 
anatómiai lokalizációit az 1. táblázatban foglaltuk 
össze. 
Az élethosszig tartó fertó'zöttség, valamint az 
immunhiányos állapotokban fellépő betegség és az 
újszülötteknél észlelhető' súlyos kórlefolyás miatt 
szükséges a hatékony vakcina mielóBbi kifejlesz-
tése. Az EBV- és a HHV-8-fertó'zések megelőzése 
vakcinációval eló'segíthetné az általuk okozott 
rosszindulatú daganatos megbetegedések eló'fordu-
lásának csökkenését is. 
A gazdaszervezet és a vírus közötti komplex köl-
csönhatás nagymértékben lassítja a megfelelő' vakci-
nációs stratégia kialakítását. Mindegyik herpesvírus 
latens fertó'zést hoz létre, és ezen idő alatt csak 
néhány gén transzkripciója, esetleg transzlációja 
megy végbe; ezenkívül többféle mechanizmus révén 
gátolják az adaptív immunválaszban szerepet játszó 
citotoxikus T-lymphocyták (CTL) antigénfelismeró' 
és sejtpusztító hatását, így blokkolják a vírusanti-
gének prezentációját az M H C I hisztokompatibili-
tási antigénekkel (1). Mindezen hatásoknak 
köszönhetó'en a vírus rejtve maradhat az immun-
rendszer számára. Ismeretes továbbá, hogy a termé-
szetes fertó'zés által kialakított immunvédelem csak 
részben védi meg a szervezetet az újrafertó'zó'déstó'l, 
és az immunrendszer reaktivációk alkalmával létre-
jövő' restimulációja nem jelent tökéletes védelmet az 
újbóli reaktivációkkal szemben. Ezen adatok bir-
tokában tehát nehéz meghatározni a hatékony her-
pesvírus-vakcinával szembeni elvárásokat. Olyan 
törekvés látszik reálisnak, amely csökkentené a fer-
tó'zés helyén a replikálódó vírusok mennyiségét, így 
enyhítené az akut fertó'zés tüneteit, csökkentené a 
latensen fertó'zött sejtek számát, és így a reaktivá-
ciót is. A különböző' herpesvírusokkal kapcsolato-
san részletesebben tanulmányozott vakcinákat a 
2. táblázatban foglaltuk össze. 
Herpes simplex vírusok 
A többi herpesvírushoz hasonlóan a herpes simplex 
vírusok is igen elterjedtek a populációban. Széles 
gazdaspektrummal rendelkeznek, gyorsan szapo-
rodnak és eró'sen citolitikus hatásúak. A két herpes 
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nák felhasználásánál számos előny adódhat. A her-
pes simplex vírusok által okozott fertőzések meg-
előzésében hatékonysága az élő, attenuált vakcináé-
hoz hasonlítható. Ezen oltóanyagok alkalmazása 
esetén azonban nem kell számolni a HSV látenciájá-
val, reaktivációjával és potenciális onkogenitásával 
kapcsolatos problémákkal. Több vacciniavírus-, 
adenovirus-, varicella-zoster vírusr, adeno-associa-
ted vírus- és Salmonella typhimurium-HSV rekom-
bináns vakcina hatékonyságát mutatták ki álla-
toknál; emberi kipróbálás még nem ismert (23-28). 
Varicella-zoster vírus 
A varicella-zoster vírus (VZV) az egyetlen olyan 
herpesvirus, amelynek a megelőzésére engedélye-
zett vakcina áll rendelkezésre. A bárányhimlő kór-
okozója cseppfertó'zéssel, illetve hólyagbennékkel 
terjed. A légutakban végbemenő lokális szaporodás 
után a vírus a véráramba kerül, majd a bőr sejtjeit 
fertőzi meg, és azokban szaporodik. Retrográd 
axonalis transzport útján kerül az érzőganglionok 
neuronjaiba, ahol latens fertőzést alakít ki. A primer 
varicella ép immunrendszerű gyermek esetén általá-
ban jóindulatú betegség, de felnőtteknél, újszülöt-
teknél és csökkent immunfunkciójú egyéneknél 
súlyos komplikációk léphetnek'.fel. A celluláris 
immunrendszer fontos szerepet játszik a vírussza-
porodás visszaszorításában (29). Csökként cellulá-
ris immunválasz következtében a vírusszaporodás 
elhúzódó; gyakoriak a szövődményes kórformák,-
így a pneumonia, a máj és a központi idegrendszer 
fertőződése, valamint haemorrhagiás varicella. A 
leginkább veszélyeztetettek a leukaemiás gyerme-
kek és a veleszületett'immunhiányos állapotban 
szenvedők (30). . •• . • * 
A celluláris immunválasz idős korban vagy beteg-
ség, immunszuppresszív terápia esetén bekövetkező 
csökkenését teszik felelőssé az ezen embercsopor-
toknál megfigyelt herpes zoster (övsömör) kiala-
kulásáért, amely a VZV reaktivációját jelenti (31). 
Fontos tehát a populáció varicellaspecifikus cel-
luláris immunválaszának fenntartása, noha bizony-
talan, hogy a restimuláció elsősorban szubklinikus 
reaktivációk vagy a vírussal való újrafertőződések 
eredménye-e (32, 33). Ezen tényezők ismerete fon-
tos az esetleges tömeges vakcináció hatásának és 
annak megítélése szempontjából, hogy szükséges-e 
szeropozitív, VZV-hordozók vakcinálása. 
Az Oka vírustörzset tartalmazó vakcinát, amely-
ben élő, attenuált vírus található, Japánban fejlesz-
tették ki. A vírustörzset az 1970-es évek elején egy 
Oka nevű varicellás gyermekből izolálták; tengeri-
malac eredetű és humán embrionális, valamint 
humán diploid (WI-38) sejtekben véghezvitt 
sorozatos passzálással attenuálták (34). A varicella-
vakcinát azóta számos országban, köztük Dél-
Koreában, az USA-ban és Európa több országában, 
így Magyarországon is engedélyezték. A vakcina-
törzs gyakorlatilag minden vírusantigént kifejez; 
antiviralis ellenanyagokat, lymphocytaproliferációs 
választ, citotoxikus T-lymphocytákat (CTL) egy-
aránt indukál (33). Egészséges, egy alkalommal 
vakcinált gyermekeknél a szerokonverzió 97%-os, 
hosszú távon 85-90%-uk védett a varicellamegbete-
gedéssel szemben (36, 37). Mindezek ellenére elő-
fordul a fertőzésveszélynek gyakran kitett, vakci-
nált iskolás gyermekek között vad típusú, VZV által 
okozott megbetegedés, de a posztvakcinációs vari-
cella ritka és szerencsére szinte minden esetben 
enyhébb lefolyású, mint a természetes fertőzés. A 
vakcinavírus képes latens fertőzés kialakítására, 
reaktivációra, és zostert okozhat. Azonban a ren-
delkezésre álló adatok szerint leukaemiás gyerme-
keknél vakcinációt követően lényegesen ritkábban 
fordult elő zoster, mint természetes fertőzés után, 
és a betegség lefolyása is enyhébbé vált (36). Nor-
mális immunrendszerű gyermekeknél a vakcinációt 
követően ritka a kiütés, ezért feltételezhető, hogy;, 
reaktiváció is ritkán fog előfordulni (38). 
A Magyarországon Varilrix néven forgalomban, 
lévő vakcina alkalmazása kilenc hónaposnál idő-
sebb, az USA-ban forgalomban lévő vakcina (Vari-
vax) beadása pedig 12-18 hónapos kor között java-
solt. 13 éves kor fölött két vakcinadózis adása aján-
lott. Hazánkban a varicellavakcina az általános 
vakcinációs programba még nem került be, csak 
magas rizikócsoportba tartozó (leukaemiás, im-
munszupprimált, szervtranszplantációra váró, kró-
nikus betegségben szenvedő, veszélyeztetettek kör-
nyezetében élő) gyermekek oltását engedélyezték 
(39). Immunkompetens egyéneknél az Oka vakcina 
biztonságos; leggyakoribb mellékhatás az oltás 
helyére lokalizálódó diszkomfort, láz, kiütés az 
oltás helyén, esetleg testszerte enyhe, varicellához 
hasonló eruptió. A védőoltás kontraindikált vak-
cinakomponensekkel (zselatin, neomycin) szem-
beni túlérzékenység, kezeletlen aktív tuberkulózis 
és terhesség esetén. Bizonyos esetekben a vakcina 
alkalmazása fokozott elővigyázatosságot, körülte-
kintést és egyedi elbírálást igényel. Fontos a beteg' 
általános állapotának, immunstatusának mérlegelése 
és a folyamatban lévő gyógyszeres terápia hatá-
sainak és mellékhatásainak - monitorozása. Ellen-
javallttá válhat a vakcina beadása malignus betegsé-
gek, primer vagy szerzett immunhiányos állapotok 
(például AIDS-szel együtt járó immunszupprimált 
állapot) esetén, celluláris immundeficientia, hypo-
gammaglobulinaemia és dysgammaglobulinaemia 
p Herpesvirus elleni vakcinák 
fennállásakor. Immúnszuppresszív dózisban adott, . 
g szisztémás szteroidkezelés alkalmazásakor a vak-
^ cina csak a terápia minimum három hónapos szüne-
j teltetése után adható be. Vér, plazma vagy immun-
j globulinok adása után a vakcina beadásával legalább 
J öt hónapot kell várni (40). , 
| A tömeges vakcináció egyik fontos célja a popu-
j lációban cirkuláló vad varicellavírus eló'fordulásá-
P nak csökkentése lenne, egyrészt a védó'oltásban 
á nem részesültek, másrészt a csökkent immunfunk-
ciójú egyének védelmében. A tömeges vakcináció 
a kérdése azonban nem egyértelmű. A vakcina indu-
lj kálta immunválasz csökkenésével a vakcináltak fel-
[j nó'ttkorban válhatnak fogékonnyá az idó'sebb kor-
e' ban jellemző', súlyos lefolyású varicellával szem-
f ben. A populáció immunkészültségének fenntar-
tó tása érdekében ezért indokolttá válhat egy második 
s oltás alkalmazása. A vírusspecifikus immunválasz 
¡j idó'skori vakcinációval létrehozott ismételt stimu-
lálásával csökkenthető' a zosteres esetek száma (41, 
v' 42). Felmerülhet a varicellafertó'zésen korábban át 
v nem esett felnó'ttek védó'oltásának szükségessége 
v is, a természetes fertó'zés kapcsán ebben az élet-
y korban megfigyelt komplikációk kivédése érdé-
it kében. A klinikai tünetek kivédésére az Oka vak-
h cina esetleges posztexpozíciós alkalmazását is java-
id s o l j á k f « ; . 1 ' 
! ' 1 .' 
J Cytomegalovirus 
i n 
v A cytomegalovirus-fertó'zés közvetlen kontaktus-
c sal, nyállal, szexuális úton, vértranszfúzióval, szerv-
n transzplantációval vagy transplacentaris úton terjed. 
tJ A szüló'csatornán való áthaladás közben is fertó'-
a! zó'dhet az újszülött. A populáció átfertó'zöttsége 
igen nagy, felnó'ttkorra az emberek 50-100%-a át-
¿í esik az infekción. Ennek klinikai következménye a 
¡j gazdaszervezet immunstatusától függ. Egészséges 
f( immunrendszerű gyermekeknél és felnó'tteknél a 
(j fertó'zés általában tünetmentes formában zajlik, 
I illetve fiatal felnó'tteknél mononucleosis infectiosa 
. k szindróma jön létre. Súlyos következményekkel jár 
| r ( a cytomegalovirus-fertó'zés újszülötteknél, immun-
tj' hiányos állapot esetén és transzplantációt követó'en. 
1
 v j A vírus a primer fertó'zés után gyakorlatilag minden 
, v; esetben látenciát alakít ki a gazdaszervezetben. Az 
I k: utóbbi idóBen gyűlnek az adatok a CMV-fertó'zés-
i ff nek az atherosclerosis és az angioplasties műtétek 
1 ("j utáni restenosis kialakulásában játszott etiológiai 
I lg szerepére vonatkozóan is (44-46). 
• fc' A humán cytomegalovirus jelenleg a leggyako-
I pj ribb congenitalis fejlődési rendellenességet okozó 
I éj fertó'zó' ágens. Az újszülöttek 0,5-2,5%-a születik 
n! intrauterin korban lezajlott HCMV-fertó'zéssel; a 
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fertó'zés következményei születéskor az érintett 
gyermekek körülbelül 10-15%-ánál figyelhetó'k 
meg. A fertó'zés a legsúlyosabb esetekben a magzat 
méhen belüli elhalásához vezet. A születés után 
súlyos tünetekkel jelentkező' cytomegaliás zárvány-
betegség az érintett gyermekek körülbelül 5%-ánál 
fordul eló'. Ugyancsak 5%-ban figyelhető' meg atí-
pusos megbetegedés a központi idegrendszer érin-
tettségével. Az esetek zömében (a fertó'zött gyer-
mekek 90%-ánál) az infekció tünetei közvetlenül a 
születés után nem láthatók, de ezen gyermekek 
10-15%-ánál (azaz az összes élve született gyermek 
körülbelül egy ezrelékénél) négy-öt éves korra 
késó'i következmények - mentális retardáció, Chori-
oretinitis, microcephalia és halláskárosodás - ala-
kulhatnak ki (47, 48). 
A csontvelő'-, illetve szervtranszplantációt követó' 
CMV-infekcióból eredó' szövó'dmények az érintet-
tek 20-60%-ánál jelentkeznek (pneumonia, hepati-
tis, nephritis, encephalitis, csontveló'-depresszió, 
bakteriális és gombás fertó'zések iránti esendó'ség 
formájában) (49, 50). Humán immundeficientia 
vírus- (HIV-) fertó'zést követó'en az esetek 20%-
ában figyelhető' meg súlyos, cytomegalovirus 
okozta betegség. 
Komoly következményekkel járó intrauterin 
fertó'zések általában olyan anyák gyermekeinél 
figyelhetó'k meg, akiknél a terhesség alatt primer 
CMV-fertó'zés zajlott le. Szeropozitív terhes anyák 
egy részénél a CMV reaktiválódik a terhesség alatt, 
a vírus áthatol a placentán és megfertó'zi a magza-
tot; tartós vírusürítés is létrejöhet, de ilyen esetek-
ben ritka a szervi károsodás (48, 51). Hasonlókép-
pen fontos tényező' a donor és a recipiens CMV-
szerostatusa a transzplantációt követó'en kialakuló 
betegség szempontjából: súlyos, gyakran élet-
veszélyes megbetegedés szeropozitív donor és sze-
ronegatív recipiens esetében gyakori, míg sze-
ropozitív recipiensnél a tünetek általában enyhék 
(49). Ezek a megfigyelések arra utalnak, hogy a 
vírusspecifikus immunitás védelmet jelent a CMV 
okozta megbetegedéssel szemben, a természetes 
immunitás azonban nem védi meg sem a szeropo-
zitív AIDS-betegeket, sem az egészséges szero-
pozitív egyéneket az újrafertó'zó'déstó'l vagy a reak-
tivációtól (52-55). A vírus ki tud térni az immun-
felügyelet alól, és a primer infekciót követó'en kró-
nikus vagy latens vírusfertó'zést alakít ki. A reak-
tivációval járó vírusürítés lehetővé teszi új gazda- , 
szervezetek fertó'zó'dését. 
A szeropozitivitás CMV-specifikus celluláris 
immunitással is együtt jár; nem tisztázott azonban, 
hogy a CMV okozta betegségekkel szembeni véde-
lemért milyen arányban feleló's a humorális és 
milyen arányban a celluláris immunitás. A celluláris 
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